<?xml version='1.0' encoding='UTF-8'?><?xml-stylesheet href="http://www.blogger.com/styles/atom.css" type="text/css"?><feed xmlns='http://www.w3.org/2005/Atom' xmlns:openSearch='http://a9.com/-/spec/opensearchrss/1.0/' xmlns:georss='http://www.georss.org/georss' xmlns:gd='http://schemas.google.com/g/2005' xmlns:thr='http://purl.org/syndication/thread/1.0'><id>tag:blogger.com,1999:blog-46256947993340856</id><updated>2011-11-22T18:13:55.120-08:00</updated><title type='text'>Fenilcetonúria</title><subtitle type='html'>Blog destinado a esclarecer as dúvidas sobre a Fenilcetonúria desde a sua descoberta até os tratamentos mais recentes!</subtitle><link rel='http://schemas.google.com/g/2005#feed' type='application/atom+xml' href='http://biobio-pku.blogspot.com/feeds/posts/default'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/46256947993340856/posts/default?max-results=100'/><link rel='alternate' type='text/html' href='http://biobio-pku.blogspot.com/'/><link rel='hub' href='http://pubsubhubbub.appspot.com/'/><author><name>Grupo de PKU</name><uri>http://www.blogger.com/profile/13253571819442069873</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><generator version='7.00' uri='http://www.blogger.com'>Blogger</generator><openSearch:totalResults>22</openSearch:totalResults><openSearch:startIndex>1</openSearch:startIndex><openSearch:itemsPerPage>100</openSearch:itemsPerPage><entry><id>tag:blogger.com,1999:blog-46256947993340856.post-2539383652131897595</id><published>2009-07-10T06:59:00.000-07:00</published><updated>2009-07-13T07:20:27.050-07:00</updated><title type='text'>Fenilcetonúria e o estresse oxidativo</title><content type='html'>&lt;a href="http://2.bp.blogspot.com/_btpyAerDQPU/SltCo5BFYOI/AAAAAAAAAO4/so9LdnjoXqM/s1600-h/ilustra.jpg"&gt;&lt;img style="TEXT-ALIGN: center; MARGIN: 0px auto 10px; WIDTH: 400px; DISPLAY: block; HEIGHT: 300px; CURSOR: hand" id="BLOGGER_PHOTO_ID_5357949451954905314" border="0" alt="" src="http://2.bp.blogspot.com/_btpyAerDQPU/SltCo5BFYOI/AAAAAAAAAO4/so9LdnjoXqM/s400/ilustra.jpg" /&gt;&lt;/a&gt;&lt;br /&gt;&lt;div&gt;&lt;span style="color:#000000;"&gt;&lt;span style="font-size:100%;"&gt;&lt;span style="font-family:trebuchet ms;"&gt;Várias pesquisas vem sendo realizadas a respeito da participação do estresse oxidativo no desenvolvimento da doença não tratada devido ao acúmulo de metabólitos tóxicos (no caso da fenilcetonúria: ácido fenilpirúvico, ácido feniláctico e ácido fenilacético). Esse acúmulo de metabólitos tóxicos podem levar ao aumento de radicais livres e até mesmo a diminuição da ação de antioxidantes.&lt;br /&gt;Para saber mais detalhes sobre o estresse oxidativo e a fenilcetonúria veja os artigos sobre esse assunto. São bastante interessantes!&lt;/span&gt;&lt;br /&gt;&lt;/span&gt;&lt;br /&gt;&lt;/span&gt;&lt;a href="http://www.lume.ufrgs.br/bitstream/handle/10183/10481/000598849.pdf?sequence=1"&gt;http://www.lume.ufrgs.br/bitstream/handle/10183/10481/000598849.pdf?sequence=1&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.lume.ufrgs.br/bitstream/handle/10183/15098/000669797.pdf?sequence=1"&gt;http://www.lume.ufrgs.br/bitstream/handle/10183/15098/000669797.pdf?sequence=1&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.lume.ufrgs.br/bitstream/handle/10183/10062/000594195.pdf?sequence=1"&gt;http://www.lume.ufrgs.br/bitstream/handle/10183/10062/000594195.pdf?sequence=1&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Amanda Biete&lt;/div&gt;&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/46256947993340856-2539383652131897595?l=biobio-pku.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://biobio-pku.blogspot.com/feeds/2539383652131897595/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=46256947993340856&amp;postID=2539383652131897595' title='2 Comentários'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/46256947993340856/posts/default/2539383652131897595'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/46256947993340856/posts/default/2539383652131897595'/><link rel='alternate' type='text/html' href='http://biobio-pku.blogspot.com/2009/07/fenilcetonuria-e-o-estresse-oxidativo.html' title='Fenilcetonúria e o estresse oxidativo'/><author><name>Grupo de PKU</name><uri>http://www.blogger.com/profile/13253571819442069873</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><media:thumbnail xmlns:media='http://search.yahoo.com/mrss/' url='http://2.bp.blogspot.com/_btpyAerDQPU/SltCo5BFYOI/AAAAAAAAAO4/so9LdnjoXqM/s72-c/ilustra.jpg' height='72' width='72'/><thr:total>2</thr:total></entry><entry><id>tag:blogger.com,1999:blog-46256947993340856.post-7717605213917902261</id><published>2008-11-19T08:59:00.000-08:00</published><updated>2008-11-19T09:03:42.725-08:00</updated><title type='text'>Anvisa vai monitorar Fenilalanina </title><content type='html'>&lt;span style="font-weight: bold; color: rgb(102, 0, 204);font-size:180%;" &gt;&lt;br /&gt;&lt;/span&gt;&lt;div style="text-align: justify;"&gt;&lt;span style="font-weight: bold;font-size:100%;" &gt;&lt;span style="font-family:trebuchet ms;"&gt;&lt;span style="color: rgb(102, 0, 204);font-size:180%;" &gt;"&lt;/span&gt;A Agência Nacional de Vigilância Sanitária (Anvisa) vai disponibilizar, dentro de um ano(2009), uma nova Tabela de Fenilalanina que indicará a quantidade dessa substância em diversos alimentos. O objetivo da inovação é orientar a dieta dos portadores de fenilcetonúria.&lt;/span&gt;&lt;br /&gt;&lt;span style="font-family:trebuchet ms;"&gt; O cronograma para a implementação do documento foi apresentada à Justiça Federal pela Anvisa no início do mês, para cumprir um acordo feito com o Ministério Público Federal em uma ação civil pública que exigia a indicação da quantidade de fenilalanina nos rótulos de alimentos. Além de inserir a tabela na internet, a agência irá distribuir versões impressas para centros que fazem o acompanhamento de pacientes que possuem a doença.&lt;/span&gt;&lt;br /&gt;&lt;span style="font-family:trebuchet ms;"&gt; Calcula-se que um em cada 10 mil recém-nascidos seja portador de fenilcetonúria.  A doença está relacionada a uma alteração genética rara que envolve o metabolismo de proteínas. Uma pessoa com fenilcetonúria não tem a quantidade normal de uma enzima para quebrar o aminoácido. Por isso, qualquer alimento com fenilalanina não é digerido corretamente, e a substância se acumula no organismo, causando problemas no cérebro e em outros órgãos&lt;span style="color: rgb(102, 0, 204);font-size:180%;" &gt;."&lt;/span&gt;&lt;/span&gt;&lt;br /&gt;&lt;/span&gt;   	&lt;meta equiv="CONTENT-TYPE" content="text/html; charset=utf-8"&gt; 	&lt;title&gt;&lt;/title&gt; 	&lt;meta name="GENERATOR" content="OpenOffice.org 2.4  (Unix)"&gt; 	&lt;style type="text/css"&gt; 	&lt;!-- 		@page { margin: 2cm } 		P { margin-bottom: 0.21cm } 	--&gt; 	&lt;/style&gt;  &lt;p class="western"  style="margin: 0.35cm; background: rgb(255, 255, 255) none repeat scroll 0% 0%; -moz-background-clip: -moz-initial; -moz-background-origin: -moz-initial; -moz-background-inline-policy: -moz-initial; font-weight: bold; font-family: lucida grande;font-family:trebuchet ms;"&gt; &lt;span style="color: rgb(0, 0, 0);font-size:85%;" &gt;16/09/2008&lt;/span&gt;&lt;/p&gt; &lt;span style="font-weight: bold;font-size:100%;" &gt;&lt;span style="font-size:85%;"&gt;&lt;br /&gt;&lt;/span&gt;&lt;span style="color: rgb(204, 51, 204); font-family: lucida grande;font-family:trebuchet ms;font-size:85%;"  &gt;By: Jersica Oliveira&lt;/span&gt;&lt;br /&gt;&lt;br /&gt;&lt;/span&gt;   	&lt;meta equiv="CONTENT-TYPE" content="text/html; charset=utf-8"&gt; 	&lt;title&gt;&lt;/title&gt; 	&lt;meta name="GENERATOR" content="OpenOffice.org 2.4  (Unix)"&gt; 	&lt;style type="text/css"&gt; 	&lt;!-- 		@page { margin: 2cm } 		P { margin-bottom: 0.21cm } 	--&gt; 	&lt;/style&gt;  &lt;p class="western"  style="margin: 0.35cm; background: rgb(255, 255, 255) none repeat scroll 0% 0%; -moz-background-clip: -moz-initial; -moz-background-origin: -moz-initial; -moz-background-inline-policy: -moz-initial; font-weight: bold; color: rgb(102, 0, 204);font-family:trebuchet ms;"&gt; &lt;span style="font-size:85%;"&gt;&lt;i&gt;Fonte: CFN&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;br /&gt;&lt;/div&gt;&lt;br /&gt;&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/46256947993340856-7717605213917902261?l=biobio-pku.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://biobio-pku.blogspot.com/feeds/7717605213917902261/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=46256947993340856&amp;postID=7717605213917902261' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/46256947993340856/posts/default/7717605213917902261'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/46256947993340856/posts/default/7717605213917902261'/><link rel='alternate' type='text/html' href='http://biobio-pku.blogspot.com/2008/11/anvisa-vai-monitorar-fenilalanina.html' title='Anvisa vai monitorar Fenilalanina '/><author><name>Grupo de PKU</name><uri>http://www.blogger.com/profile/13253571819442069873</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-46256947993340856.post-1698144231632782903</id><published>2008-11-15T15:29:00.000-08:00</published><updated>2008-11-19T09:14:49.856-08:00</updated><title type='text'>Artigos</title><content type='html'>&lt;a onblur="try {parent.deselectBloggerImageGracefully();} catch(e) {}" href="http://3.bp.blogspot.com/_btpyAerDQPU/SSRJftaqFCI/AAAAAAAAAOo/YpMV4L7Mrs8/s1600-h/Pappoulla_gravida.jpg"&gt;&lt;img style="margin: 0px auto 10px; display: block; text-align: center; cursor: pointer; width: 266px; height: 400px;" src="http://3.bp.blogspot.com/_btpyAerDQPU/SSRJftaqFCI/AAAAAAAAAOo/YpMV4L7Mrs8/s400/Pappoulla_gravida.jpg" alt="" id="BLOGGER_PHOTO_ID_5270418273046500386" border="0" /&gt;&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;div style="text-align: justify;"&gt;&lt;span style="font-size:100%;"&gt;&lt;span style="font-weight: bold;font-family:trebuchet ms;" &gt;Este é um artigo sobre a fenilcetonúria materna e mostra, através do relato de um caso, que mulheres grávidas com hiperfenilalaninemia tratadas com uma dieta restritiva em relação ao aminoácido fenilalanina tiveram filhos que não apresentaram defeitos congênitos  ou alterações físicas, já as mães fenilcetonúricas não tratadas tiveram crianças com problemas auditivos, de fala e microc&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:100%;"&gt;&lt;span style="font-weight: bold;font-family:trebuchet ms;" &gt;efalia. Isso mostra a importância de as mães com hiperfenilalaninemia seguirem uma dieta balanceada para que o bebê não sofra conseqüências, além da importância do pré-n&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:100%;"&gt;&lt;span style="font-weight: bold;font-family:trebuchet ms;" &gt;atal que é bastante importante no monitoramento da gestante e da criança.&lt;/span&gt;&lt;/span&gt;&lt;br /&gt;&lt;span style="font-size:100%;"&gt;&lt;span style="font-weight: bold;font-family:trebuchet ms;" &gt;Trata-se de um artigo veementemente interessante vale a pena conferir!&lt;/span&gt;&lt;/span&gt;&lt;br /&gt;&lt;/div&gt;&lt;br /&gt;&lt;a style="font-weight: bold; color: rgb(51, 51, 255);" href="http://www.scielo.br/scielo.php?pid=S0100-72032004001000009&amp;amp;script=sci_arttext&amp;amp;tlng=en"&gt;http://www.scielo.br/scielo.php?pid=S0100-72032004001000009&amp;amp;script=sci_arttext&amp;amp;tlng=en&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;div style="text-align: justify;"&gt;&lt;span style="font-weight: bold;font-size:100%;" &gt;&lt;span style="font-family:trebuchet ms;"&gt;Este artigo é bastante interessante e enfatiza o tratamento nutricional da fenilcetonúria. Ele mostra a importância de se ter atenção ao substitu&lt;/span&gt;&lt;/span&gt;&lt;span style="font-weight: bold;font-size:100%;" &gt;&lt;span style="font-family:trebuchet ms;"&gt;ir alimentos ricos em fenilalanina da dieta dos fenilcetonúricos, para que sejam recomendados alimentos que tenham um aporte nutricional correto para cada faixa etária. E mostra também a importância do monitoramento das pessoas que possuem tal doença. É um artigo que realmente merece ser lido, visto que fala da doença por inteiro, explicando o que é a PKU, o metabolismo, o diagn&lt;/span&gt;&lt;/span&gt;&lt;span style="font-weight: bold;font-size:100%;" &gt;&lt;span style="font-family:trebuchet ms;"&gt;óstico da doença e o tratamento.&lt;/span&gt;&lt;/span&gt;&lt;br /&gt;&lt;/div&gt;&lt;br /&gt;&lt;a style="font-weight: bold; color: rgb(51, 51, 255);" href="http://www.spp.pt/Userfiles/File/App/Artigos/6/20080422131427_APP_VOL_38_N1_CR_Tratamento_Nutricional_fenilcetonuria.pd"&gt;http://www.spp.pt/Userfiles/File/App/Artigos&lt;/a&gt;&lt;a style="font-weight: bold; color: rgb(51, 51, 255);" href="http://www.spp.pt/Userfiles/File/App/Artigos/6/20080422131427_APP_VOL_38_N1_CR_Tratamento_Nutricional_fenilcetonuria.pd"&gt;/6/20080422131427_APP_VOL_38_N1_CR_Tratamento_Nutricional_fenilcetonuria.pd&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;/a&gt;&lt;br /&gt;&lt;a onblur="try {parent.deselectBloggerImageGracefully();} catch(e) {}" href="http://2.bp.blogspot.com/_btpyAerDQPU/SSRIkn11ZhI/AAAAAAAAAOg/rfCkTWAECr8/s1600-h/pezinho.gif"&gt;&lt;img style="margin: 0px auto 10px; display: block; text-align: center; cursor: pointer; width: 160px; height: 159px;" src="http://2.bp.blogspot.com/_btpyAerDQPU/SSRIkn11ZhI/AAAAAAAAAOg/rfCkTWAECr8/s400/pezinho.gif" alt="" id="BLOGGER_PHOTO_ID_5270417257937593874" border="0" /&gt;&lt;/a&gt;&lt;br /&gt;&lt;div style="text-align: justify;"&gt;&lt;span style="font-weight: bold;font-family:trebuchet ms;font-size:100%;"  &gt;Achei bastante interessante esse artigo que mostra um trabalho feito para avaliar a compreensão dos pais em relação ao teste do pezinho(triagem neonatal), observando que muitos pais ainda não sabem o quanto é importante para a saúde de seus filhos a realização desse teste. Mostra também que alguns pais não têm nem o interesse de saber para que serve o teste do pezinho e quais doenças ele pode detectar. &lt;/span&gt;&lt;br /&gt;&lt;/div&gt;&lt;br /&gt;&lt;br /&gt;&lt;span style="font-weight: bold; color: rgb(51, 51, 255);"&gt;http://scielo.bvs-psi.org.br/scielo.php?pid=S0104-12822007000100002&amp;amp;script=sci_arttext&lt;/span&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;span style="color: rgb(204, 51, 204); font-weight: bold; font-style: italic;"&gt;By: Camila Biete&lt;/span&gt;&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/46256947993340856-1698144231632782903?l=biobio-pku.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://biobio-pku.blogspot.com/feeds/1698144231632782903/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=46256947993340856&amp;postID=1698144231632782903' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/46256947993340856/posts/default/1698144231632782903'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/46256947993340856/posts/default/1698144231632782903'/><link rel='alternate' type='text/html' href='http://biobio-pku.blogspot.com/2008/11/artigos.html' title='Artigos'/><author><name>Grupo de PKU</name><uri>http://www.blogger.com/profile/13253571819442069873</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><media:thumbnail xmlns:media='http://search.yahoo.com/mrss/' url='http://3.bp.blogspot.com/_btpyAerDQPU/SSRJftaqFCI/AAAAAAAAAOo/YpMV4L7Mrs8/s72-c/Pappoulla_gravida.jpg' height='72' width='72'/><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-46256947993340856.post-56412688279318883</id><published>2008-11-14T15:17:00.000-08:00</published><updated>2008-11-24T16:41:28.447-08:00</updated><title type='text'>Fenilalanina e Neurotransmissores </title><content type='html'>&lt;a onblur="try {parent.deselectBloggerImageGracefully();} catch(e) {}" href="http://3.bp.blogspot.com/_btpyAerDQPU/SR4IyhDIfUI/AAAAAAAAAN4/7dvAxTY0UUM/s1600-h/sintadr.jpg"&gt;&lt;img id="BLOGGER_PHOTO_ID_5268658278028049730" style="DISPLAY: block; MARGIN: 0px auto 10px; WIDTH: 292px; CURSOR: pointer; HEIGHT: 400px; TEXT-ALIGN: center" alt="" src="http://3.bp.blogspot.com/_btpyAerDQPU/SR4IyhDIfUI/AAAAAAAAAN4/7dvAxTY0UUM/s400/sintadr.jpg" border="0" /&gt;&lt;/a&gt;&lt;br /&gt;&lt;div style="TEXT-ALIGN: justify"&gt;&lt;meta content="text/html; charset=utf-8" equiv="Content-Type"&gt;&lt;meta content="Word.Document" name="ProgId"&gt;&lt;meta content="Microsoft Word 9" name="Generator"&gt;&lt;meta content="Microsoft Word 9" name="Originator"&gt;&lt;link href="file:///C:/DOCUME%7E1/Marina/CONFIG%7E1/Temp/msoclip1/01/clip_filelist.xml" rel="File-List"&gt;&lt;link href="file:///C:/DOCUME%7E1/Marina/CONFIG%7E1/Temp/msoclip1/01/clip_editdata.mso" rel="Edit-Time-Data"&gt;&lt;style&gt; v\:* {behavior:url(#default#VML);} o\:* {behavior:url(#default#VML);} w\:* {behavior:url(#default#VML);} .shape {behavior:url(#default#VML);} &lt;/style&gt;&lt;br /&gt;&lt;style&gt; &lt;!--  /* Style Definitions */ p.MsoNormal, li.MsoNormal, div.MsoNormal 	{mso-style-parent:""; 	margin:0cm; 	margin-bottom:.0001pt; 	mso-pagination:widow-orphan; 	font-size:12.0pt; 	font-family:"Times New Roman"; 	mso-fareast-font-family:"Times New Roman";} a:link, span.MsoHyperlink 	{color:blue; 	text-decoration:underline; 	text-underline:single;} a:visited, span.MsoHyperlinkFollowed 	{color:purple; 	text-decoration:underline; 	text-underline:single;} p 	{margin-right:0cm; 	mso-margin-top-alt:auto; 	mso-margin-bottom-alt:auto; 	margin-left:0cm; 	mso-pagination:widow-orphan; 	font-size:12.0pt; 	font-family:"Times New Roman"; 	mso-fareast-font-family:"Times New Roman";} @page Section1 	{size:612.0pt 792.0pt; 	margin:70.85pt 3.0cm 70.85pt 3.0cm; 	mso-header-margin:36.0pt; 	mso-footer-margin:36.0pt; 	mso-paper-source:0;} div.Section1 	{page:Section1;} --&gt; &lt;/style&gt;&lt;/div&gt;&lt;div style="TEXT-ALIGN: justify"&gt;&lt;/div&gt;&lt;p style="FONT-WEIGHT: bold; TEXT-INDENT: 35.4pt"&gt;&lt;span lang="PT"  style="font-size:100%;"&gt;"A fenilalanina é um aminoácido essencial que pode atravessar as barreiras de sangue no cérebro o que significa que ela pode ter um efeito direto na química do cérebro. Uma vez que está no corpo este pode ser convertido em tirosina, outro aminoácido. Este aminoácido sintetiza a dopamina a norepinifrina(catecolaminas), que promove alerta mental.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-WEIGHT: bold; TEXT-INDENT: 35.4pt"&gt;&lt;span lang="PT"  style="font-size:100%;"&gt;Catecolaminas são compostos químicos derivados dos aminoácidos tirosina e fenilalanina. As catecolaminas são solúveis em água, são liberadas pela glândula supra-renal em dituações de stress ou hipoglicemia.&lt;?xml:namespace prefix = o /&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="FONT-WEIGHT: bold; FONT-FAMILY: trebuchet ms"&gt;&lt;/div&gt;&lt;p style="FONT-WEIGHT: bold; TEXT-INDENT: 35.4pt"&gt;&lt;span lang="PT"  style="font-size:100%;"&gt;A fenilalanina realça o humor, a disposição e o ânimo, diminui as dores, auxilia no memória e no aprendizado, e suprimi o apetite."&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-WEIGHT: bold; TEXT-INDENT: 35.4pt"&gt;&lt;span lang="PT"  style="font-size:100%;"&gt;Como os fenilcetonúricos não possuem a enzima fenilalanina hidroxilase, haverá pouca ou quase nenhuma transformação de fenilalanina em tirosina e, portanto haverá deficiência também na sintetização de catecolaminas.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-WEIGHT: bold; TEXT-INDENT: 35.4pt"&gt;&lt;span style="COLOR: rgb(102,0,204); FONT-STYLE: italic"&gt;By: Jersica Oliveira&lt;/span&gt;&lt;br /&gt;&lt;/p&gt;&lt;p style="FONT-WEIGHT: bold; TEXT-INDENT: 35.4pt"&gt;&lt;span lang="PT"  style="font-size:100%;"&gt;Fonte: &lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;a href="http://pt.wikipedia.org/wiki/Catecolamina"&gt;http://pt.wikipedia.org/wiki/Catecolamina&lt;/a&gt;&lt;/p&gt;&lt;p&gt;&lt;a href="http://www.nutrivea-po.com/phenylalanine.htm"&gt;http://www.nutrivea-po.com/phenylalanine.htm&lt;/a&gt;&lt;/p&gt;&lt;p&gt;&lt;span style="TEXT-DECORATION: underline"&gt;&lt;/span&gt;&lt;/p&gt;&lt;a href="by:%20Jersica%20Oliveira"&gt;&lt;span style="TEXT-DECORATION: underline"&gt;&lt;/span&gt;&lt;/a&gt;&lt;br /&gt;&lt;p&gt;&lt;span style="font-size:14;"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;div style="TEXT-ALIGN: justify"&gt;&lt;span style="font-size:100%;"&gt;&lt;br /&gt;&lt;/span&gt;&lt;br /&gt;&lt;/div&gt;&lt;br /&gt;&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/46256947993340856-56412688279318883?l=biobio-pku.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://biobio-pku.blogspot.com/feeds/56412688279318883/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=46256947993340856&amp;postID=56412688279318883' title='2 Comentários'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/46256947993340856/posts/default/56412688279318883'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/46256947993340856/posts/default/56412688279318883'/><link rel='alternate' type='text/html' href='http://biobio-pku.blogspot.com/2008/11/fenilalanina-e-neurotransmissores.html' title='Fenilalanina e Neurotransmissores '/><author><name>Grupo de PKU</name><uri>http://www.blogger.com/profile/13253571819442069873</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><media:thumbnail xmlns:media='http://search.yahoo.com/mrss/' url='http://3.bp.blogspot.com/_btpyAerDQPU/SR4IyhDIfUI/AAAAAAAAAN4/7dvAxTY0UUM/s72-c/sintadr.jpg' height='72' width='72'/><thr:total>2</thr:total></entry><entry><id>tag:blogger.com,1999:blog-46256947993340856.post-7374603240204971173</id><published>2008-11-10T09:19:00.000-08:00</published><updated>2008-11-14T17:23:11.880-08:00</updated><title type='text'>Incidência de PKU/HPA em diversas partes do mundo</title><content type='html'>&lt;a onblur="try {parent.deselectBloggerImageGracefully();} catch(e) {}" href="http://4.bp.blogspot.com/_btpyAerDQPU/SR4kefLC7oI/AAAAAAAAAOI/67meKRo8JtU/s1600-h/14.jpg"&gt;&lt;img style="margin: 0px auto 10px; display: block; text-align: center; cursor: pointer; width: 300px; height: 59px;" src="http://4.bp.blogspot.com/_btpyAerDQPU/SR4kefLC7oI/AAAAAAAAAOI/67meKRo8JtU/s400/14.jpg" alt="" id="BLOGGER_PHOTO_ID_5268688720252563074" border="0" /&gt;&lt;/a&gt;&lt;br /&gt;&lt;a onblur="try {parent.deselectBloggerImageGracefully();} catch(e) {}" href="http://3.bp.blogspot.com/_btpyAerDQPU/SR4kZJT68VI/AAAAAAAAAOA/MsdZ8RgyhaM/s1600-h/rotacao_terra.gif"&gt;&lt;img style="margin: 0px auto 10px; display: block; text-align: center; cursor: pointer; width: 300px; height: 300px;" src="http://3.bp.blogspot.com/_btpyAerDQPU/SR4kZJT68VI/AAAAAAAAAOA/MsdZ8RgyhaM/s400/rotacao_terra.gif" alt="" id="BLOGGER_PHOTO_ID_5268688628484862290" border="0" /&gt;&lt;/a&gt;&lt;br /&gt;&lt;div style="text-align: justify;"&gt; &lt;span style="font-weight: bold;font-size:100%;" &gt;&lt;span style="font-family:trebuchet ms;"&gt;&lt;br /&gt;&lt;span style="color: rgb(102, 51, 255);font-size:180%;" &gt;"&lt;/span&gt;A PKU ocorre em todos os grupos étnicos e, devido à grande variabilidade genética, a incidência em recém-nascidos pode variar de 1:2.600 até 1:26.000, sendo a média de 1:10.000.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;p  style="text-align: justify; font-weight: bold;font-family:trebuchet ms;"&gt;&lt;span style="font-size:100%;"&gt;           Na Europa Ocidental, a freqüência da doença é em média de 1:8.000 recém-nascidos, apesar de grandes diferenças entre os vários países. Nos Países Baixos, a incidência foi calculada em 1:18.000 no período de 1974 a 1989. No Reino Unido a incidência é de 1:10.000,&lt;sup&gt; &lt;/sup&gt;enquanto na Irlanda é duas vezes maior, afetando 1 em 4.000 recém nascidos. &lt;/span&gt;&lt;/p&gt;&lt;div style="text-align: justify; font-family: trebuchet ms; font-weight: bold;"&gt;       &lt;/div&gt;&lt;p  style="text-align: justify; font-weight: bold;font-family:trebuchet ms;"&gt;&lt;span style="font-size:100%;"&gt;          A incidência de PKU também pode sofrer variações geográficas dentro de um mesmo país. Na Espanha, por exemplo, a incidência é de 1:7.000 na área central, 1:13.000 nas regiões de Cantabria e Castilha de León e 1:25.254 na região da Galícia. &lt;/span&gt;&lt;/p&gt;&lt;div style="text-align: justify; font-family: trebuchet ms; font-weight: bold;"&gt;      &lt;/div&gt;&lt;p  style="text-align: justify; font-weight: bold;font-family:trebuchet ms;"&gt;&lt;span style="font-size:100%;"&gt;           Na Áustria, o "Programa de proteção para recém-nascidos com erros no metabolismo" registrou no período de março de 1966 a setembro de 1994 307 casos, dentre os quais 249 com PKU (incidência de 1:9.622) e 58 com HPA (incidência de 1:41.309). &lt;/span&gt;&lt;/p&gt;&lt;div style="text-align: justify; font-family: trebuchet ms; font-weight: bold;"&gt;      &lt;/div&gt;&lt;p  style="text-align: justify; font-weight: bold;font-family:trebuchet ms;"&gt;&lt;span style="font-size:100%;"&gt;           Na Hungria, país com 10 milhões de habitantes, no qual existem dois centros para PKU, foram registrados pelo Centro de proteção à PKU" em Budapeste, durante o período de 1975 a 1994, 160 casos de PKU clássica, o que corresponde a uma incidência de 1:9.000, entre um total de 1,5 milhões de recém-nascidos. &lt;/span&gt;&lt;/p&gt;&lt;div style="text-align: justify; font-family: trebuchet ms; font-weight: bold;"&gt;      &lt;/div&gt;&lt;p  style="text-align: justify; font-weight: bold;font-family:trebuchet ms;"&gt;&lt;span style="font-size:100%;"&gt;           Cabalska et al (1996) reportam que a ocorrência de PKU clássica na população da Polônia é 1:8.000, enquanto que para HPA é 1:40.000. Já na Turquia, a incidência de PKU é de 1:4.370 e de HPA de 1:8.971 recém-nascidos. &lt;/span&gt;&lt;/p&gt;&lt;div style="text-align: justify; font-family: trebuchet ms; font-weight: bold;"&gt;      &lt;/div&gt;&lt;p  style="text-align: justify; font-weight: bold;font-family:trebuchet ms;"&gt;&lt;span style="font-size:100%;"&gt;           No Brasil, Schmidt et al (1987) estimam que na cidade de São Paulo 1:12.000 a 1:15.000 recém-nascidos são portadores de PKU, com base em levantamento realizado em postos de saúde e berçários. Já na região sul do país, Jardim et al (1996) reportam que a razão é de 1:12.500, não sendo registrados os casos de HPA.&lt;span style="color: rgb(102, 0, 204);font-size:180%;" &gt;"&lt;/span&gt;&lt;br /&gt;&lt;/span&gt;&lt;/p&gt;&lt;p  style="text-align: justify; font-weight: bold;font-family:trebuchet ms;"&gt;&lt;span style="font-size:100%;"&gt;Fonte:&lt;/span&gt;&lt;a href="http://www.scielosp.org/scielo.php?script=sci_arttext&amp;amp;pid=S0034-89102000000100016" target="_blank"&gt;http://www.scielosp.org/&lt;wbr&gt;scielo.php?script=sci_arttext&amp;amp;&lt;wbr&gt;pid=S0034-89102000000100016&lt;/a&gt;&lt;/p&gt;&lt;div  style="text-align: justify; font-weight: bold; color: rgb(204, 51, 204);font-family:trebuchet ms;"&gt;&lt;span style="font-size:100%;"&gt;          By Camila Biete&lt;/span&gt;&lt;/div&gt;&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/46256947993340856-7374603240204971173?l=biobio-pku.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://biobio-pku.blogspot.com/feeds/7374603240204971173/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=46256947993340856&amp;postID=7374603240204971173' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/46256947993340856/posts/default/7374603240204971173'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/46256947993340856/posts/default/7374603240204971173'/><link rel='alternate' type='text/html' href='http://biobio-pku.blogspot.com/2008/11/incidncia-de-pku.html' title='Incidência de PKU/HPA em diversas partes do mundo'/><author><name>Grupo de PKU</name><uri>http://www.blogger.com/profile/13253571819442069873</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><media:thumbnail xmlns:media='http://search.yahoo.com/mrss/' url='http://4.bp.blogspot.com/_btpyAerDQPU/SR4kefLC7oI/AAAAAAAAAOI/67meKRo8JtU/s72-c/14.jpg' height='72' width='72'/><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-46256947993340856.post-5415157056205677697</id><published>2008-11-10T08:21:00.000-08:00</published><updated>2008-11-20T12:25:49.652-08:00</updated><title type='text'>Efeito da fenillanina na atividade dos complexos da cadeia de transporte de elétrons</title><content type='html'>&lt;a onblur="try {parent.deselectBloggerImageGracefully();} catch(e) {}" href="http://3.bp.blogspot.com/_btpyAerDQPU/SRhfzonO5WI/AAAAAAAAANY/KzrZSMEXTsc/s1600-h/250px-Phenylalanine_hydroxylase_brighter.jpg"&gt;&lt;img id="BLOGGER_PHOTO_ID_5267065104889734498" style="DISPLAY: block; MARGIN: 0px auto 10px; WIDTH: 250px; CURSOR: pointer; HEIGHT: 263px; TEXT-ALIGN: center" alt="" src="http://3.bp.blogspot.com/_btpyAerDQPU/SRhfzonO5WI/AAAAAAAAANY/KzrZSMEXTsc/s320/250px-Phenylalanine_hydroxylase_brighter.jpg" border="0" /&gt;&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;div style="FONT-WEIGHT: bold; TEXT-ALIGN: justifyfont-family:trebuchet ms;" &gt;&lt;span style="font-size:100%;"&gt;"A Fenilalanina é um aminoácido essencial que pode atravessar as barreiras de sangue no cérebro o que significa que ela pode ter um efeito direto na química do cérebro.&lt;br /&gt;Analisando-se os efeitos dos metabólitos da fenilalanina constatou-se que esses não eram encontrados em concentrações altas o suficiente para serem relacionados com distúrbios do cérebro de pacientes com PKU.&lt;br /&gt;Então a própria fenilananina é vista como o agente neurotóxico na PKU.&lt;br /&gt;Em PKU o excesso de fenilalanina pode competir com outros aminoácidos pelo transporte através da barreira hematoencafélica, resultando na depleção de metabólitos muito importantes.&lt;br /&gt;Os resultados dos estudos sobre os efeitos da fenilalanina na cadeia de transporte de elétrons mostram que este aminoácido inibe os complexos 1 e 3 por competição com o NADH ao nível do complexo1 e diminui a atividade da succinato desidrogenase.&lt;br /&gt;Considerando a SDH e a cadeia de transporte de elétrons para o suprimento energético cerebral, os resultados sugerem que o déficit energético possa contribuir para a neurotoxicidade da fenilalanina em PKU."&lt;br /&gt;&lt;br /&gt;&lt;span style="COLOR: rgb(102,51,255); FONT-STYLE: italic"&gt;by: Jersica Oliveira&lt;br /&gt;&lt;br /&gt;Fonte: &lt;/span&gt;&lt;/span&gt;&lt;br /&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="FONT-WEIGHT: bold"&gt;&lt;a href="http://www.lume.ufrgs.br/%20handle/10183/2536?show=full" target="_blank" rel="nofollow"&gt;http://www.lume.ufrgs.br/ handle/10183/2536?show=&lt;span style="font-size:+0;"&gt;full&lt;/span&gt;&lt;/a&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/46256947993340856-5415157056205677697?l=biobio-pku.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://biobio-pku.blogspot.com/feeds/5415157056205677697/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=46256947993340856&amp;postID=5415157056205677697' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/46256947993340856/posts/default/5415157056205677697'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/46256947993340856/posts/default/5415157056205677697'/><link rel='alternate' type='text/html' href='http://biobio-pku.blogspot.com/2008/11/efeito-da-fenillanina-na-atividade-dos.html' title='Efeito da fenillanina na atividade dos complexos da cadeia de transporte de elétrons'/><author><name>Grupo de PKU</name><uri>http://www.blogger.com/profile/13253571819442069873</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><media:thumbnail xmlns:media='http://search.yahoo.com/mrss/' url='http://3.bp.blogspot.com/_btpyAerDQPU/SRhfzonO5WI/AAAAAAAAANY/KzrZSMEXTsc/s72-c/250px-Phenylalanine_hydroxylase_brighter.jpg' height='72' width='72'/><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-46256947993340856.post-4627569449665546287</id><published>2008-11-10T08:05:00.000-08:00</published><updated>2008-11-14T15:15:00.835-08:00</updated><title type='text'>Aleitamento Materno</title><content type='html'>&lt;a onblur="try {parent.deselectBloggerImageGracefully();} catch(e) {}" href="http://3.bp.blogspot.com/_btpyAerDQPU/SRhcZUNrJLI/AAAAAAAAANA/2UUMOvAZE34/s1600-h/aleitamento2.jpg"&gt;&lt;img style="margin: 0px auto 10px; display: block; text-align: center; cursor: pointer; width: 320px; height: 213px;" src="http://3.bp.blogspot.com/_btpyAerDQPU/SRhcZUNrJLI/AAAAAAAAANA/2UUMOvAZE34/s320/aleitamento2.jpg" alt="" id="BLOGGER_PHOTO_ID_5267061354202342578" border="0" /&gt;&lt;/a&gt;&lt;span style="font-size:100%;"&gt;&lt;br /&gt;&lt;br /&gt;&lt;/span&gt;&lt;meta equiv="Content-Type" content="text/html; charset=utf-8"&gt;&lt;meta name="ProgId" content="Word.Document"&gt;&lt;meta name="Generator" content="Microsoft Word 12"&gt;&lt;meta name="Originator" content="Microsoft Word 12"&gt;&lt;link style="font-family: trebuchet ms; font-weight: bold;" rel="File-List" href="file:///C:%5CDOCUME%7E1%5CNATALI%7E1%5CCONFIG%7E1%5CTemp%5Cmsohtmlclip1%5C01%5Cclip_filelist.xml"&gt;&lt;link style="font-family: trebuchet ms; font-weight: bold;" rel="themeData" href="file:///C:%5CDOCUME%7E1%5CNATALI%7E1%5CCONFIG%7E1%5CTemp%5Cmsohtmlclip1%5C01%5Cclip_themedata.thmx"&gt;&lt;link style="font-family: trebuchet ms; font-weight: bold;" rel="colorSchemeMapping" href="file:///C:%5CDOCUME%7E1%5CNATALI%7E1%5CCONFIG%7E1%5CTemp%5Cmsohtmlclip1%5C01%5Cclip_colorschememapping.xml"&gt;&lt;!--[if gte mso 9]&gt;&lt;xml&gt;  &lt;w:worddocument&gt;   &lt;w:view&gt;Normal&lt;/w:View&gt;   &lt;w:zoom&gt;0&lt;/w:Zoom&gt;   &lt;w:trackmoves/&gt;   &lt;w:trackformatting/&gt;   &lt;w:hyphenationzone&gt;21&lt;/w:HyphenationZone&gt;   &lt;w:punctuationkerning/&gt;   &lt;w:validateagainstschemas/&gt;   &lt;w:saveifxmlinvalid&gt;false&lt;/w:SaveIfXMLInvalid&gt;   &lt;w:ignoremixedcontent&gt;false&lt;/w:IgnoreMixedContent&gt;   &lt;w:alwaysshowplaceholdertext&gt;false&lt;/w:AlwaysShowPlaceholderText&gt;   &lt;w:donotpromoteqf/&gt;   &lt;w:lidthemeother&gt;PT-BR&lt;/w:LidThemeOther&gt;   &lt;w:lidthemeasian&gt;X-NONE&lt;/w:LidThemeAsian&gt;   &lt;w:lidthemecomplexscript&gt;X-NONE&lt;/w:LidThemeComplexScript&gt;   &lt;w:compatibility&gt;    &lt;w:breakwrappedtables/&gt;    &lt;w:snaptogridincell/&gt;    &lt;w:wraptextwithpunct/&gt;    &lt;w:useasianbreakrules/&gt;    &lt;w:dontgrowautofit/&gt;    &lt;w:splitpgbreakandparamark/&gt;    &lt;w:dontvertaligncellwithsp/&gt;    &lt;w:dontbreakconstrainedforcedtables/&gt;    &lt;w:dontvertalignintxbx/&gt;    &lt;w:word11kerningpairs/&gt;    &lt;w:cachedcolbalance/&gt;   &lt;/w:Compatibility&gt;   &lt;w:browserlevel&gt;MicrosoftInternetExplorer4&lt;/w:BrowserLevel&gt;   &lt;m:mathpr&gt;    &lt;m:mathfont val="Cambria Math"&gt;    &lt;m:brkbin val="before"&gt;    &lt;m:brkbinsub val="&amp;#45;-"&gt;    &lt;m:smallfrac val="off"&gt;    &lt;m:dispdef/&gt;    &lt;m:lmargin val="0"&gt;    &lt;m:rmargin val="0"&gt;    &lt;m:defjc val="centerGroup"&gt;    &lt;m:wrapindent val="1440"&gt;    &lt;m:intlim val="subSup"&gt;    &lt;m:narylim val="undOvr"&gt;   &lt;/m:mathPr&gt;&lt;/w:WordDocument&gt; &lt;/xml&gt;&lt;![endif]--&gt;&lt;!--[if gte mso 9]&gt;&lt;xml&gt;  &lt;w:latentstyles deflockedstate="false" defunhidewhenused="true" defsemihidden="true" defqformat="false" defpriority="99" latentstylecount="267"&gt;   &lt;w:lsdexception locked="false" priority="0" semihidden="false" unhidewhenused="false" qformat="true" name="Normal"&gt;   &lt;w:lsdexception locked="false" priority="9" semihidden="false" unhidewhenused="false" qformat="true" name="heading 1"&gt;   &lt;w:lsdexception locked="false" priority="9" qformat="true" name="heading 2"&gt;   &lt;w:lsdexception locked="false" priority="9" qformat="true" name="heading 3"&gt;   &lt;w:lsdexception locked="false" priority="9" qformat="true" name="heading 4"&gt;   &lt;w:lsdexception locked="false" priority="9" qformat="true" name="heading 5"&gt;   &lt;w:lsdexception locked="false" priority="9" qformat="true" name="heading 6"&gt;   &lt;w:lsdexception locked="false" priority="9" qformat="true" name="heading 7"&gt;   &lt;w:lsdexception locked="false" priority="9" qformat="true" name="heading 8"&gt;   &lt;w:lsdexception locked="false" priority="9" qformat="true" name="heading 9"&gt;   &lt;w:lsdexception locked="false" priority="39" name="toc 1"&gt;   &lt;w:lsdexception locked="false" priority="39" name="toc 2"&gt;   &lt;w:lsdexception locked="false" priority="39" name="toc 3"&gt;   &lt;w:lsdexception locked="false" priority="39" name="toc 4"&gt;   &lt;w:lsdexception locked="false" priority="39" name="toc 5"&gt;   &lt;w:lsdexception locked="false" priority="39" name="toc 6"&gt;   &lt;w:lsdexception locked="false" priority="39" name="toc 7"&gt;   &lt;w:lsdexception locked="false" priority="39" name="toc 8"&gt;   &lt;w:lsdexception locked="false" priority="39" name="toc 9"&gt;   &lt;w:lsdexception locked="false" priority="35" qformat="true" name="caption"&gt;   &lt;w:lsdexception locked="false" priority="10" semihidden="false" unhidewhenused="false" qformat="true" name="Title"&gt;   &lt;w:lsdexception locked="false" priority="1" name="Default Paragraph Font"&gt;   &lt;w:lsdexception locked="false" priority="11" semihidden="false" unhidewhenused="false" qformat="true" name="Subtitle"&gt;   &lt;w:lsdexception locked="false" priority="0" name="Hyperlink"&gt;   &lt;w:lsdexception locked="false" priority="22" semihidden="false" unhidewhenused="false" qformat="true" name="Strong"&gt;   &lt;w:lsdexception locked="false" priority="20" semihidden="false" unhidewhenused="false" qformat="true" name="Emphasis"&gt;   &lt;w:lsdexception locked="false" priority="59" semihidden="false" unhidewhenused="false" name="Table Grid"&gt;   &lt;w:lsdexception locked="false" unhidewhenused="false" name="Placeholder Text"&gt;   &lt;w:lsdexception locked="false" priority="1" semihidden="false" unhidewhenused="false" qformat="true" name="No Spacing"&gt;   &lt;w:lsdexception locked="false" priority="60" semihidden="false" unhidewhenused="false" name="Light Shading"&gt;   &lt;w:lsdexception locked="false" priority="61" semihidden="false" unhidewhenused="false" name="Light List"&gt;   &lt;w:lsdexception locked="false" priority="62" semihidden="false" unhidewhenused="false" name="Light Grid"&gt;   &lt;w:lsdexception locked="false" priority="63" semihidden="false" unhidewhenused="false" name="Medium Shading 1"&gt;   &lt;w:lsdexception locked="false" priority="64" semihidden="false" unhidewhenused="false" name="Medium Shading 2"&gt;   &lt;w:lsdexception locked="false" priority="65" semihidden="false" unhidewhenused="false" name="Medium List 1"&gt;   &lt;w:lsdexception locked="false" priority="66" semihidden="false" unhidewhenused="false" name="Medium List 2"&gt;   &lt;w:lsdexception locked="false" priority="67" semihidden="false" unhidewhenused="false" name="Medium Grid 1"&gt;   &lt;w:lsdexception locked="false" priority="68" semihidden="false" unhidewhenused="false" name="Medium Grid 2"&gt;   &lt;w:lsdexception locked="false" priority="69" semihidden="false" unhidewhenused="false" name="Medium Grid 3"&gt;   &lt;w:lsdexception locked="false" priority="70" semihidden="false" unhidewhenused="false" name="Dark List"&gt;   &lt;w:lsdexception locked="false" priority="71" semihidden="false" unhidewhenused="false" name="Colorful Shading"&gt;   &lt;w:lsdexception locked="false" priority="72" semihidden="false" unhidewhenused="false" name="Colorful List"&gt;   &lt;w:lsdexception locked="false" priority="73" semihidden="false" unhidewhenused="false" name="Colorful Grid"&gt;   &lt;w:lsdexception locked="false" priority="60" semihidden="false" unhidewhenused="false" name="Light Shading Accent 1"&gt;   &lt;w:lsdexception locked="false" priority="61" semihidden="false" unhidewhenused="false" name="Light List Accent 1"&gt;   &lt;w:lsdexception locked="false" priority="62" semihidden="false" unhidewhenused="false" name="Light Grid Accent 1"&gt;   &lt;w:lsdexception locked="false" priority="63" semihidden="false" unhidewhenused="false" name="Medium Shading 1 Accent 1"&gt;   &lt;w:lsdexception locked="false" priority="64" semihidden="false" unhidewhenused="false" name="Medium Shading 2 Accent 1"&gt;   &lt;w:lsdexception locked="false" priority="65" semihidden="false" unhidewhenused="false" name="Medium List 1 Accent 1"&gt;   &lt;w:lsdexception locked="false" unhidewhenused="false" name="Revision"&gt;   &lt;w:lsdexception locked="false" priority="34" semihidden="false" unhidewhenused="false" qformat="true" name="List Paragraph"&gt;   &lt;w:lsdexception locked="false" priority="29" semihidden="false" unhidewhenused="false" qformat="true" name="Quote"&gt;   &lt;w:lsdexception locked="false" priority="30" semihidden="false" unhidewhenused="false" qformat="true" name="Intense Quote"&gt;   &lt;w:lsdexception locked="false" priority="66" semihidden="false" unhidewhenused="false" name="Medium List 2 Accent 1"&gt;   &lt;w:lsdexception locked="false" priority="67" semihidden="false" unhidewhenused="false" name="Medium Grid 1 Accent 1"&gt;   &lt;w:lsdexception locked="false" priority="68" semihidden="false" unhidewhenused="false" name="Medium Grid 2 Accent 1"&gt;   &lt;w:lsdexception locked="false" priority="69" semihidden="false" unhidewhenused="false" name="Medium Grid 3 Accent 1"&gt;   &lt;w:lsdexception locked="false" priority="70" semihidden="false" unhidewhenused="false" name="Dark List Accent 1"&gt;   &lt;w:lsdexception locked="false" priority="71" semihidden="false" unhidewhenused="false" name="Colorful Shading Accent 1"&gt;   &lt;w:lsdexception locked="false" priority="72" semihidden="false" unhidewhenused="false" name="Colorful List Accent 1"&gt;   &lt;w:lsdexception locked="false" priority="73" semihidden="false" unhidewhenused="false" name="Colorful Grid Accent 1"&gt;   &lt;w:lsdexception locked="false" priority="60" semihidden="false" unhidewhenused="false" name="Light Shading Accent 2"&gt;   &lt;w:lsdexception locked="false" priority="61" semihidden="false" unhidewhenused="false" name="Light List Accent 2"&gt;   &lt;w:lsdexception locked="false" priority="62" semihidden="false" unhidewhenused="false" name="Light Grid Accent 2"&gt;   &lt;w:lsdexception locked="false" priority="63" semihidden="false" unhidewhenused="false" name="Medium Shading 1 Accent 2"&gt;   &lt;w:lsdexception locked="false" priority="64" semihidden="false" unhidewhenused="false" name="Medium Shading 2 Accent 2"&gt;   &lt;w:lsdexception locked="false" priority="65" semihidden="false" unhidewhenused="false" name="Medium List 1 Accent 2"&gt;   &lt;w:lsdexception locked="false" priority="66" semihidden="false" unhidewhenused="false" name="Medium List 2 Accent 2"&gt;   &lt;w:lsdexception locked="false" priority="67" semihidden="false" unhidewhenused="false" name="Medium Grid 1 Accent 2"&gt;   &lt;w:lsdexception locked="false" priority="68" semihidden="false" unhidewhenused="false" name="Medium Grid 2 Accent 2"&gt;   &lt;w:lsdexception locked="false" priority="69" semihidden="false" unhidewhenused="false" name="Medium Grid 3 Accent 2"&gt;   &lt;w:lsdexception locked="false" priority="70" semihidden="false" unhidewhenused="false" name="Dark List Accent 2"&gt;   &lt;w:lsdexception locked="false" priority="71" semihidden="false" unhidewhenused="false" name="Colorful Shading Accent 2"&gt;   &lt;w:lsdexception locked="false" priority="72" semihidden="false" unhidewhenused="false" name="Colorful List Accent 2"&gt;   &lt;w:lsdexception locked="false" priority="73" semihidden="false" unhidewhenused="false" name="Colorful Grid Accent 2"&gt;   &lt;w:lsdexception locked="false" priority="60" semihidden="false" unhidewhenused="false" name="Light Shading Accent 3"&gt;   &lt;w:lsdexception locked="false" priority="61" semihidden="false" unhidewhenused="false" name="Light List Accent 3"&gt;   &lt;w:lsdexception locked="false" priority="62" semihidden="false" unhidewhenused="false" name="Light Grid Accent 3"&gt;   &lt;w:lsdexception locked="false" priority="63" semihidden="false" unhidewhenused="false" name="Medium Shading 1 Accent 3"&gt;   &lt;w:lsdexception locked="false" priority="64" semihidden="false" unhidewhenused="false" name="Medium Shading 2 Accent 3"&gt;   &lt;w:lsdexception locked="false" priority="65" semihidden="false" unhidewhenused="false" name="Medium List 1 Accent 3"&gt;   &lt;w:lsdexception locked="false" priority="66" semihidden="false" unhidewhenused="false" name="Medium List 2 Accent 3"&gt;   &lt;w:lsdexception locked="false" priority="67" semihidden="false" unhidewhenused="false" name="Medium Grid 1 Accent 3"&gt;   &lt;w:lsdexception locked="false" priority="68" semihidden="false" unhidewhenused="false" name="Medium Grid 2 Accent 3"&gt;   &lt;w:lsdexception locked="false" priority="69" semihidden="false" unhidewhenused="false" name="Medium Grid 3 Accent 3"&gt;   &lt;w:lsdexception locked="false" priority="70" semihidden="false" unhidewhenused="false" name="Dark List Accent 3"&gt;   &lt;w:lsdexception locked="false" priority="71" semihidden="false" unhidewhenused="false" name="Colorful Shading Accent 3"&gt;   &lt;w:lsdexception locked="false" priority="72" semihidden="false" unhidewhenused="false" name="Colorful List Accent 3"&gt;   &lt;w:lsdexception locked="false" priority="73" semihidden="false" unhidewhenused="false" name="Colorful Grid Accent 3"&gt;   &lt;w:lsdexception locked="false" priority="60" semihidden="false" unhidewhenused="false" name="Light Shading Accent 4"&gt;   &lt;w:lsdexception locked="false" priority="61" semihidden="false" unhidewhenused="false" name="Light List Accent 4"&gt;   &lt;w:lsdexception locked="false" priority="62" semihidden="false" unhidewhenused="false" name="Light Grid Accent 4"&gt;   &lt;w:lsdexception locked="false" priority="63" semihidden="false" unhidewhenused="false" name="Medium Shading 1 Accent 4"&gt;   &lt;w:lsdexception locked="false" priority="64" semihidden="false" unhidewhenused="false" name="Medium Shading 2 Accent 4"&gt;   &lt;w:lsdexception locked="false" priority="65" semihidden="false" unhidewhenused="false" name="Medium List 1 Accent 4"&gt;   &lt;w:lsdexception locked="false" priority="66" semihidden="false" unhidewhenused="false" name="Medium List 2 Accent 4"&gt;   &lt;w:lsdexception locked="false" priority="67" semihidden="false" unhidewhenused="false" name="Medium Grid 1 Accent 4"&gt;   &lt;w:lsdexception locked="false" priority="68" semihidden="false" unhidewhenused="false" name="Medium Grid 2 Accent 4"&gt;   &lt;w:lsdexception locked="false" priority="69" semihidden="false" unhidewhenused="false" name="Medium Grid 3 Accent 4"&gt;   &lt;w:lsdexception locked="false" priority="70" semihidden="false" unhidewhenused="false" name="Dark List Accent 4"&gt;   &lt;w:lsdexception locked="false" priority="71" semihidden="false" unhidewhenused="false" name="Colorful Shading Accent 4"&gt;   &lt;w:lsdexception locked="false" priority="72" semihidden="false" unhidewhenused="false" name="Colorful List Accent 4"&gt;   &lt;w:lsdexception locked="false" priority="73" semihidden="false" unhidewhenused="false" name="Colorful Grid Accent 4"&gt;   &lt;w:lsdexception locked="false" priority="60" semihidden="false" unhidewhenused="false" name="Light Shading Accent 5"&gt;   &lt;w:lsdexception locked="false" priority="61" semihidden="false" unhidewhenused="false" name="Light List Accent 5"&gt;   &lt;w:lsdexception locked="false" priority="62" semihidden="false" unhidewhenused="false" name="Light Grid Accent 5"&gt;   &lt;w:lsdexception locked="false" priority="63" semihidden="false" unhidewhenused="false" name="Medium Shading 1 Accent 5"&gt;   &lt;w:lsdexception locked="false" priority="64" semihidden="false" unhidewhenused="false" name="Medium Shading 2 Accent 5"&gt;   &lt;w:lsdexception locked="false" priority="65" semihidden="false" unhidewhenused="false" name="Medium List 1 Accent 5"&gt;   &lt;w:lsdexception locked="false" priority="66" semihidden="false" unhidewhenused="false" name="Medium List 2 Accent 5"&gt;   &lt;w:lsdexception locked="false" priority="67" semihidden="false" unhidewhenused="false" name="Medium Grid 1 Accent 5"&gt;   &lt;w:lsdexception locked="false" priority="68" semihidden="false" unhidewhenused="false" name="Medium Grid 2 Accent 5"&gt;   &lt;w:lsdexception locked="false" priority="69" semihidden="false" unhidewhenused="false" name="Medium Grid 3 Accent 5"&gt;   &lt;w:lsdexception locked="false" priority="70" semihidden="false" unhidewhenused="false" name="Dark List Accent 5"&gt;   &lt;w:lsdexception locked="false" priority="71" semihidden="false" unhidewhenused="false" name="Colorful Shading Accent 5"&gt;   &lt;w:lsdexception locked="false" priority="72" semihidden="false" unhidewhenused="false" name="Colorful List Accent 5"&gt;   &lt;w:lsdexception locked="false" priority="73" semihidden="false" unhidewhenused="false" name="Colorful Grid Accent 5"&gt;   &lt;w:lsdexception locked="false" priority="60" semihidden="false" unhidewhenused="false" name="Light Shading Accent 6"&gt;   &lt;w:lsdexception locked="false" priority="61" semihidden="false" unhidewhenused="false" name="Light List Accent 6"&gt;   &lt;w:lsdexception locked="false" priority="62" semihidden="false" unhidewhenused="false" name="Light Grid Accent 6"&gt;   &lt;w:lsdexception locked="false" priority="63" semihidden="false" unhidewhenused="false" name="Medium Shading 1 Accent 6"&gt;   &lt;w:lsdexception locked="false" priority="64" semihidden="false" unhidewhenused="false" name="Medium Shading 2 Accent 6"&gt;   &lt;w:lsdexception locked="false" priority="65" semihidden="false" unhidewhenused="false" name="Medium List 1 Accent 6"&gt;   &lt;w:lsdexception locked="false" priority="66" semihidden="false" unhidewhenused="false" name="Medium List 2 Accent 6"&gt;   &lt;w:lsdexception locked="false" priority="67" semihidden="false" unhidewhenused="false" name="Medium Grid 1 Accent 6"&gt;   &lt;w:lsdexception locked="false" priority="68" semihidden="false" unhidewhenused="false" name="Medium Grid 2 Accent 6"&gt;   &lt;w:lsdexception locked="false" priority="69" semihidden="false" unhidewhenused="false" name="Medium Grid 3 Accent 6"&gt;   &lt;w:lsdexception locked="false" priority="70" semihidden="false" unhidewhenused="false" name="Dark List Accent 6"&gt;   &lt;w:lsdexception locked="false" priority="71" semihidden="false" unhidewhenused="false" name="Colorful Shading Accent 6"&gt;   &lt;w:lsdexception locked="false" priority="72" semihidden="false" unhidewhenused="false" name="Colorful List Accent 6"&gt;   &lt;w:lsdexception locked="false" priority="73" semihidden="false" unhidewhenused="false" name="Colorful Grid Accent 6"&gt;   &lt;w:lsdexception locked="false" priority="19" semihidden="false" unhidewhenused="false" qformat="true" name="Subtle Emphasis"&gt;   &lt;w:lsdexception locked="false" priority="21" semihidden="false" unhidewhenused="false" qformat="true" name="Intense Emphasis"&gt;   &lt;w:lsdexception locked="false" priority="31" semihidden="false" unhidewhenused="false" qformat="true" name="Subtle Reference"&gt;   &lt;w:lsdexception locked="false" priority="32" semihidden="false" unhidewhenused="false" qformat="true" name="Intense Reference"&gt;   &lt;w:lsdexception locked="false" priority="33" semihidden="false" unhidewhenused="false" qformat="true" name="Book Title"&gt;   &lt;w:lsdexception locked="false" priority="37" name="Bibliography"&gt;   &lt;w:lsdexception locked="false" priority="39" qformat="true" name="TOC Heading"&gt;  &lt;/w:LatentStyles&gt; &lt;/xml&gt;&lt;![endif]--&gt;&lt;style&gt; &lt;!--  /* Font Definitions */  @font-face 	{font-family:"Cambria Math"; 	panose-1:2 4 5 3 5 4 6 3 2 4; 	mso-font-charset:1; 	mso-generic-font-family:roman; 	mso-font-format:other; 	mso-font-pitch:variable; 	mso-font-signature:0 0 0 0 0 0;}  /* Style Definitions */  p.MsoNormal, li.MsoNormal, div.MsoNormal 	{mso-style-unhide:no; 	mso-style-qformat:yes; 	mso-style-parent:""; 	margin:0cm; 	margin-bottom:.0001pt; 	mso-pagination:widow-orphan; 	font-size:12.0pt; 	font-family:"Times New Roman","serif"; 	mso-fareast-font-family:"Times New Roman";} a:link, span.MsoHyperlink 	{mso-style-unhide:no; 	color:blue; 	text-decoration:underline; 	text-underline:single;} a:visited, span.MsoHyperlinkFollowed 	{mso-style-noshow:yes; 	mso-style-priority:99; 	color:purple; 	mso-themecolor:followedhyperlink; 	text-decoration:underline; 	text-underline:single;} .MsoChpDefault 	{mso-style-type:export-only; 	mso-default-props:yes; 	font-size:10.0pt; 	mso-ansi-font-size:10.0pt; 	mso-bidi-font-size:10.0pt;} @page Section1 	{size:595.3pt 841.9pt; 	margin:70.85pt 3.0cm 70.85pt 3.0cm; 	mso-header-margin:35.4pt; 	mso-footer-margin:35.4pt; 	mso-paper-source:0;} div.Section1 	{page:Section1;} --&gt; &lt;/style&gt;&lt;!--[if gte mso 10]&gt; &lt;style&gt;  /* Style Definitions */  table.MsoNormalTable 	{mso-style-name:"Tabela normal"; 	mso-tstyle-rowband-size:0; 	mso-tstyle-colband-size:0; 	mso-style-noshow:yes; 	mso-style-priority:99; 	mso-style-qformat:yes; 	mso-style-parent:""; 	mso-padding-alt:0cm 5.4pt 0cm 5.4pt; 	mso-para-margin:0cm; 	mso-para-margin-bottom:.0001pt; 	mso-pagination:widow-orphan; 	font-size:11.0pt; 	font-family:"Calibri","sans-serif"; 	mso-ascii-font-family:Calibri; 	mso-ascii-theme-font:minor-latin; 	mso-fareast-font-family:"Times New Roman"; 	mso-fareast-theme-font:minor-fareast; 	mso-hansi-font-family:Calibri; 	mso-hansi-theme-font:minor-latin; 	mso-bidi-font-family:"Times New Roman"; 	mso-bidi-theme-font:minor-bidi;} &lt;/style&gt; &lt;![endif]--&gt;  &lt;p class="MsoNormal"  style="text-align: justify; text-indent: 35.4pt; font-weight: bold;font-family:trebuchet ms;"&gt;&lt;span style="font-size:100%;"&gt;A fenicetonúria é tratada com base em uma dieta restrita em fenilalanina, em bebês de até um ano de vida são considerados adequados níveis de fenilalanina entre 2 mg/dL e 6mg/dL então no tratamento convencional recomenda-se a suspensão do aleitamento materno.&lt;o:p&gt;&lt;/o:p&gt;&lt;/span&gt;&lt;/p&gt;  &lt;p class="MsoNormal"  style="text-align: justify; text-indent: 35.4pt; font-weight: bold;font-family:trebuchet ms;"&gt;&lt;span style="font-size:100%;"&gt;Conhecendo a importância da amamentação para a saúde dos bebês estudos foram feitos para avaliar os efeitos do leite materno usado como fonte de fenilalanina em bebês. &lt;o:p&gt;&lt;/o:p&gt;&lt;/span&gt;&lt;/p&gt;  &lt;p class="MsoNormal"  style="text-align: justify; text-indent: 35.4pt; font-weight: bold;font-family:trebuchet ms;"&gt;&lt;span style="font-size:100%;"&gt;No estudo foram avaliados 35 lactentes mantidos em &lt;span style="color: rgb(204, 51, 204);"&gt;aleitamento materno &lt;/span&gt;e outros 35 submetidos ao tratamento tradicional. Eram dados aos bebês mamadeiras a cada 3 horas e leite materno em livre demanda.&lt;o:p&gt;&lt;/o:p&gt;&lt;/span&gt;&lt;/p&gt;  &lt;p class="MsoNormal"  style="text-align: justify; text-indent: 35.4pt; font-weight: bold;font-family:trebuchet ms;"&gt;&lt;span style="font-size:100%;"&gt;Na avaliação dos resultados constatou-se não haver diferenças significativas entre o grupo de lactentes amamentado e o grupo controle quanto aos níveis sanguíneos de fenilalanina e os índices peso/idade e estatura/idade, sendo possível, portanto a manutenção do aleitamento materno.&lt;o:p&gt;&lt;/o:p&gt;&lt;/span&gt;&lt;/p&gt;  &lt;p class="MsoNormal"  style="text-align: justify; text-indent: 35.4pt; font-weight: bold;font-family:trebuchet ms;"&gt;&lt;span style="font-size:100%;"&gt;&lt;i style=""&gt;Apesar de ter o intuito de preservar o hábito da amamentação o artigo poderia salientar quais as vantagens que os bebês e as mães teriam com a amamentação. Então se quiserem mais informações sobre &lt;span style=""&gt; &lt;/span&gt;as vantagens da amamentação para os bebês acesse o link &lt;a href="http://www.pgr.mpf.gov.br/pgr/saude/nutricao/impamamentacao.htm"&gt;http://www.pgr.mpf.gov.br/pgr/saude/nutricao/impamamentacao.htm&lt;/a&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;  &lt;p class="MsoNormal"  style="text-align: justify; font-weight: bold;font-family:trebuchet ms;"&gt;&lt;span style="font-size:100%;"&gt;&lt;o:p&gt; &lt;/o:p&gt;&lt;/span&gt;&lt;/p&gt;&lt;span style="font-size:100%;"&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a onblur="try {parent.deselectBloggerImageGracefully();} catch(e) {}" href="http://3.bp.blogspot.com/_btpyAerDQPU/SRhcUDHUmxI/AAAAAAAAAM4/AooXn7n2O8A/s1600-h/mae+e+bebe.jpg"&gt;&lt;img style="margin: 0px auto 10px; display: block; text-align: center; cursor: pointer; width: 320px; height: 238px;" src="http://3.bp.blogspot.com/_btpyAerDQPU/SRhcUDHUmxI/AAAAAAAAAM4/AooXn7n2O8A/s320/mae+e+bebe.jpg" alt="" id="BLOGGER_PHOTO_ID_5267061263712951058" border="0" /&gt;&lt;/a&gt;&lt;/span&gt;&lt;span style="font-weight: bold; font-style: italic; color: rgb(102, 0, 204);font-family:trebuchet ms;font-size:100%;"  &gt;by: Jersica Oliveira&lt;/span&gt;&lt;br /&gt;&lt;br /&gt;&lt;span style="font-weight: bold;"&gt;Fonte:&lt;/span&gt;&lt;span style="font-weight: bold;"&gt; &lt;/span&gt;&lt;span style="color: rgb(51, 51, 255); font-weight: bold;font-size:100%;" &gt;&lt;a rel="nofollow" target="_blank"&gt;&lt;span style="font-family:Times New Roman;"&gt;http://www.scielo.br/scielo.php?pid=S0021-75572007000600009&amp;amp;script=sci_arttext&amp;amp;tlng=pt&lt;/span&gt;&lt;/a&gt;&lt;br /&gt;&lt;/span&gt;&lt;br /&gt;&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/46256947993340856-4627569449665546287?l=biobio-pku.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://biobio-pku.blogspot.com/feeds/4627569449665546287/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=46256947993340856&amp;postID=4627569449665546287' title='1 Comentários'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/46256947993340856/posts/default/4627569449665546287'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/46256947993340856/posts/default/4627569449665546287'/><link rel='alternate' type='text/html' href='http://biobio-pku.blogspot.com/2008/11/aleitamento-materno.html' title='Aleitamento Materno'/><author><name>Grupo de PKU</name><uri>http://www.blogger.com/profile/13253571819442069873</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><media:thumbnail xmlns:media='http://search.yahoo.com/mrss/' url='http://3.bp.blogspot.com/_btpyAerDQPU/SRhcZUNrJLI/AAAAAAAAANA/2UUMOvAZE34/s72-c/aleitamento2.jpg' height='72' width='72'/><thr:total>1</thr:total></entry><entry><id>tag:blogger.com,1999:blog-46256947993340856.post-223427482844246955</id><published>2008-11-08T14:51:00.000-08:00</published><updated>2008-11-08T14:58:17.702-08:00</updated><title type='text'>Tratamento com Remédios</title><content type='html'>&lt;a onblur="try {parent.deselectBloggerImageGracefully();} catch(e) {}" href="http://2.bp.blogspot.com/_btpyAerDQPU/SRYYnYNwLcI/AAAAAAAAAMw/1q0fnvdh9cQ/s1600-h/NeoPheweb2.png"&gt;&lt;img style="margin: 0px auto 10px; display: block; text-align: center; cursor: pointer; width: 240px; height: 263px;" src="http://2.bp.blogspot.com/_btpyAerDQPU/SRYYnYNwLcI/AAAAAAAAAMw/1q0fnvdh9cQ/s320/NeoPheweb2.png" alt="" id="BLOGGER_PHOTO_ID_5266423879050472898" border="0" /&gt;&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;div style="text-align: justify;"&gt;&lt;span style="font-weight: bold;font-family:trebuchet ms;font-size:100%;"  &gt;&lt;span style="font-style: italic; color: rgb(102, 0, 204);"&gt;Além da dietoterapia normal com dieta pobre em&lt;/span&gt;&lt;/span&gt;&lt;span style="font-weight: bold;font-family:trebuchet ms;font-size:100%;"  &gt;&lt;span style="font-style: italic; color: rgb(102, 0, 204);"&gt; fenilalanina e as fórmulas, há também um tratamento com remédios que a cada dia vem sendo mais estudados. É o PreKUnil, um suplemento dietético. &lt;/span&gt;&lt;/span&gt;&lt;br /&gt;&lt;/div&gt;&lt;span style="font-weight: bold;font-family:trebuchet ms;font-size:100%;"  &gt;&lt;span style="font-style: italic; color: rgb(102, 0, 204);"&gt;&lt;br /&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;div style="text-align: justify;"&gt;&lt;span style="font-weight: bold; font-family: trebuchet ms;font-family:trebuchet ms;font-size:100%;"  &gt; &lt;span style="color: rgb(102, 0, 204);font-size:180%;" &gt;“&lt;/span&gt;São comprimidos que contém uma quantidade e&lt;/span&gt;&lt;span style="font-weight: bold; font-family: trebuchet ms;font-family:trebuchet ms;font-size:100%;"  &gt;levada de triptofano e tirosina, precursores da serotonina, dopamina e norepinefrina. Mediante a inibição competitiva, combatem o aumento da fenilalanina que chega nas células nervosas, reduzindo deste modo, o efeito prejudicial na produção de neurotransmissores. Eles também contêm quantidades suplementares de sete aminoácidos essenciais (2). A dose adequada é calcul&lt;/span&gt;&lt;span style="font-weight: bold; font-family: trebuchet ms;font-family:trebuchet ms;font-size:100%;"  &gt;ada de acordo com o peso do paciente, sendo este multiplicado pelo fator 0.388. Afirmam seus idealizadores que esta forma de tratamento permite uma ação menos radical nos hábitos alimentares no início do tratamento, de tal modo, que determinada quantidades de alimentos ricos em proteínas, como a carne, podem ser mantidos.&lt;span style="color: rgb(102, 0, 204);font-size:180%;" &gt;”&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: trebuchet ms;font-size:100%;" &gt;&lt;br /&gt;&lt;/span&gt;&lt;br /&gt;&lt;br /&gt;&lt;a onblur="try {parent.deselectBloggerImageGracefully();} catch(e) {}" href="http://3.bp.blogspot.com/_btpyAerDQPU/SRYYWF9OojI/AAAAAAAAAMo/8UJZE9IAiHM/s1600-h/PHOTO_479406_6450_214324_main.jpg"&gt;&lt;img style="margin: 0px auto 10px; display: block; text-align: center; cursor: pointer; width: 200px; height: 227px;" src="http://3.bp.blogspot.com/_btpyAerDQPU/SRYYWF9OojI/AAAAAAAAAMo/8UJZE9IAiHM/s320/PHOTO_479406_6450_214324_main.jpg" alt="" id="BLOGGER_PHOTO_ID_5266423582091551282" border="0" /&gt;&lt;/a&gt;&lt;span style="font-size:100%;"&gt;&lt;br /&gt;&lt;br /&gt;&lt;/span&gt;&lt;span style="font-weight: bold;font-family:trebuchet ms;font-size:100%;"  &gt;Esses comprimidos são utilizados na Dinamarca há 13 anos, sendo constatado êxito com 68 adolescentes que garantem ter, a partir deste tratamento, uma vida normal sem a necessidade de uma dieta tão rigorosa na restrição de pr&lt;/span&gt;&lt;span style="font-weight: bold;font-family:trebuchet ms;font-size:100%;"  &gt;oteínas.&lt;/span&gt;&lt;span style="font-size:100%;"&gt;&lt;br /&gt;&lt;/span&gt;&lt;span style="font-weight: bold;font-family:trebuchet ms;font-size:100%;"  &gt;Serão feitos estudos com fenilcetonúricos diagnosticados tardiamente e submetidos a um tratamento com PreKUnil na Universidade Federal de Viçosa em parceria com a Universidade Federal do Paraná&lt;/span&gt;&lt;span style="font-size:100%;"&gt;.&lt;br /&gt;&lt;/span&gt;&lt;br /&gt;&lt;br /&gt;&lt;span style="font-weight: bold; font-style: italic; color: rgb(204, 51, 204);"&gt;by: Amanda Biete&lt;/span&gt;&lt;br /&gt;&lt;br /&gt;Fonte: &lt;a href="http://www.ufv.br/dbg/trab2002/DHG/DHG009.htm" target="_blank"&gt;http://www.ufv.br/dbg/&lt;wbr&gt;trab2002/DHG/DHG009.htm&lt;/a&gt;&lt;/div&gt;&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/46256947993340856-223427482844246955?l=biobio-pku.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://biobio-pku.blogspot.com/feeds/223427482844246955/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=46256947993340856&amp;postID=223427482844246955' title='15 Comentários'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/46256947993340856/posts/default/223427482844246955'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/46256947993340856/posts/default/223427482844246955'/><link rel='alternate' type='text/html' href='http://biobio-pku.blogspot.com/2008/11/tratamento-com-remdios.html' title='Tratamento com Remédios'/><author><name>Grupo de PKU</name><uri>http://www.blogger.com/profile/13253571819442069873</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><media:thumbnail xmlns:media='http://search.yahoo.com/mrss/' url='http://2.bp.blogspot.com/_btpyAerDQPU/SRYYnYNwLcI/AAAAAAAAAMw/1q0fnvdh9cQ/s72-c/NeoPheweb2.png' height='72' width='72'/><thr:total>15</thr:total></entry><entry><id>tag:blogger.com,1999:blog-46256947993340856.post-6034307385716317287</id><published>2008-11-08T14:11:00.000-08:00</published><updated>2009-07-10T05:18:56.417-07:00</updated><title type='text'>Dietoterapia</title><content type='html'>&lt;a onblur="try {parent.deselectBloggerImageGracefully();} catch(e) {}" href="http://2.bp.blogspot.com/_btpyAerDQPU/SRYUdB3pVlI/AAAAAAAAAMg/qSCEnvYfvJs/s1600-h/maca.jpg"&gt;&lt;img style="TEXT-ALIGN: center; MARGIN: 0px auto 10px; WIDTH: 320px; DISPLAY: block; HEIGHT: 240px; CURSOR: pointer" id="BLOGGER_PHOTO_ID_5266419303206966866" border="0" alt="" src="http://2.bp.blogspot.com/_btpyAerDQPU/SRYUdB3pVlI/AAAAAAAAAMg/qSCEnvYfvJs/s320/maca.jpg" /&gt;&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;meta content="text/html; charset=utf-8" equiv="Content-Type"&gt;&lt;meta name="ProgId" content="Word.Document"&gt;&lt;meta name="Generator" content="Microsoft Word 9"&gt;&lt;meta name="Originator" content="Microsoft Word 9"&gt;&lt;link rel="File-List" href="file:///C:/DOCUME%7E1/Marina/CONFIG%7E1/Temp/msoclip1/01/clip_filelist.xml"&gt;&lt;style&gt; &lt;!--  /* Style Definitions */ p.MsoNormal, li.MsoNormal, div.MsoNormal 	{mso-style-parent:""; 	margin:0cm; 	margin-bottom:.0001pt; 	mso-pagination:widow-orphan; 	font-size:12.0pt; 	font-family:"Times New Roman"; 	mso-fareast-font-family:"Times New Roman";} @page Section1 	{size:612.0pt 792.0pt; 	margin:70.85pt 3.0cm 70.85pt 3.0cm; 	mso-header-margin:35.4pt; 	mso-footer-margin:35.4pt; 	mso-paper-source:0;} div.Section1 	{page:Section1;} --&gt; &lt;/style&gt;&lt;br /&gt;&lt;p class="MsoNormal"&gt;&lt;p style="FONT-WEIGHT: bold;font-family:trebuchet ms;" class="MsoNormal" &gt;&lt;span style="font-size:100%;"&gt;&lt;?xml:namespace prefix = o /&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/span&gt;&lt;/p&gt;&lt;span style="font-size:100%;"&gt;Em razão de não metabolizarem fenilalanina, os fenilcetonúricos devem ter um cuidado todo especial com a sua alimentação, não comendo alimentos que contenham este aminoácido. Sua dieta é bastante rigorosa, sendo restritos alimentos ricos em proteínas, como carne, ovos, pão, leguminosas (feijão, soja, etc.), alguns cereais (trigo, milho, etc.) e também evitar o leite e seus derivados. O consumo de lipídeos e carboidratos de origem vegetal pode ser livre.&lt;/span&gt; &lt;p&gt;&lt;/p&gt;&lt;p style="TEXT-ALIGN: justify; FONT-WEIGHT: boldfont-family:trebuchet ms;" class="MsoNormal" &gt;&lt;span style="font-size:100%;"&gt;Apesar dessas restrições, os fenilcetonúricos devem ingerir quantidades pequenas de fenilalanina para não adquirir uma síndrome carencial. Por isso, devem comer frutas e hortaliças que contêm este aminoácido em pouca quantidade.&lt;br /&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="TEXT-ALIGN: justify; FONT-FAMILY: trebuchet ms; FONT-WEIGHT: bold"&gt;&lt;/div&gt;&lt;p style="TEXT-ALIGN: justify; FONT-WEIGHT: boldfont-family:trebuchet ms;" class="MsoNormal" &gt;&lt;span style="font-size:100%;"&gt;Esse cuidado com a alimentação é essencial, visto que é assim que o fenilcetonúrico garante seu desenvolvimento mental e seu crescimento saudável. &lt;/span&gt;&lt;/p&gt;&lt;div style="TEXT-ALIGN: justify; FONT-FAMILY: trebuchet ms; FONT-WEIGHT: bold"&gt;&lt;/div&gt;&lt;p style="TEXT-ALIGN: justify; FONT-WEIGHT: boldfont-family:trebuchet ms;" class="MsoNormal" &gt;&lt;span style="font-size:100%;"&gt;Para os pais é um trabalho a mais, pois enquanto bebê é fácil controlar a ingestão de alimentos do seu filho, porém o problema vem mais à frente: a adolescência! Por isso é importante a conscientização do afetado, pois ele, sem seguir o tratamento, certamente, desenvolverá os sintomas característicos da doença.&lt;/span&gt;&lt;/p&gt;&lt;p style="TEXT-ALIGN: justify; FONT-WEIGHT: boldfont-family:trebuchet ms;" class="MsoNormal" &gt;&lt;br /&gt;&lt;/p&gt;&lt;p style="TEXT-ALIGN: justify; FONT-WEIGHT: boldfont-family:trebuchet ms;" class="MsoNormal" &gt;&lt;span style="font-size:100%;"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="TEXT-ALIGN: justify; FONT-WEIGHT: boldfont-family:trebuchet ms;" class="MsoNormal" &gt;&lt;a onblur="try {parent.deselectBloggerImageGracefully();} catch(e) {}" href="http://3.bp.blogspot.com/_btpyAerDQPU/SRYTx8G7vLI/AAAAAAAAAMY/BuYPs9F34x8/s1600-h/809.jpg"&gt;&lt;img style="TEXT-ALIGN: center; MARGIN: 0px auto 10px; WIDTH: 200px; DISPLAY: block; HEIGHT: 260px; CURSOR: pointer" id="BLOGGER_PHOTO_ID_5266418562926099634" border="0" alt="" src="http://3.bp.blogspot.com/_btpyAerDQPU/SRYTx8G7vLI/AAAAAAAAAMY/BuYPs9F34x8/s320/809.jpg" /&gt;&lt;/a&gt;&lt;/p&gt;&lt;div style="TEXT-ALIGN: justify; FONT-FAMILY: trebuchet ms; FONT-WEIGHT: bold"&gt;&lt;/div&gt;&lt;p style="TEXT-ALIGN: justify; FONT-WEIGHT: bold" class="MsoNormal" face="trebuchet ms"&gt;&lt;p style="TEXT-ALIGN: justify; FONT-WEIGHT: bold" class="MsoNormal" face="trebuchet ms"&gt;&lt;span style="font-size:100%;"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="TEXT-ALIGN: justify; FONT-FAMILY: trebuchet ms; FONT-WEIGHT: bold"&gt;&lt;/div&gt;&lt;span style="font-size:100%;"&gt;&lt;br /&gt;&lt;/span&gt;&lt;p&gt;&lt;/p&gt;&lt;p style="TEXT-ALIGN: justify; FONT-FAMILY: trebuchet ms; FONT-WEIGHT: bold" class="MsoNormal"&gt;&lt;span style="font-size:100%;"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="TEXT-ALIGN: justify; FONT-FAMILY: trebuchet ms; FONT-WEIGHT: bold" class="MsoNormal"&gt;&lt;span style="font-size:100%;"&gt;Além da restrição de alimentos ricos em phe, também é necessário o uso de fórmulas que além de não conterem fenilalanina, contém uma mistura de aminoácido&lt;/span&gt;&lt;span style="font-size:100%;"&gt;s, vitaminas, minerais, gordura e oligoelementos. Essas fórmulas são de acordo com a idade do fenilcetonúrico, havendo fórmulas para menores de 1 ano de idade, para maiores de 1 ano e até fórmulas que podem ser usadas sem distinção de idade.&lt;/span&gt;&lt;/p&gt;&lt;p style="TEXT-ALIGN: justify;font-family:trebuchet ms;" class="MsoNormal" &gt;&lt;span style="font-size:100%;"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="TEXT-ALIGN: justify;font-family:trebuchet ms;" class="MsoNormal" &gt;&lt;span style="font-size:100%;"&gt;&lt;a onblur="try {parent.deselectBloggerImageGracefully();} catch(e) {}" href="http://2.bp.blogspot.com/_btpyAerDQPU/SRYPAlifU0I/AAAAAAAAALY/_02F2WcPFXE/s1600-h/pku_2.jpg"&gt;&lt;img style="TEXT-ALIGN: center; MARGIN: 0px auto 10px; WIDTH: 200px; DISPLAY: block; HEIGHT: 200px; CURSOR: pointer" id="BLOGGER_PHOTO_ID_5266413317007561538" border="0" alt="" src="http://2.bp.blogspot.com/_btpyAerDQPU/SRYPAlifU0I/AAAAAAAAALY/_02F2WcPFXE/s320/pku_2.jpg" /&gt;&lt;/a&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="TEXT-ALIGN: justify"&gt;&lt;/div&gt;&lt;p style="TEXT-ALIGN: justify" class="MsoNormal"&gt;&lt;o:p&gt;&lt;/o:p&gt; &lt;/p&gt;&lt;div style="TEXT-ALIGN: justify"&gt;&lt;/div&gt;&lt;p style="TEXT-ALIGN: justify" class="MsoNormal"&gt;&lt;span style="font-family:trebuchet ms;font-size:100%;"&gt;&lt;span style="FONT-WEIGHT: bold"&gt;Hoje, há uma imensa variedade de produtos especiais para fenilcetonúricos, ou seja, pobres em phe, que tem por finalidade “amenizar” a restrição feita pra diversos alimentos. Temos como exemplos: molhos, farinha de trigo, macarrão e até chocolate!&lt;/span&gt;&lt;/span&gt;&lt;a onblur="try {parent.deselectBloggerImageGracefully();} catch(e) {}" href="http://2.bp.blogspot.com/_btpyAerDQPU/SRYPVExZX4I/AAAAAAAAALg/l1Igv9boxSE/s1600-h/SACHET+-+Milupa+PKU+2+Tomato.jpg"&gt;&lt;img style="TEXT-ALIGN: center; MARGIN: 0px auto 10px; WIDTH: 118px; DISPLAY: block; HEIGHT: 320px; CURSOR: pointer" id="BLOGGER_PHOTO_ID_5266413668988968834" border="0" alt="" src="http://2.bp.blogspot.com/_btpyAerDQPU/SRYPVExZX4I/AAAAAAAAALg/l1Igv9boxSE/s320/SACHET+-+Milupa+PKU+2+Tomato.jpg" /&gt;&lt;/a&gt;&lt;/p&gt;&lt;p style="TEXT-ALIGN: justify" class="MsoNormal"&gt;&lt;br /&gt;&lt;/p&gt;&lt;p style="TEXT-ALIGN: justify" class="MsoNormal"&gt;&lt;span style="COLOR: rgb(204,51,204); FONT-WEIGHT: bold"&gt;by: Amanda Biete&lt;/span&gt;&lt;br /&gt;&lt;/p&gt;&lt;p style="TEXT-ALIGN: justify" class="MsoNormal"&gt;&lt;br /&gt;&lt;/p&gt;&lt;p style="TEXT-ALIGN: justify" class="MsoNormal"&gt;&lt;span style="COLOR: rgb(102,51,255); FONT-WEIGHT: bold"&gt;Fontes&lt;/span&gt;&lt;a onblur="try {parent.deselectBloggerImageGracefully();} catch(e) {}" href="http://2.bp.blogspot.com/_btpyAerDQPU/SRYPnJSRG6I/AAAAAAAAAL4/eUZKb20WCWk/s1600-h/rilla_choco1.jpg"&gt;: &lt;/a&gt;&lt;a href="http://www.ufv.br/dbg/trab2002/DHG/DHG009.htm" target="_blank"&gt;http://www.ufv.br/dbg/&lt;wbr&gt;trab2002/DHG/DHG009.htm&lt;/a&gt;&lt;/p&gt;&lt;p style="TEXT-ALIGN: justify" class="MsoNormal"&gt;&lt;a href="http://www.ufv.br/dbg/trab2002/DHG/DHG009.htm" target="_blank"&gt;&lt;/a&gt;&lt;a href="http://www.drashirleydecampos.com.br/noticias/10383"&gt;http://www.drashirleydecampos.com.br/noticias/10383&lt;/a&gt;&lt;/p&gt;&lt;p style="TEXT-ALIGN: justify" class="MsoNormal"&gt;&lt;a href="http://www.nib.unicamp.br/fenilbrasil/protocol.htm"&gt;"Protocolo Clínico e Diretrizes Terapêuticas da Fenilcetonúria"&lt;/a&gt; (Ministério da Saúde)&lt;/p&gt;&lt;p class="MsoNormal"&gt;&lt;o:p&gt;&lt;/o:p&gt; &lt;/p&gt;&lt;p style="TEXT-ALIGN: justify" class="MsoNormal"&gt;&lt;span lang="ES-TRAD"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/span&gt; &lt;/p&gt;&lt;br /&gt;&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/46256947993340856-6034307385716317287?l=biobio-pku.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://biobio-pku.blogspot.com/feeds/6034307385716317287/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=46256947993340856&amp;postID=6034307385716317287' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/46256947993340856/posts/default/6034307385716317287'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/46256947993340856/posts/default/6034307385716317287'/><link rel='alternate' type='text/html' href='http://biobio-pku.blogspot.com/2008/11/dietoterapia.html' title='Dietoterapia'/><author><name>Grupo de PKU</name><uri>http://www.blogger.com/profile/13253571819442069873</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><media:thumbnail xmlns:media='http://search.yahoo.com/mrss/' url='http://2.bp.blogspot.com/_btpyAerDQPU/SRYUdB3pVlI/AAAAAAAAAMg/qSCEnvYfvJs/s72-c/maca.jpg' height='72' width='72'/><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-46256947993340856.post-857659617088766691</id><published>2008-11-07T07:03:00.001-08:00</published><updated>2008-11-08T15:00:56.440-08:00</updated><title type='text'>Isto É (Reportagem)</title><content type='html'>&lt;div style="text-align: justify;"&gt;&lt;span style="font-weight: bold; font-style: italic; color: rgb(102, 0, 204);"&gt; Olá pessoal estou postando uma matéria bastante interessante tirada do site da revista IstoÉ- Independente que mostra como uma mãe reagiu ao saber que o filho tinha fenilcetonúria e como algumas pessoas foram preconceituosas em relação a isso. Vale a pena conferir!&lt;/span&gt;&lt;br /&gt;&lt;/div&gt;&lt;br /&gt;&lt;a onblur="try {parent.deselectBloggerImageGracefully();} catch(e) {}" href="http://3.bp.blogspot.com/_btpyAerDQPU/SQxjsxulHdI/AAAAAAAAAIo/GVGD7BvhMCk/s1600-h/semvergonhadeserdoente2_74.jpg"&gt;&lt;br /&gt;&lt;/a&gt;&lt;div id=":l1" class="ArwC7c ckChnd"&gt;&lt;p style="margin-bottom: 0cm;"&gt;&lt;a onblur="try {parent.deselectBloggerImageGracefully();} catch(e) {}" href="http://1.bp.blogspot.com/_btpyAerDQPU/SRRY171jI_I/AAAAAAAAAKQ/POZSMU9r7uE/s1600-h/semvergonhadeserdoente2_74.jpg"&gt;&lt;img style="margin: 0px auto 10px; display: block; text-align: center; cursor: pointer; width: 172px; height: 215px;" src="http://1.bp.blogspot.com/_btpyAerDQPU/SRRY171jI_I/AAAAAAAAAKQ/POZSMU9r7uE/s320/semvergonhadeserdoente2_74.jpg" alt="" id="BLOGGER_PHOTO_ID_5265931547921556466" border="0" /&gt;&lt;/a&gt;&lt;/p&gt;&lt;p style="margin-bottom: 0cm; text-align: justify; font-family: trebuchet ms;"&gt;&lt;span style="font-size:100%;"&gt;"Sem vergonha de ser doente&lt;br /&gt;Pacientes assumem mais facilmente sua condição. Dessa maneira, ganham novo fôlego contra a doença.&lt;br /&gt;&lt;br /&gt;Um dos maiores choques sofridos até hoje por Marta Kokron, 40 anos, foi ouvir de algumas pessoas que seria melhor esconder que seu filho Thomas, então um bebê, era portador de fenilcetonúria. Caracterizada pela incapacidade de o corpo metabolizar o aminoácido fenilalanina, a doença pode levar à deficiência mental se não for controlada. Obviamente, ela não deu ouvidos ao que escutou. Ao contrário, tratou de falar claramente sobre o problema não só com o filho como também com familiares, amigos e sociedade em geral. O resultado é que o menino, hoje um belo garoto de nove anos, tornou-se um símbolo de que é possível viver bem, apesar da enfermidade. Thomas aparece, por exemplo, na capa dos folhetos do Instituto Canguru – instituição de apoio aos pacientes de doenças metabólicas e seus familiares –, fazendo um emblemático sinal de positivo com as mãos."&lt;br /&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin-bottom: 0cm; font-family: trebuchet ms;"&gt;&lt;span style="font-size:100%;"&gt;Clique aqui e veja a matéria na íntegra:&lt;a href="http://www.terra.com.br/istoe/edicoes/1976/artigo60828-1.htm"&gt;  &lt;/a&gt;&lt;a href="http://www.terra.com.br/istoe/edicoes/1976/artigo60828-1.htm" target="_blank"&gt;http://www.terra.com.br/istoe/&lt;wbr&gt;edicoes/1976/artigo60828-1.htm&lt;/a&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-bottom: 0cm; font-family: trebuchet ms;"&gt;&lt;span style="font-size:100%;"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-bottom: 0cm;"&gt;&lt;span style="font-weight: bold; color: rgb(204, 51, 204); font-family: trebuchet ms;font-size:100%;" &gt;by: Camila Biete&lt;/span&gt;&lt;br /&gt;&lt;/p&gt;&lt;p style="margin-bottom: 0cm;"&gt;&lt;a href="http://www.terra.com.br/istoe/edicoes/1976/artigo60828-1.htm" target="_blank"&gt;&lt;br /&gt;&lt;/a&gt;&lt;/p&gt; &lt;/div&gt;&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/46256947993340856-857659617088766691?l=biobio-pku.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://biobio-pku.blogspot.com/feeds/857659617088766691/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=46256947993340856&amp;postID=857659617088766691' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/46256947993340856/posts/default/857659617088766691'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/46256947993340856/posts/default/857659617088766691'/><link rel='alternate' type='text/html' href='http://biobio-pku.blogspot.com/2008/11/isto-reportagem.html' title='Isto É (Reportagem)'/><author><name>Grupo de PKU</name><uri>http://www.blogger.com/profile/13253571819442069873</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><media:thumbnail xmlns:media='http://search.yahoo.com/mrss/' url='http://1.bp.blogspot.com/_btpyAerDQPU/SRRY171jI_I/AAAAAAAAAKQ/POZSMU9r7uE/s72-c/semvergonhadeserdoente2_74.jpg' height='72' width='72'/><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-46256947993340856.post-1030901928993892882</id><published>2008-11-05T02:29:00.000-08:00</published><updated>2008-11-10T08:55:21.730-08:00</updated><title type='text'>“Aspartame: um doce veneno ?” (Curiosidades)</title><content type='html'>&lt;a onblur="try {parent.deselectBloggerImageGracefully();} catch(e) {}" href="http://4.bp.blogspot.com/_btpyAerDQPU/SRF3ORMTJQI/AAAAAAAAAKA/MtJxVw9oDJs/s1600-h/cocaaa.jpg"&gt;&lt;img style="margin: 0px auto 10px; display: block; text-align: center; cursor: pointer; width: 262px; height: 320px;" src="http://4.bp.blogspot.com/_btpyAerDQPU/SRF3ORMTJQI/AAAAAAAAAKA/MtJxVw9oDJs/s320/cocaaa.jpg" alt="" id="BLOGGER_PHOTO_ID_5265120526389683458" border="0" /&gt;&lt;/a&gt;&lt;br /&gt;&lt;span style="font-size:100%;"&gt;&lt;br /&gt;&lt;/span&gt;&lt;meta equiv="Content-Type" content="text/html; charset=utf-8"&gt;&lt;meta name="ProgId" content="Word.Document"&gt;&lt;meta name="Generator" content="Microsoft Word 12"&gt;&lt;meta name="Originator" content="Microsoft Word 12"&gt;&lt;link rel="File-List" href="file:///C:%5CDOCUME%7E1%5CEDIVAL%7E1%5CCONFIG%7E1%5CTemp%5Cmsohtmlclip1%5C01%5Cclip_filelist.xml"&gt;&lt;link rel="themeData" href="file:///C:%5CDOCUME%7E1%5CEDIVAL%7E1%5CCONFIG%7E1%5CTemp%5Cmsohtmlclip1%5C01%5Cclip_themedata.thmx"&gt;&lt;link rel="colorSchemeMapping" href="file:///C:%5CDOCUME%7E1%5CEDIVAL%7E1%5CCONFIG%7E1%5CTemp%5Cmsohtmlclip1%5C01%5Cclip_colorschememapping.xml"&gt;&lt;!--[if gte mso 9]&gt;&lt;xml&gt;  &lt;w:worddocument&gt;   &lt;w:view&gt;Normal&lt;/w:View&gt;   &lt;w:zoom&gt;0&lt;/w:Zoom&gt;   &lt;w:trackmoves/&gt;   &lt;w:trackformatting/&gt;   &lt;w:hyphenationzone&gt;21&lt;/w:HyphenationZone&gt;   &lt;w:punctuationkerning/&gt;   &lt;w:validateagainstschemas/&gt;   &lt;w:saveifxmlinvalid&gt;false&lt;/w:SaveIfXMLInvalid&gt;   &lt;w:ignoremixedcontent&gt;false&lt;/w:IgnoreMixedContent&gt;   &lt;w:alwaysshowplaceholdertext&gt;false&lt;/w:AlwaysShowPlaceholderText&gt;   &lt;w:donotpromoteqf/&gt;   &lt;w:lidthemeother&gt;PT-BR&lt;/w:LidThemeOther&gt;   &lt;w:lidthemeasian&gt;X-NONE&lt;/w:LidThemeAsian&gt;   &lt;w:lidthemecomplexscript&gt;X-NONE&lt;/w:LidThemeComplexScript&gt;   &lt;w:compatibility&gt;    &lt;w:breakwrappedtables/&gt;    &lt;w:snaptogridincell/&gt;    &lt;w:wraptextwithpunct/&gt;    &lt;w:useasianbreakrules/&gt;    &lt;w:dontgrowautofit/&gt;    &lt;w:splitpgbreakandparamark/&gt;    &lt;w:dontvertaligncellwithsp/&gt;    &lt;w:dontbreakconstrainedforcedtables/&gt;    &lt;w:dontvertalignintxbx/&gt;    &lt;w:word11kerningpairs/&gt;    &lt;w:cachedcolbalance/&gt;   &lt;/w:Compatibility&gt;   &lt;w:browserlevel&gt;MicrosoftInternetExplorer4&lt;/w:BrowserLevel&gt;   &lt;m:mathpr&gt;    &lt;m:mathfont val="Cambria Math"&gt;    &lt;m:brkbin val="before"&gt;    &lt;m:brkbinsub val="&amp;#45;-"&gt;    &lt;m:smallfrac val="off"&gt;    &lt;m:dispdef/&gt;    &lt;m:lmargin val="0"&gt;    &lt;m:rmargin val="0"&gt;    &lt;m:defjc val="centerGroup"&gt;    &lt;m:wrapindent val="1440"&gt;    &lt;m:intlim val="subSup"&gt;    &lt;m:narylim val="undOvr"&gt;   &lt;/m:mathPr&gt;&lt;/w:WordDocument&gt; &lt;/xml&gt;&lt;![endif]--&gt;&lt;!--[if gte mso 9]&gt;&lt;xml&gt;  &lt;w:latentstyles deflockedstate="false" defunhidewhenused="true" defsemihidden="true" defqformat="false" defpriority="99" latentstylecount="267"&gt;   &lt;w:lsdexception locked="false" priority="0" semihidden="false" unhidewhenused="false" qformat="true" name="Normal"&gt;   &lt;w:lsdexception locked="false" priority="9" semihidden="false" unhidewhenused="false" qformat="true" name="heading 1"&gt;   &lt;w:lsdexception locked="false" priority="9" qformat="true" name="heading 2"&gt;   &lt;w:lsdexception locked="false" priority="9" qformat="true" name="heading 3"&gt;   &lt;w:lsdexception locked="false" priority="9" qformat="true" name="heading 4"&gt;   &lt;w:lsdexception locked="false" priority="9" qformat="true" name="heading 5"&gt;   &lt;w:lsdexception locked="false" priority="9" qformat="true" name="heading 6"&gt;   &lt;w:lsdexception locked="false" priority="9" qformat="true" name="heading 7"&gt;   &lt;w:lsdexception locked="false" priority="9" qformat="true" name="heading 8"&gt;   &lt;w:lsdexception locked="false" priority="9" qformat="true" name="heading 9"&gt;   &lt;w:lsdexception locked="false" priority="39" name="toc 1"&gt;   &lt;w:lsdexception locked="false" priority="39" name="toc 2"&gt;   &lt;w:lsdexception locked="false" priority="39" name="toc 3"&gt;   &lt;w:lsdexception locked="false" priority="39" name="toc 4"&gt;   &lt;w:lsdexception locked="false" priority="39" name="toc 5"&gt;   &lt;w:lsdexception locked="false" priority="39" name="toc 6"&gt;   &lt;w:lsdexception locked="false" priority="39" name="toc 7"&gt;   &lt;w:lsdexception locked="false" priority="39" name="toc 8"&gt;   &lt;w:lsdexception locked="false" priority="39" name="toc 9"&gt;   &lt;w:lsdexception locked="false" priority="35" qformat="true" name="caption"&gt;   &lt;w:lsdexception locked="false" priority="10" semihidden="false" unhidewhenused="false" qformat="true" name="Title"&gt;   &lt;w:lsdexception locked="false" priority="1" name="Default Paragraph Font"&gt;   &lt;w:lsdexception locked="false" priority="11" semihidden="false" unhidewhenused="false" qformat="true" name="Subtitle"&gt;   &lt;w:lsdexception locked="false" priority="22" semihidden="false" unhidewhenused="false" qformat="true" name="Strong"&gt;   &lt;w:lsdexception locked="false" priority="20" semihidden="false" unhidewhenused="false" qformat="true" name="Emphasis"&gt;   &lt;w:lsdexception locked="false" priority="59" semihidden="false" unhidewhenused="false" name="Table Grid"&gt;   &lt;w:lsdexception locked="false" unhidewhenused="false" name="Placeholder Text"&gt;   &lt;w:lsdexception locked="false" priority="1" semihidden="false" unhidewhenused="false" qformat="true" name="No Spacing"&gt;   &lt;w:lsdexception locked="false" priority="60" semihidden="false" unhidewhenused="false" name="Light Shading"&gt;   &lt;w:lsdexception locked="false" priority="61" semihidden="false" unhidewhenused="false" name="Light List"&gt;   &lt;w:lsdexception locked="false" priority="62" semihidden="false" unhidewhenused="false" name="Light Grid"&gt;   &lt;w:lsdexception locked="false" priority="63" semihidden="false" unhidewhenused="false" name="Medium Shading 1"&gt;   &lt;w:lsdexception locked="false" priority="64" semihidden="false" unhidewhenused="false" name="Medium Shading 2"&gt;   &lt;w:lsdexception locked="false" priority="65" semihidden="false" unhidewhenused="false" name="Medium List 1"&gt;   &lt;w:lsdexception locked="false" priority="66" semihidden="false" unhidewhenused="false" name="Medium List 2"&gt;   &lt;w:lsdexception locked="false" priority="67" semihidden="false" unhidewhenused="false" name="Medium Grid 1"&gt;   &lt;w:lsdexception locked="false" priority="68" semihidden="false" unhidewhenused="false" name="Medium Grid 2"&gt;   &lt;w:lsdexception locked="false" priority="69" semihidden="false" unhidewhenused="false" name="Medium Grid 3"&gt;   &lt;w:lsdexception locked="false" priority="70" semihidden="false" unhidewhenused="false" name="Dark List"&gt;   &lt;w:lsdexception locked="false" priority="71" semihidden="false" unhidewhenused="false" name="Colorful Shading"&gt;   &lt;w:lsdexception locked="false" priority="72" semihidden="false" unhidewhenused="false" name="Colorful List"&gt;   &lt;w:lsdexception locked="false" priority="73" semihidden="false" unhidewhenused="false" name="Colorful Grid"&gt;   &lt;w:lsdexception locked="false" priority="60" semihidden="false" unhidewhenused="false" name="Light Shading Accent 1"&gt;   &lt;w:lsdexception locked="false" priority="61" semihidden="false" unhidewhenused="false" name="Light List Accent 1"&gt;   &lt;w:lsdexception locked="false" priority="62" semihidden="false" unhidewhenused="false" name="Light Grid Accent 1"&gt;   &lt;w:lsdexception locked="false" priority="63" semihidden="false" unhidewhenused="false" name="Medium Shading 1 Accent 1"&gt;   &lt;w:lsdexception locked="false" priority="64" semihidden="false" unhidewhenused="false" name="Medium Shading 2 Accent 1"&gt;   &lt;w:lsdexception locked="false" priority="65" semihidden="false" unhidewhenused="false" name="Medium List 1 Accent 1"&gt;   &lt;w:lsdexception locked="false" unhidewhenused="false" name="Revision"&gt;   &lt;w:lsdexception locked="false" priority="34" semihidden="false" unhidewhenused="false" qformat="true" name="List Paragraph"&gt;   &lt;w:lsdexception locked="false" priority="29" semihidden="false" unhidewhenused="false" qformat="true" name="Quote"&gt;   &lt;w:lsdexception locked="false" priority="30" semihidden="false" unhidewhenused="false" qformat="true" name="Intense Quote"&gt;   &lt;w:lsdexception locked="false" priority="66" semihidden="false" unhidewhenused="false" name="Medium List 2 Accent 1"&gt;   &lt;w:lsdexception locked="false" priority="67" semihidden="false" unhidewhenused="false" name="Medium Grid 1 Accent 1"&gt;   &lt;w:lsdexception locked="false" priority="68" semihidden="false" unhidewhenused="false" name="Medium Grid 2 Accent 1"&gt;   &lt;w:lsdexception locked="false" priority="69" semihidden="false" unhidewhenused="false" name="Medium Grid 3 Accent 1"&gt;   &lt;w:lsdexception locked="false" priority="70" semihidden="false" unhidewhenused="false" name="Dark List Accent 1"&gt;   &lt;w:lsdexception locked="false" priority="71" semihidden="false" unhidewhenused="false" name="Colorful Shading Accent 1"&gt;   &lt;w:lsdexception locked="false" priority="72" semihidden="false" unhidewhenused="false" name="Colorful List Accent 1"&gt;   &lt;w:lsdexception locked="false" priority="73" semihidden="false" unhidewhenused="false" name="Colorful Grid Accent 1"&gt;   &lt;w:lsdexception locked="false" priority="60" semihidden="false" unhidewhenused="false" name="Light Shading Accent 2"&gt;   &lt;w:lsdexception locked="false" priority="61" semihidden="false" unhidewhenused="false" name="Light List Accent 2"&gt;   &lt;w:lsdexception locked="false" priority="62" semihidden="false" unhidewhenused="false" name="Light Grid Accent 2"&gt;   &lt;w:lsdexception locked="false" priority="63" semihidden="false" unhidewhenused="false" name="Medium Shading 1 Accent 2"&gt;   &lt;w:lsdexception locked="false" priority="64" semihidden="false" unhidewhenused="false" name="Medium Shading 2 Accent 2"&gt;   &lt;w:lsdexception locked="false" priority="65" semihidden="false" unhidewhenused="false" name="Medium List 1 Accent 2"&gt;   &lt;w:lsdexception locked="false" priority="66" semihidden="false" unhidewhenused="false" name="Medium List 2 Accent 2"&gt;   &lt;w:lsdexception locked="false" priority="67" semihidden="false" unhidewhenused="false" name="Medium Grid 1 Accent 2"&gt;   &lt;w:lsdexception locked="false" priority="68" semihidden="false" unhidewhenused="false" name="Medium Grid 2 Accent 2"&gt;   &lt;w:lsdexception locked="false" priority="69" semihidden="false" unhidewhenused="false" name="Medium Grid 3 Accent 2"&gt;   &lt;w:lsdexception locked="false" priority="70" semihidden="false" unhidewhenused="false" name="Dark List Accent 2"&gt;   &lt;w:lsdexception locked="false" priority="71" semihidden="false" unhidewhenused="false" name="Colorful Shading Accent 2"&gt;   &lt;w:lsdexception locked="false" priority="72" semihidden="false" unhidewhenused="false" name="Colorful List Accent 2"&gt;   &lt;w:lsdexception locked="false" priority="73" semihidden="false" unhidewhenused="false" name="Colorful Grid Accent 2"&gt;   &lt;w:lsdexception locked="false" priority="60" semihidden="false" unhidewhenused="false" name="Light Shading Accent 3"&gt;   &lt;w:lsdexception locked="false" priority="61" semihidden="false" unhidewhenused="false" name="Light List Accent 3"&gt;   &lt;w:lsdexception locked="false" priority="62" semihidden="false" unhidewhenused="false" name="Light Grid Accent 3"&gt;   &lt;w:lsdexception locked="false" priority="63" semihidden="false" unhidewhenused="false" name="Medium Shading 1 Accent 3"&gt;   &lt;w:lsdexception locked="false" priority="64" semihidden="false" unhidewhenused="false" name="Medium Shading 2 Accent 3"&gt;   &lt;w:lsdexception locked="false" priority="65" semihidden="false" unhidewhenused="false" name="Medium List 1 Accent 3"&gt;   &lt;w:lsdexception locked="false" priority="66" semihidden="false" unhidewhenused="false" name="Medium List 2 Accent 3"&gt;   &lt;w:lsdexception locked="false" priority="67" semihidden="false" unhidewhenused="false" name="Medium Grid 1 Accent 3"&gt;   &lt;w:lsdexception locked="false" priority="68" semihidden="false" unhidewhenused="false" name="Medium Grid 2 Accent 3"&gt;   &lt;w:lsdexception locked="false" priority="69" semihidden="false" unhidewhenused="false" name="Medium Grid 3 Accent 3"&gt;   &lt;w:lsdexception locked="false" priority="70" semihidden="false" unhidewhenused="false" name="Dark List Accent 3"&gt;   &lt;w:lsdexception locked="false" priority="71" semihidden="false" unhidewhenused="false" name="Colorful Shading Accent 3"&gt;   &lt;w:lsdexception locked="false" priority="72" semihidden="false" unhidewhenused="false" name="Colorful List Accent 3"&gt;   &lt;w:lsdexception locked="false" priority="73" semihidden="false" unhidewhenused="false" name="Colorful Grid Accent 3"&gt;   &lt;w:lsdexception locked="false" priority="60" semihidden="false" unhidewhenused="false" name="Light Shading Accent 4"&gt;   &lt;w:lsdexception locked="false" priority="61" semihidden="false" unhidewhenused="false" name="Light List Accent 4"&gt;   &lt;w:lsdexception locked="false" priority="62" semihidden="false" unhidewhenused="false" name="Light Grid Accent 4"&gt;   &lt;w:lsdexception locked="false" priority="63" semihidden="false" unhidewhenused="false" name="Medium Shading 1 Accent 4"&gt;   &lt;w:lsdexception locked="false" priority="64" semihidden="false" unhidewhenused="false" name="Medium Shading 2 Accent 4"&gt;   &lt;w:lsdexception locked="false" priority="65" semihidden="false" unhidewhenused="false" name="Medium List 1 Accent 4"&gt;   &lt;w:lsdexception locked="false" priority="66" semihidden="false" unhidewhenused="false" name="Medium List 2 Accent 4"&gt;   &lt;w:lsdexception locked="false" priority="67" semihidden="false" unhidewhenused="false" name="Medium Grid 1 Accent 4"&gt;   &lt;w:lsdexception locked="false" priority="68" semihidden="false" unhidewhenused="false" name="Medium Grid 2 Accent 4"&gt;   &lt;w:lsdexception locked="false" priority="69" semihidden="false" unhidewhenused="false" name="Medium Grid 3 Accent 4"&gt;   &lt;w:lsdexception locked="false" priority="70" semihidden="false" unhidewhenused="false" name="Dark List Accent 4"&gt;   &lt;w:lsdexception locked="false" priority="71" semihidden="false" unhidewhenused="false" name="Colorful Shading Accent 4"&gt;   &lt;w:lsdexception locked="false" priority="72" semihidden="false" unhidewhenused="false" name="Colorful List Accent 4"&gt;   &lt;w:lsdexception locked="false" priority="73" semihidden="false" unhidewhenused="false" name="Colorful Grid Accent 4"&gt;   &lt;w:lsdexception locked="false" priority="60" semihidden="false" unhidewhenused="false" name="Light Shading Accent 5"&gt;   &lt;w:lsdexception locked="false" priority="61" semihidden="false" unhidewhenused="false" name="Light List Accent 5"&gt;   &lt;w:lsdexception locked="false" priority="62" semihidden="false" unhidewhenused="false" name="Light Grid Accent 5"&gt;   &lt;w:lsdexception locked="false" priority="63" semihidden="false" unhidewhenused="false" name="Medium Shading 1 Accent 5"&gt;   &lt;w:lsdexception locked="false" priority="64" semihidden="false" unhidewhenused="false" name="Medium Shading 2 Accent 5"&gt;   &lt;w:lsdexception locked="false" priority="65" semihidden="false" unhidewhenused="false" name="Medium List 1 Accent 5"&gt;   &lt;w:lsdexception locked="false" priority="66" semihidden="false" unhidewhenused="false" name="Medium List 2 Accent 5"&gt;   &lt;w:lsdexception locked="false" priority="67" semihidden="false" unhidewhenused="false" name="Medium Grid 1 Accent 5"&gt;   &lt;w:lsdexception locked="false" priority="68" semihidden="false" unhidewhenused="false" name="Medium Grid 2 Accent 5"&gt;   &lt;w:lsdexception locked="false" priority="69" semihidden="false" unhidewhenused="false" name="Medium Grid 3 Accent 5"&gt;   &lt;w:lsdexception locked="false" priority="70" semihidden="false" unhidewhenused="false" name="Dark List Accent 5"&gt;   &lt;w:lsdexception locked="false" priority="71" semihidden="false" unhidewhenused="false" name="Colorful Shading Accent 5"&gt;   &lt;w:lsdexception locked="false" priority="72" semihidden="false" unhidewhenused="false" name="Colorful List Accent 5"&gt;   &lt;w:lsdexception locked="false" priority="73" semihidden="false" unhidewhenused="false" name="Colorful Grid Accent 5"&gt;   &lt;w:lsdexception locked="false" priority="60" semihidden="false" unhidewhenused="false" name="Light Shading Accent 6"&gt;   &lt;w:lsdexception locked="false" priority="61" semihidden="false" unhidewhenused="false" name="Light List Accent 6"&gt;   &lt;w:lsdexception locked="false" priority="62" semihidden="false" unhidewhenused="false" name="Light Grid Accent 6"&gt;   &lt;w:lsdexception locked="false" priority="63" semihidden="false" unhidewhenused="false" name="Medium Shading 1 Accent 6"&gt;   &lt;w:lsdexception locked="false" priority="64" semihidden="false" unhidewhenused="false" name="Medium Shading 2 Accent 6"&gt;   &lt;w:lsdexception locked="false" priority="65" semihidden="false" unhidewhenused="false" name="Medium List 1 Accent 6"&gt;   &lt;w:lsdexception locked="false" priority="66" semihidden="false" unhidewhenused="false" name="Medium List 2 Accent 6"&gt;   &lt;w:lsdexception locked="false" priority="67" semihidden="false" unhidewhenused="false" name="Medium Grid 1 Accent 6"&gt;   &lt;w:lsdexception locked="false" priority="68" semihidden="false" unhidewhenused="false" name="Medium Grid 2 Accent 6"&gt;   &lt;w:lsdexception locked="false" priority="69" semihidden="false" unhidewhenused="false" name="Medium Grid 3 Accent 6"&gt;   &lt;w:lsdexception locked="false" priority="70" semihidden="false" unhidewhenused="false" name="Dark List Accent 6"&gt;   &lt;w:lsdexception locked="false" priority="71" semihidden="false" unhidewhenused="false" name="Colorful Shading Accent 6"&gt;   &lt;w:lsdexception locked="false" priority="72" semihidden="false" unhidewhenused="false" name="Colorful List Accent 6"&gt;   &lt;w:lsdexception locked="false" priority="73" semihidden="false" unhidewhenused="false" name="Colorful Grid Accent 6"&gt;   &lt;w:lsdexception locked="false" priority="19" semihidden="false" unhidewhenused="false" qformat="true" name="Subtle Emphasis"&gt;   &lt;w:lsdexception locked="false" priority="21" semihidden="false" unhidewhenused="false" qformat="true" name="Intense Emphasis"&gt;   &lt;w:lsdexception locked="false" priority="31" semihidden="false" unhidewhenused="false" qformat="true" name="Subtle Reference"&gt;   &lt;w:lsdexception locked="false" priority="32" semihidden="false" unhidewhenused="false" qformat="true" name="Intense Reference"&gt;   &lt;w:lsdexception locked="false" priority="33" semihidden="false" unhidewhenused="false" qformat="true" name="Book Title"&gt;   &lt;w:lsdexception locked="false" priority="37" name="Bibliography"&gt;   &lt;w:lsdexception locked="false" priority="39" qformat="true" name="TOC Heading"&gt;  &lt;/w:LatentStyles&gt; &lt;/xml&gt;&lt;![endif]--&gt;&lt;style&gt; &lt;!--  /* Font Definitions */  @font-face 	{font-family:"Cambria Math"; 	panose-1:2 4 5 3 5 4 6 3 2 4; 	mso-font-charset:0; 	mso-generic-font-family:roman; 	mso-font-pitch:variable; 	mso-font-signature:-1610611985 1107304683 0 0 159 0;} @font-face 	{font-family:Calibri; 	panose-1:2 15 5 2 2 2 4 3 2 4; 	mso-font-charset:0; 	mso-generic-font-family:swiss; 	mso-font-pitch:variable; 	mso-font-signature:-1610611985 1073750139 0 0 159 0;} @font-face 	{font-family:Verdana; 	panose-1:2 11 6 4 3 5 4 4 2 4; 	mso-font-charset:0; 	mso-generic-font-family:swiss; 	mso-font-pitch:variable; 	mso-font-signature:536871559 0 0 0 415 0;}  /* Style Definitions */  p.MsoNormal, li.MsoNormal, div.MsoNormal 	{mso-style-unhide:no; 	mso-style-qformat:yes; 	mso-style-parent:""; 	margin-top:0cm; 	margin-right:0cm; 	margin-bottom:10.0pt; 	margin-left:0cm; 	text-align:justify; 	mso-pagination:widow-orphan; 	font-size:11.0pt; 	font-family:"Calibri","sans-serif"; 	mso-ascii-font-family:Calibri; 	mso-ascii-theme-font:minor-latin; 	mso-fareast-font-family:Calibri; 	mso-fareast-theme-font:minor-latin; 	mso-hansi-font-family:Calibri; 	mso-hansi-theme-font:minor-latin; 	mso-bidi-font-family:"Times New Roman"; 	mso-bidi-theme-font:minor-bidi; 	mso-fareast-language:EN-US;} a:link, span.MsoHyperlink 	{mso-style-noshow:yes; 	mso-style-priority:99; 	color:blue; 	text-decoration:underline; 	text-underline:single;} a:visited, span.MsoHyperlinkFollowed 	{mso-style-noshow:yes; 	mso-style-priority:99; 	color:purple; 	mso-themecolor:followedhyperlink; 	text-decoration:underline; 	text-underline:single;} .MsoChpDefault 	{mso-style-type:export-only; 	mso-default-props:yes; 	mso-ascii-font-family:Calibri; 	mso-ascii-theme-font:minor-latin; 	mso-fareast-font-family:Calibri; 	mso-fareast-theme-font:minor-latin; 	mso-hansi-font-family:Calibri; 	mso-hansi-theme-font:minor-latin; 	mso-bidi-font-family:"Times New Roman"; 	mso-bidi-theme-font:minor-bidi; 	mso-fareast-language:EN-US;} .MsoPapDefault 	{mso-style-type:export-only; 	margin-bottom:10.0pt; 	text-align:justify;} @page Section1 	{size:595.3pt 841.9pt; 	margin:70.85pt 3.0cm 70.85pt 3.0cm; 	mso-header-margin:35.4pt; 	mso-footer-margin:35.4pt; 	mso-paper-source:0;} div.Section1 	{page:Section1;} --&gt; &lt;/style&gt;&lt;!--[if gte mso 10]&gt; &lt;style&gt;  /* Style Definitions */  table.MsoNormalTable 	{mso-style-name:"Tabela normal"; 	mso-tstyle-rowband-size:0; 	mso-tstyle-colband-size:0; 	mso-style-noshow:yes; 	mso-style-priority:99; 	mso-style-qformat:yes; 	mso-style-parent:""; 	mso-padding-alt:0cm 5.4pt 0cm 5.4pt; 	mso-para-margin-top:0cm; 	mso-para-margin-right:0cm; 	mso-para-margin-bottom:10.0pt; 	mso-para-margin-left:0cm; 	text-align:justify; 	mso-pagination:widow-orphan; 	font-size:11.0pt; 	font-family:"Calibri","sans-serif"; 	mso-ascii-font-family:Calibri; 	mso-ascii-theme-font:minor-latin; 	mso-fareast-font-family:"Times New Roman"; 	mso-fareast-theme-font:minor-fareast; 	mso-hansi-font-family:Calibri; 	mso-hansi-theme-font:minor-latin;} &lt;/style&gt; &lt;![endif]--&gt;  &lt;p class="MsoNormal" style="text-indent: 35.4pt; font-weight: bold; font-style: italic; color: rgb(102, 0, 204);"&gt;&lt;span style="font-size:100%;"&gt;Hoje, muitas pessoas (principalmente as que seguem uma dieta) tendem a trocar o açúcar pelo ASPARTAME (uma substância usada como adoçante). Se você é uma dessas pessoas: cuidado! É necessário pensar bem nas suas escolhas, tanto na hora de adoçar um cafezinho quanto na hora de escolher entre uma Coca tradicional e uma Coca Zero!&lt;/span&gt;&lt;/p&gt;  &lt;p class="MsoNormal"  style="text-indent: 35.4pt; font-family: trebuchet ms; font-weight: bold;font-family:trebuchet ms;"&gt;&lt;span style="font-size:100%;"&gt;Em Bolonha, Itália foram feitas pesquisas sobre o poder do aspartame em ratos. A primeira experiência não foi muito aceita, porém a segunda pesquisa  poderes maléficos dessa substância. Esses pesquisadores da &lt;/span&gt;&lt;span style="font-size:100%;"&gt;Ramazzini Foundation garantem e comprovam que aspartame causa câncer de mama, linfoma e até leucemia em roedores. Tal pesquisa foi publicada no Environmental Health Perspectives, nos Estados Unidos. Porém outros órgãos já fizeram pesquisas que não comprovam nada contra o aspartame.&lt;o:p&gt;&lt;/o:p&gt;&lt;/span&gt;&lt;/p&gt;  &lt;p class="MsoNormal"  style="text-indent: 35.4pt; font-family: trebuchet ms; font-weight: bold;font-family:trebuchet ms;"&gt;&lt;span style="font-size:100%;"&gt;É também  necessário que se faça uma análise do histórico dessa substância na FDA (U. S. Food &amp;amp; Drug Administration), onde mostra que 75% das reações a aditivos alimentícios são causadas pela ingestão de aspartame. Além disso há 90 sintomas relatados como causados por essa substância, como: paradas cardíacas, tontura, espasmos, ganho de peso, perda da memória; além de doenças crônicas que podem ser desencadeadas, como: Mal de Parkinson, Mal de Alzheimer, linfoma e outras.&lt;o:p&gt;&lt;/o:p&gt;&lt;/span&gt;&lt;/p&gt;  &lt;p class="MsoNormal"  style="text-indent: 35.4pt; font-family: trebuchet ms; font-weight: bold;font-family:trebuchet ms;"&gt;&lt;span style="font-size:100%;"&gt;O aspartame é constituído de ácido aspártico, metanol e fenilalanina.&lt;br /&gt;&lt;/span&gt;&lt;/p&gt;&lt;p class="MsoNormal"  style="text-indent: 35.4pt; font-family: trebuchet ms; font-weight: bold;font-family:trebuchet ms;"&gt;&lt;span style="color: rgb(102, 0, 204);font-size:100%;" &gt;Segundo o livro de &lt;span style=""&gt;Blay Lock e a &lt;/span&gt;&lt;/span&gt;&lt;span style="color: rgb(102, 0, 204);font-size:100%;" &gt;                        Dra. Shirley de Campo&lt;/span&gt;&lt;span style="color: rgb(102, 0, 204);font-size:100%;" &gt;:&lt;/span&gt;&lt;span style="font-size:100%;"&gt;&lt;br /&gt;&lt;/span&gt;&lt;span style="font-size:100%;"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/span&gt;&lt;/p&gt;  &lt;p class="MsoNormal"  style="text-indent: 35.4pt; font-family: trebuchet ms; font-weight: bold;font-family:trebuchet ms;"&gt;&lt;span style="font-size:100%;"&gt;O ácido aspártico tomado em sua forma livre, ou seja, não ligado a proteínas, aumenta a concentração de aspartato no sangue. O aspartato é um neurotransmissor importante na passagem do impulso de um neurônio para outro, porém em excesso essa substância mata alguns neurônios e promove a entrada de cálcio nas células, o que gera uma grande quantidade de radicais livres, causando danos e até a morte das células. &lt;o:p&gt;&lt;/o:p&gt;&lt;/span&gt;&lt;/p&gt;  &lt;p class="MsoNormal"  style="text-indent: 35.4pt; font-family: trebuchet ms; font-weight: bold;font-family:trebuchet ms;"&gt;&lt;span style="font-size:100%;"&gt;O metanol também é bastante perigoso, pois se aquecido a mais de 30ºC se transforma em ácido fórmico e formaldeído (substâncias tóxicas). O aspartame está em alguns alimentos que sempre serão aquecidos a essa temperaturas, como gelatinas, por exemplo. Até mesmo quando o aspartame é armazenado de forma indevida isso pode acontecer. Por isso, o metanol livre é um agravante, porém ele está em pequenas doses; alguns pesquisadores afirmam que a quantidade não promove riscos à saúde.&lt;o:p&gt;&lt;/o:p&gt;&lt;/span&gt;&lt;/p&gt;  &lt;p class="MsoNormal"  style="text-indent: 35.4pt; font-family: trebuchet ms; font-weight: bold;font-family:trebuchet ms;"&gt;&lt;span style="font-size:100%;"&gt;Já foi bem explicitado, em postagens anteriores o perigo de fenilcetonúricos ingerirem qualquer alimento contendo aspartame.&lt;o:p&gt;&lt;/o:p&gt;&lt;/span&gt;&lt;/p&gt;  &lt;p class="MsoNormal"  style="text-indent: 35.4pt; font-family: trebuchet ms; font-weight: bold;font-family:trebuchet ms;"&gt;&lt;span style="font-size:100%;"&gt;Agora, certamente, os leitores estarão pensando: “Porque, então esta substância ainda circula pelo mercado?”. É uma pergunta bastante válida, porém ainda sem resposta plausível, pois há uma divergência enorme entre comitês internacionais que protejem o aspartame e alguns pesquisadores que são completamente contra!&lt;br /&gt;&lt;/span&gt;&lt;/p&gt;  &lt;p class="MsoNormal"  style="text-indent: 35.4pt; font-family: trebuchet ms; font-weight: bold;font-family:trebuchet ms;"&gt;&lt;span style="font-size:100%;"&gt;Há vários autores, professores conceituados que publicaram livros sobre o poder do aspartame, como: Dr. Russell L. Blaylock, professor&lt;br /&gt;de neurocirurgia da Medical University of Mississippi; James e Phyllis Balch; Dr. Blaylock e outros.&lt;/span&gt;&lt;/p&gt;&lt;p class="MsoNormal"  style="text-indent: 35.4pt; font-family: trebuchet ms; font-weight: bold;font-family:trebuchet ms;"&gt;&lt;span style="font-size:100%;"&gt;No site &lt;a href="http://www.anvisa.gov.br/faqdinamica/index.asp?Secao=Usuario&amp;amp;usersecoes=28&amp;amp;userassunto=42"&gt;http://www.anvisa.gov.br/faqdinamica/index.asp?Secao=Usuario&amp;amp;usersecoes=28&amp;amp;userassunto=42  &lt;/a&gt;a vigilância sanitária refuta os argumentos de pesquisadores acima citados!&lt;br /&gt;&lt;/span&gt;&lt;/p&gt;&lt;p class="MsoNormal"  style="text-indent: 35.4pt; color: rgb(102, 0, 204); font-style: italic; font-family: trebuchet ms; font-weight: bold;font-family:trebuchet ms;"&gt;&lt;span style="font-size:100%;"&gt;Apesar disso tudo, acredito não haver motivo para pânico. Esta questão ainda está em discussão e os órgãos públicos, como a vigilância sanitária ainda confiam e não apontam problemas para o consumo dessa substância, refutando ardorosamente todos os "motivos para não consumir aspartame" expostos acima! Porém, enquanto esse impasse não é resolvido é bom ter um pouco mais de cuidado na hora de consumir alimentos com esse composto! E, afinal, em quem acreditar?&lt;/span&gt;&lt;/p&gt;&lt;p class="MsoNormal" style="text-indent: 35.4pt; color: rgb(102, 0, 204); font-style: italic; font-family: trebuchet ms; font-weight: bold;"&gt;&lt;span style="font-size:100%;"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/p&gt;&lt;p class="MsoNormal"  style="text-indent: 35.4pt; color: rgb(102, 0, 204); font-style: italic; font-family: trebuchet ms; font-weight: bold;font-family:trebuchet ms;"&gt;&lt;span style="font-size:100%;"&gt;Opção de adoçante:&lt;br /&gt;&lt;/span&gt; &lt;/p&gt;&lt;p class="MsoNormal"  style="text-indent: 35.4pt; font-family: trebuchet ms; font-weight: bold;font-family:trebuchet ms;"&gt;&lt;/p&gt;&lt;center&gt;&lt;span style="color: rgb(0, 0, 153);font-size:100%;" &gt;Neotame&lt;/span&gt;&lt;/center&gt;&lt;span style=";font-size:100%;" &gt;"O neotame é similar ao aspartame, pois também é derivado de ácido aspártico e fenilalanina. Contudo, o neotame á mais estável, porque a ligação entre os aminoácidos é mais difícil de ser quebrada. Ele foi desenvolvido há mais de 20 anos e é 8 mil vezes mais doce que o açúcar. De acordo com o site do neotame, apenas seis miligramas são necessárias para adoçar 340g de bebida. &lt;/span&gt;  &lt;p&gt;&lt;span style=";font-size:100%;" &gt;Como o neotame não se quebra em fenilalanina como o aspartame, ele pode ser consumido por fenilcetonúricos. Produtos que contêm neotame também podem ser cozidos ou assados. &lt;/span&gt;&lt;/p&gt;  &lt;p&gt;&lt;span style="font-size:100%;"&gt;O neotame foi aprovado pela FDA em 2002, e pode ser usado em bebidas, sobremesas congeladas, iogurtes, sorvetes, gomas de mascar, doces, bolos e tortas, coberturas, geléias, cereais matinais e muitos outros produtos. Como ainda é muito novo, não existem muitos produtos que o utilizam." &lt;/span&gt;&lt;/p&gt;&lt;span style="font-size:100%;"&gt;&lt;br /&gt;&lt;/span&gt;&lt;span style="font-size:100%;"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/span&gt;&lt;p&gt;&lt;/p&gt;&lt;span style="font-weight: bold;font-size:100%;" &gt;&lt;br /&gt;&lt;/span&gt;&lt;p class="MsoNormal"  style="text-indent: 35.4pt; font-family: trebuchet ms; font-weight: bold;font-family:trebuchet ms;"&gt;&lt;span style="font-size:100%;"&gt;&lt;span style="color: rgb(102, 0, 204);"&gt;Fonte:&lt;/span&gt; &lt;/span&gt;&lt;span style="font-size:100%;"&gt;Fonte: Livro de Blay Lock &lt;o:p&gt;&lt;/o:p&gt;&lt;/span&gt;&lt;/p&gt;  &lt;p class="MsoNormal"  style="text-indent: 35.4pt; font-family: trebuchet ms; font-weight: bold;font-family:trebuchet ms;"&gt;&lt;span style="font-size:100%;"&gt;Dra. Shirley de Campos&lt;o:p&gt;&lt;/o:p&gt;&lt;/span&gt;&lt;/p&gt;  &lt;p class="MsoNormal"  style="text-indent: 35.4pt; font-family: trebuchet ms; font-weight: bold;font-family:trebuchet ms;"&gt;&lt;span style="font-size:100%;"&gt;Jornal Brasil&lt;/span&gt;&lt;span style="font-size:100%;"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/span&gt;&lt;/p&gt;  &lt;p class="MsoNormal"  style="text-indent: 35.4pt; font-family: trebuchet ms; font-weight: bold;font-family:trebuchet ms;"&gt;&lt;span style="font-size:100%;"&gt;Para saber mais sobre o aspartame e saber os procedimentos das pesquisas com roedores acesse:&lt;/span&gt;&lt;/p&gt;  &lt;p class="MsoNormal"  style="text-indent: 35.4pt; font-family: trebuchet ms; font-weight: bold;font-family:trebuchet ms;"&gt;&lt;span style="font-size:100%;"&gt;&lt;a href="http://www.saude.ribeiraopreto.sp.gov.br/ssaude/noticias/i16principal.asp?pagina=/ssaude/noticias/2007/0706/I16070628estu.htm"&gt;http://www.saude.ribeiraopreto.sp.gov.br/ssaude/noticias/i16principal.asp?pagina=/ssaude/noticias/2007/0706/I16070628estu.htm&lt;/a&gt;&lt;/span&gt;&lt;/p&gt;  &lt;p class="MsoNormal"  style="text-indent: 35.4pt; font-family: trebuchet ms; font-weight: bold;font-family:trebuchet ms;"&gt;&lt;span style="font-size:100%;"&gt;&lt;a href="http://www.drashirleydecampos.com.br/noticias/3879" target="_blank"&gt;&lt;span style=""&gt;http://www.drashirleydecampos.&lt;wbr&gt;com.br/noticias/3879&lt;/span&gt;&lt;/a&gt;&lt;br /&gt;&lt;/span&gt;&lt;/p&gt;&lt;p class="MsoNormal" face="trebuchet ms" style="text-indent: 35.4pt; font-family: trebuchet ms; font-weight: bold;"&gt;&lt;span style="font-size:100%;"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/p&gt;  &lt;p class="MsoNormal"&gt;&lt;span style=";font-family:&amp;quot;;font-size:10;"  &gt;&lt;o:p&gt; &lt;span style="color: rgb(204, 51, 204); font-family: trebuchet ms; font-weight: bold;font-family:trebuchet ms;font-size:100%;"  &gt;by: Amanda Biete&lt;/span&gt;&lt;br /&gt;&lt;/o:p&gt;&lt;/span&gt;&lt;/p&gt;  &lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/46256947993340856-1030901928993892882?l=biobio-pku.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://biobio-pku.blogspot.com/feeds/1030901928993892882/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=46256947993340856&amp;postID=1030901928993892882' title='2 Comentários'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/46256947993340856/posts/default/1030901928993892882'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/46256947993340856/posts/default/1030901928993892882'/><link rel='alternate' type='text/html' href='http://biobio-pku.blogspot.com/2008/11/aspartame-um-doce-veneno-curiosidades.html' title='“Aspartame: um doce veneno ?” (Curiosidades)'/><author><name>Grupo de PKU</name><uri>http://www.blogger.com/profile/13253571819442069873</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><media:thumbnail xmlns:media='http://search.yahoo.com/mrss/' url='http://4.bp.blogspot.com/_btpyAerDQPU/SRF3ORMTJQI/AAAAAAAAAKA/MtJxVw9oDJs/s72-c/cocaaa.jpg' height='72' width='72'/><thr:total>2</thr:total></entry><entry><id>tag:blogger.com,1999:blog-46256947993340856.post-1573594156692459849</id><published>2008-11-05T02:22:00.000-08:00</published><updated>2008-11-10T08:54:28.124-08:00</updated><title type='text'>Bioquímica da Fenilcetonúria</title><content type='html'>&lt;a onblur="try {parent.deselectBloggerImageGracefully();} catch(e) {}" href="http://1.bp.blogspot.com/_btpyAerDQPU/SRRgCWaZXSI/AAAAAAAAAKY/0Iz8zP0DU_U/s1600-h/Fenilcetonuria.gif"&gt;&lt;img style="margin: 0px auto 10px; display: block; text-align: center; cursor: pointer; width: 320px; height: 235px;" src="http://1.bp.blogspot.com/_btpyAerDQPU/SRRgCWaZXSI/AAAAAAAAAKY/0Iz8zP0DU_U/s320/Fenilcetonuria.gif" alt="" id="BLOGGER_PHOTO_ID_5265939457795251490" border="0" /&gt;&lt;/a&gt;&lt;br /&gt;&lt;p style="margin-bottom: 0cm; font-family: trebuchet ms; font-weight: bold;"&gt;&lt;span style="font-size:100%;"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin-bottom: 0cm; font-family: trebuchet ms; font-weight: bold;"&gt; &lt;/p&gt;  &lt;p style="margin-bottom: 0cm; text-align: justify; font-family: trebuchet ms; font-weight: bold;"&gt;&lt;span style="font-size:100%;"&gt;          Como vocês viram nas postagens anteriores a fenilcetonúria é uma doença que ocorre devido à falta ou ineficiência da enzima fenilalanina hidroxilase. Agora serão mostradas e explicadas as reações que ficam prejudicadas devido à deficiência de tal enzima.&lt;a onblur="try {parent.deselectBloggerImageGracefully();} catch(e) {}" href="http://3.bp.blogspot.com/_btpyAerDQPU/SRF1Zq4Z9II/AAAAAAAAAJw/_bVo8WiODmk/s1600-h/fenilalanina.jpg"&gt;&lt;img style="margin: 0px auto 10px; display: block; text-align: center; cursor: pointer; width: 332px; height: 400px;" src="http://3.bp.blogspot.com/_btpyAerDQPU/SRF1Zq4Z9II/AAAAAAAAAJw/_bVo8WiODmk/s400/fenilalanina.jpg" alt="" id="BLOGGER_PHOTO_ID_5265118523240871042" border="0" /&gt;&lt;/a&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin-bottom: 0cm; text-align: justify; font-family: trebuchet ms; font-weight: bold;"&gt;&lt;span style="font-size:100%;"&gt;          Nessa reação a fenilalanina e o oxigênio são substratos, enquanto há formação de água e tirosina. É uma reação que necessita de uma coenzima reduzida (NADH) que será oxidada (NAD+). Tal reação é catalisada pela enzima fenilalanina hidroxilase, que tem como coenzima a tetraidrobipterina oxidada a diidrobiopterina. Essa é uma reação hepática, ou seja, ocorre no fígado e está presente em pessoas que não são fenilcetonúricas. Nas pessoas que possuem tal doença, como a fenilalanina hidroxilase está ausente a fenilalanina não é transformada em tirosina.&lt;a onblur="try {parent.deselectBloggerImageGracefully();} catch(e) {}" href="http://3.bp.blogspot.com/_btpyAerDQPU/SRF1TKzbufI/AAAAAAAAAJo/dsCMv_y0FDc/s1600-h/degradacao_fenilalamina.gif"&gt;&lt;img style="margin: 0px auto 10px; display: block; text-align: center; cursor: pointer; width: 322px; height: 400px;" src="http://3.bp.blogspot.com/_btpyAerDQPU/SRF1TKzbufI/AAAAAAAAAJo/dsCMv_y0FDc/s400/degradacao_fenilalamina.gif" alt="" id="BLOGGER_PHOTO_ID_5265118411550865906" border="0" /&gt;&lt;/a&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-bottom: 0cm; font-family: trebuchet ms; font-weight: bold;"&gt;&lt;span style="font-size:100%;"&gt;&lt;a onblur="try {parent.deselectBloggerImageGracefully();} catch(e) {}" href="http://4.bp.blogspot.com/_btpyAerDQPU/SRF0a_I9d0I/AAAAAAAAAJg/QDfowSKHJik/s1600-h/degradacao_fenilalamina.gif"&gt;&lt;br /&gt;&lt;/a&gt;&lt;/span&gt;&lt;/p&gt;  &lt;p style="margin-bottom: 0cm; text-align: justify; font-family: trebuchet ms; font-weight: bold;"&gt;&lt;span style="font-size:100%;"&gt;         Quando não se forma tirosina há o acúmulo de fenilalanina e de fenilpiruvato no sangue e nos tecidos. O fenilpiruvato é descarboxilado (fenilacetato) ou reduzido (fenilactato) e assim é excretado.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-bottom: 0cm; text-align: justify; font-family: trebuchet ms; font-weight: bold;"&gt;&lt;span style="font-size:100%;"&gt;Fonte: Lehninger Princípios da Bioquímica Quarta Edição&lt;br /&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-bottom: 0cm; text-align: justify;"&gt;&lt;span style="font-weight: bold;font-size:100%;" &gt;&lt;span style="font-family: trebuchet ms;"&gt;by: Camila Biete&lt;/span&gt;&lt;/span&gt;&lt;br /&gt;&lt;/p&gt;&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/46256947993340856-1573594156692459849?l=biobio-pku.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://biobio-pku.blogspot.com/feeds/1573594156692459849/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=46256947993340856&amp;postID=1573594156692459849' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/46256947993340856/posts/default/1573594156692459849'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/46256947993340856/posts/default/1573594156692459849'/><link rel='alternate' type='text/html' href='http://biobio-pku.blogspot.com/2008/11/bioqumica.html' title='Bioquímica da Fenilcetonúria'/><author><name>Grupo de PKU</name><uri>http://www.blogger.com/profile/13253571819442069873</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><media:thumbnail xmlns:media='http://search.yahoo.com/mrss/' url='http://1.bp.blogspot.com/_btpyAerDQPU/SRRgCWaZXSI/AAAAAAAAAKY/0Iz8zP0DU_U/s72-c/Fenilcetonuria.gif' height='72' width='72'/><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-46256947993340856.post-6416181186642152423</id><published>2008-11-04T07:16:00.000-08:00</published><updated>2008-11-05T01:28:16.449-08:00</updated><title type='text'>Questões 2 e 3 - aula do dia 04/11/08</title><content type='html'>&lt;div style="text-align: justify; font-weight: bold;"&gt;2) Relacione a variação das concentrações dos hormônios observada na tabela 1 com as concentrações de NEFA  e glicerol antes e após a infusão de glicose para SB e NSB.&lt;br /&gt;&lt;br /&gt;A corticosterona é um glicocorticóide que estimula a gliconeogênese, na tabela a concentração desse hormônio diminui após a infusão da glicose. A [NEFA] diminui apóis a infusão de glicose, visto que não será necessário degradar ácidos graxos livres se há glicose e a [glicerol] diminui pelo mesmo motivo, por isso a corticosterona diminui, ela estimula a gliconeogênese e se há glicose não é necessário degradar glicerol e ácidos graxos para formar mais glicose. A [glucagon] diminui também, visto que não haverá necessidade de degradação, pois há glicose. Já a [insulina] aumenta, pois há glicose no sangue e é necessária levá-la até os tecidos.&lt;br /&gt;&lt;br /&gt;3) Observe o gráfico 3. B-hidroxibutirato é um marcador de qual processo do metabolismo energético? Porque esse processo ocorre? Porque a concentração desta substância cai após a infusão de glicose para SB?&lt;br /&gt;&lt;br /&gt;O B-hidroxibutirato é marcador do metabolismo de lipídeos, mais precisamente a cetogênese, visto que os pingüins estão em jejum prolongado. Neste estado de hipoglicemia há quebra de lipídeos, assim o acetil-CoA formado a partir da B-oxidadação se transforma em corpos cetônicos. Além disso, o oxaloacetato antes usado no ciclo de Krebs será usado na gliconeogênese, assim o acetil-CoA não será completamente oxidado e formará mais corpos cetônicos. Após a infusão de glicose não será tão necessária a gliconeogênese, pois já haverá glicose disponível e diminuirá também o consumo de lipídeos e consequentemente diminuirá também a transformação de acetil-CoA em corpos cetônicos.&lt;/div&gt;&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/46256947993340856-6416181186642152423?l=biobio-pku.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://biobio-pku.blogspot.com/feeds/6416181186642152423/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=46256947993340856&amp;postID=6416181186642152423' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/46256947993340856/posts/default/6416181186642152423'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/46256947993340856/posts/default/6416181186642152423'/><link rel='alternate' type='text/html' href='http://biobio-pku.blogspot.com/2008/11/questes-2-e-3-aula-do-dia-041108.html' title='Questões 2 e 3 - aula do dia 04/11/08'/><author><name>Grupo de PKU</name><uri>http://www.blogger.com/profile/13253571819442069873</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-46256947993340856.post-1852645881877831966</id><published>2008-11-01T07:23:00.000-07:00</published><updated>2009-07-13T07:25:11.367-07:00</updated><title type='text'>A importância do Nutricionista</title><content type='html'>&lt;a onblur="try {parent.deselectBloggerImageGracefully();} catch(e) {}" href="http://3.bp.blogspot.com/_btpyAerDQPU/SQxnuwlJOjI/AAAAAAAAAJQ/oxQiMfVdiVo/s1600-h/NUTRICAO_UFRGScapa_m.jpg"&gt;&lt;img style="TEXT-ALIGN: center; MARGIN: 0px auto 10px; WIDTH: 320px; DISPLAY: block; HEIGHT: 237px; CURSOR: pointer" id="BLOGGER_PHOTO_ID_5263696117501606450" border="0" alt="" src="http://3.bp.blogspot.com/_btpyAerDQPU/SQxnuwlJOjI/AAAAAAAAAJQ/oxQiMfVdiVo/s320/NUTRICAO_UFRGScapa_m.jpg" /&gt;&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;div&gt;&lt;meta content="text/html; charset=utf-8" equiv="CONTENT-TYPE"&gt;&lt;meta name="GENERATOR" content="OpenOffice.org 2.4  (Unix)"&gt;&lt;style type="text/css"&gt; 	&lt;!-- 		@page { margin: 2cm } 		P { margin-bottom: 0.21cm } 	--&gt; 	&lt;/style&gt;&lt;/div&gt;&lt;p style="TEXT-ALIGN: justify; FONT-STYLE: italic; MARGIN-BOTTOM: 0cm; COLOR: rgb(102,0,204); FONT-WEIGHT: bold" class="western"&gt;Como nosso grupo é formado por três futuras nutricionistas não poderíamos deixar de comentar sobre a importância desta LINDA profissão no tratamento de pacientes com fenilcetonúria!&lt;/p&gt;&lt;div style="TEXT-ALIGN: justify"&gt;&lt;/div&gt;&lt;p style="TEXT-ALIGN: justify; MARGIN-BOTTOM: 0cm; FONT-WEIGHT: boldfont-family:trebuchet ms;" class="western" &gt;&lt;span style="font-size:100%;"&gt;O nutricionista especializado neste tipo de doença (Nutrição Clínica) tem um papel fundamental na vida dos fenilcetonúricos, visto que o seu tratamento é essencialmente uma dieta bastante rigorosa.&lt;/span&gt;&lt;/p&gt;&lt;div style="TEXT-ALIGN: justify; FONT-FAMILY: trebuchet ms; FONT-WEIGHT: bold"&gt;&lt;/div&gt;&lt;p style="TEXT-ALIGN: justify; MARGIN-BOTTOM: 0cm; FONT-WEIGHT: boldfont-family:trebuchet ms;" class="western" &gt;&lt;span style="font-size:100%;"&gt;A dieta do fenilcetonúrico deve ser, certamente, pobre em fenilalanina, um aminoácido essencial, portanto devem ser retiradas proteínas, principalmente as de origem animal. Os detalhes da dieta será discutido em Dietoterapia!&lt;/span&gt;&lt;/p&gt;&lt;div style="TEXT-ALIGN: justify; FONT-FAMILY: trebuchet ms; FONT-WEIGHT: bold"&gt;&lt;/div&gt;&lt;p style="TEXT-ALIGN: justify; MARGIN-BOTTOM: 0cm; FONT-WEIGHT: boldfont-family:trebuchet ms;" class="western" &gt;&lt;span style="font-size:100%;"&gt;A Nutrição deve se preocupar ainda em orientar os pais e outras pessoas que estiverem encarregados da alimentação da criança em relação a todos os detalhes da dieta e das fórmulas a serem usadas, bem como salientar a importância de inserir a criança na escolha de seus alimentos desde cedo para se acostumarem e entenderem sua doenças e suas necessidades.&lt;/span&gt;&lt;/p&gt;&lt;div style="TEXT-ALIGN: justify; FONT-FAMILY: trebuchet ms; FONT-WEIGHT: bold"&gt;&lt;/div&gt;&lt;p style="TEXT-ALIGN: justify; MARGIN-BOTTOM: 0cm; FONT-WEIGHT: boldfont-family:trebuchet ms;" class="western" &gt;&lt;span style="font-size:100%;"&gt;A dieta não deve ser manuscrita para evitar erros. É interessante que o nutricionista monte um registro a ser preenchido pela mãe a cada alimentação de seu filho. Além disso, esse registro deve ser revisto juntamente com a mãe, correlacionando cada alimento e suas composições, principalmente o nível de fenilalanina ingerido. &lt;/span&gt;&lt;/p&gt;&lt;div style="TEXT-ALIGN: justify; FONT-FAMILY: trebuchet ms; FONT-WEIGHT: bold"&gt;&lt;/div&gt;&lt;p style="TEXT-ALIGN: justify; MARGIN-BOTTOM: 0cm; FONT-WEIGHT: boldfont-family:trebuchet ms;" class="western" &gt;&lt;span style="font-size:100%;"&gt;É ainda importante lembrar que o nutricionista deve agir em conjunto com o médico do paciente, discutindo e decidindo, cada um na sua especialidade o melhor para a saúde e o desenvolvimento do fenilcetonúrico.&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN-BOTTOM: 0cm; FONT-WEIGHT: boldfont-family:trebuchet ms;" class="western" &gt;&lt;span style="FONT-STYLE: italic; COLOR: rgb(204,51,204)font-size:100%;" &gt;by: Amanda Biete&lt;/span&gt;&lt;span style="font-size:100%;"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/p&gt;&lt;span style="font-size:100%;"&gt;&lt;br /&gt;&lt;/span&gt;&lt;span style="COLOR: rgb(102,0,204); FONT-WEIGHT: boldfont-family:trebuchet ms;font-size:100%;"  &gt;Fonte: &lt;/span&gt;&lt;span style="font-size:100%;"&gt;&lt;span style="FONT-WEIGHT: bold;font-family:trebuchet ms;" &gt;Nutrição_Mitchell, Rynbergen, Anderson e Dibble&lt;/span&gt;&lt;br /&gt;&lt;br /&gt;&lt;/span&gt;&lt;br /&gt;&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/46256947993340856-1852645881877831966?l=biobio-pku.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://biobio-pku.blogspot.com/feeds/1852645881877831966/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=46256947993340856&amp;postID=1852645881877831966' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/46256947993340856/posts/default/1852645881877831966'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/46256947993340856/posts/default/1852645881877831966'/><link rel='alternate' type='text/html' href='http://biobio-pku.blogspot.com/2008/11/importncia-do-nutricionista.html' title='A importância do Nutricionista'/><author><name>Grupo de PKU</name><uri>http://www.blogger.com/profile/13253571819442069873</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><media:thumbnail xmlns:media='http://search.yahoo.com/mrss/' url='http://3.bp.blogspot.com/_btpyAerDQPU/SQxnuwlJOjI/AAAAAAAAAJQ/oxQiMfVdiVo/s72-c/NUTRICAO_UFRGScapa_m.jpg' height='72' width='72'/><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-46256947993340856.post-4794458418304280433</id><published>2008-11-01T06:33:00.000-07:00</published><updated>2008-11-10T08:52:55.292-08:00</updated><title type='text'>Manifestações Clínicas</title><content type='html'>&lt;a onblur="try {parent.deselectBloggerImageGracefully();} catch(e) {}" href="http://4.bp.blogspot.com/_btpyAerDQPU/SQxdHPvFayI/AAAAAAAAAIg/GC2b5kjtofg/s1600-h/menininhas+pku.jpg"&gt;&lt;img style="margin: 0px auto 10px; display: block; text-align: center; cursor: pointer; width: 320px; height: 254px;" src="http://4.bp.blogspot.com/_btpyAerDQPU/SQxdHPvFayI/AAAAAAAAAIg/GC2b5kjtofg/s320/menininhas+pku.jpg" alt="" id="BLOGGER_PHOTO_ID_5263684443553753890" border="0" /&gt;&lt;/a&gt;                                                      Bethany &amp;amp; Angela (irmãs com PKU)&lt;br /&gt;&lt;span style="font-size:100%;"&gt;&lt;br /&gt;&lt;/span&gt;&lt;div style="text-align: justify; font-weight: bold; font-family: trebuchet ms;"&gt;&lt;span style="font-size:100%;"&gt;A fenilcetonúria como já vimos é uma hiperfenilalaninemia que ocorre devido à deficiência da enzima fenilalanina hidroxilase ( 97% dos casos), no entanto ela pode ser causada devido à defeitos em outras partes da via catalítica que transforma fenilalanina em tirosina (3% dos casos), caracterizando assim três tipos de fenilcetonúria (PKU): PKU tipo I, PKU tipo II e PKU tipo III. Descreverei agora essas três formas que dá origem à doença.&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a onblur="try {parent.deselectBloggerImageGracefully();} catch(e) {}" href="http://3.bp.blogspot.com/_btpyAerDQPU/SRYAW_W_85I/AAAAAAAAAKo/wzZWRA9MIHc/s1600-h/femilc2.jpg"&gt;&lt;img style="margin: 0px auto 10px; display: block; text-align: center; cursor: pointer; width: 320px; height: 234px;" src="http://3.bp.blogspot.com/_btpyAerDQPU/SRYAW_W_85I/AAAAAAAAAKo/wzZWRA9MIHc/s320/femilc2.jpg" alt="" id="BLOGGER_PHOTO_ID_5266397209221395346" border="0" /&gt;&lt;/a&gt;&lt;br /&gt;A PKU do tipo I é caracterizada pela deficiência ou ausência da enzima fenilalanina hidroxilase e pode ocorrer de três formas:&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;* Fenilcetonúria clássica: Nesse tipo de manifestação a atividade da enzima fenilalanina hidroxilase é menor que 1%, fazendo com que a quantidade de fenilalanina presente no sangue seja maior que 20mg/dl.&lt;br /&gt;&lt;br /&gt;* Fenilcetonúria leve: Na manifestação leve da fenilcetonúria a atividade dessa enzima é de 1 a 3% e os níveis de fenilalanina presente no sangue ficam entre 4 e 10mg/dl.&lt;br /&gt;&lt;br /&gt;* Fenilcetonúria permanente ou benigna: Nesse tipo de manifestação a atividade enzimática é maior que 3% e os níveis plasmáticos de fenilalanina encontram-se entre 4 e 10mg/dl.&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;A PKU  do tipo II é causada pela deficiência da enzima diidrobiopteridina-redutase, importante pelo fato de que é ela quem regenera a tetraidrobiopterina, uma coenzima muito importante para que a fenilalanina hidroxilase possa catalisar a reação que transforma a fenilalanina em tirosina. (Tudo isso será explicado no tópico bioquímica da fenilcetonúria).&lt;br /&gt;A PKU do tipo III ocorre devido a um defeito em uma das enzimas que sintetizam a tetraidrobiopterina.&lt;br /&gt;&lt;br /&gt;&lt;/span&gt;&lt;span style="color: rgb(102, 0, 204);font-size:100%;" &gt;by: Camila Biete&lt;/span&gt;&lt;span style="font-size:100%;"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/div&gt;&lt;span style="color: rgb(102, 0, 204); font-weight: bold; font-family: trebuchet ms;font-size:100%;" &gt;&lt;br /&gt;Fonte: &lt;/span&gt;&lt;span style="font-size:100%;"&gt;&lt;br /&gt;&lt;/span&gt;&lt;p style="margin-bottom: 0cm; font-weight: bold; font-family: trebuchet ms;"&gt;&lt;span style="font-size:85%;"&gt;ESCOLA SUPERIOR DE CIÊNCIAS DA SAÚDE&lt;/span&gt;&lt;/p&gt; &lt;p style="margin-bottom: 0cm; font-weight: bold; font-family: trebuchet ms;"&gt;&lt;span style="font-size:85%;"&gt;CURSO DE GRADUAÇÃO EM MEDICINA&lt;/span&gt;&lt;/p&gt; &lt;p style="margin-bottom: 0cm; font-weight: bold; font-family: trebuchet ms;"&gt;&lt;span style="font-size:85%;"&gt;ELETIVA: PERINATOLOGIA&lt;/span&gt;&lt;/p&gt; &lt;p style="margin-bottom: 0cm; font-weight: bold; font-family: trebuchet ms;"&gt;&lt;span style="font-size:85%;"&gt;PROFESSORES: MARIA TERESINHA DE CARDOSO&lt;/span&gt;&lt;/p&gt;  &lt;p style="margin-bottom: 0cm; font-weight: bold; font-family: trebuchet ms;" align="center"&gt;&lt;span style="font-size:85%;"&gt;                               PAULO R. MARGOTTO&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-bottom: 0cm; font-weight: bold; font-family: trebuchet ms;" align="center"&gt;&lt;span style="font-size:85%;"&gt;Alunos:Fernanda Ferreira CardosoSylvia Maria Leite Freire&lt;/span&gt;&lt;/p&gt; &lt;p style="margin-bottom: 0cm; font-weight: bold; font-family: trebuchet ms;" align="center"&gt;&lt;span style="font-size:85%;"&gt;Viviane de Oliveira Pereira&lt;/span&gt;&lt;/p&gt; &lt;p style="margin-bottom: 0cm; font-weight: bold; font-family: trebuchet ms;" align="center"&gt;&lt;span style="font-size:85%;"&gt;Viviane Q. de Macedo Alcântara]&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-bottom: 0cm;"&gt; &lt;/p&gt;&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/46256947993340856-4794458418304280433?l=biobio-pku.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://biobio-pku.blogspot.com/feeds/4794458418304280433/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=46256947993340856&amp;postID=4794458418304280433' title='2 Comentários'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/46256947993340856/posts/default/4794458418304280433'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/46256947993340856/posts/default/4794458418304280433'/><link rel='alternate' type='text/html' href='http://biobio-pku.blogspot.com/2008/11/fenilcetonria-como-j-vimos-uma.html' title='Manifestações Clínicas'/><author><name>Grupo de PKU</name><uri>http://www.blogger.com/profile/13253571819442069873</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><media:thumbnail xmlns:media='http://search.yahoo.com/mrss/' url='http://4.bp.blogspot.com/_btpyAerDQPU/SQxdHPvFayI/AAAAAAAAAIg/GC2b5kjtofg/s72-c/menininhas+pku.jpg' height='72' width='72'/><thr:total>2</thr:total></entry><entry><id>tag:blogger.com,1999:blog-46256947993340856.post-901492595453662758</id><published>2008-11-01T06:02:00.000-07:00</published><updated>2008-11-10T08:48:41.148-08:00</updated><title type='text'>Contando a História</title><content type='html'>&lt;div style="text-align: justify;"&gt;&lt;span style="color: rgb(102, 0, 204); font-style: italic; font-weight: bold;"&gt;Para todos entenderem como surgiu a PKU está aí a linha do tempo... um pouquinho de história!!&lt;/span&gt;&lt;br /&gt;&lt;/div&gt;&lt;br /&gt;&lt;br /&gt;&lt;a onblur="try {parent.deselectBloggerImageGracefully();} catch(e) {}" href="http://3.bp.blogspot.com/_btpyAerDQPU/SQxUSH2cGnI/AAAAAAAAAHw/eaCNBE5ae0w/s1600-h/Folling+pku.jpg"&gt;&lt;img style="margin: 0px auto 10px; display: block; text-align: center; cursor: pointer; width: 150px; height: 108px;" src="http://3.bp.blogspot.com/_btpyAerDQPU/SQxUSH2cGnI/AAAAAAAAAHw/eaCNBE5ae0w/s320/Folling+pku.jpg" alt="" id="BLOGGER_PHOTO_ID_5263674734811028082" border="0" /&gt;&lt;/a&gt;   	&lt;meta equiv="CONTENT-TYPE" content="text/html; charset=utf-8"&gt; 	&lt;title&gt;&lt;/title&gt; 	&lt;meta name="GENERATOR" content="OpenOffice.org 2.4  (Unix)"&gt; 	&lt;style type="text/css"&gt; 	&lt;!-- 		@page { margin: 2cm } 		P { margin-bottom: 0.21cm } 	--&gt; 	&lt;/style&gt;   &lt;ul style="text-align: justify; font-family: trebuchet ms; font-weight: bold;"&gt;&lt;li&gt;&lt;span style="font-size:100%;"&gt;Em 1934, Fölling descreveu a PKU através de exames em dois irmãos que apresentaram ácido fenilpirúvico, um dos metabólitos da fenilalanina (phe), na urina.&lt;/span&gt;&lt;/li&gt;&lt;/ul&gt;&lt;br /&gt;&lt;br /&gt;&lt;p class="western" style="margin-bottom: 0cm;"&gt;&lt;a onblur="try {parent.deselectBloggerImageGracefully();} catch(e) {}" href="http://3.bp.blogspot.com/_btpyAerDQPU/SQxVd06Rw7I/AAAAAAAAAH4/ANd_djc2ff0/s1600-h/250px-Phenylalanine_hydroxylase_brighter.jpg"&gt;&lt;img style="margin: 0px auto 10px; display: block; text-align: center; cursor: pointer; width: 169px; height: 178px;" src="http://3.bp.blogspot.com/_btpyAerDQPU/SQxVd06Rw7I/AAAAAAAAAH4/ANd_djc2ff0/s320/250px-Phenylalanine_hydroxylase_brighter.jpg" alt="" id="BLOGGER_PHOTO_ID_5263676035396912050" border="0" /&gt;&lt;/a&gt;&lt;/p&gt;&lt;ul style="text-align: justify; font-family: trebuchet ms; font-weight: bold;"&gt;&lt;li&gt;&lt;span style="font-size:100%;"&gt;Em 1937, Quastel e Pentose sugerem o nome à doença: Pheylketonuria (PKU)H. Bickel descobre, em 1953, que a fenilalanina-hidroxilase é a enzima deficiente4 na oxidação da phe, demostrando isso no tecido hepático de um paciente fenilcetonúrico. Tempos depois, Bickel descobre também que uma dieta pobre neste aminoácido (phe) abaixam o seu nível no sangue e tratadas precocemente com essa dieta evitaria retardo mental.&lt;/span&gt;&lt;/li&gt;&lt;/ul&gt;&lt;span style="font-weight: bold;font-size:100%;" &gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a style="font-family: trebuchet ms;" onblur="try {parent.deselectBloggerImageGracefully();} catch(e) {}" href="http://3.bp.blogspot.com/_btpyAerDQPU/SQxWI8BBrrI/AAAAAAAAAIA/ICVMQzyLI1w/s1600-h/pezinho.jpg"&gt;&lt;img style="margin: 0px auto 10px; display: block; text-align: center; cursor: pointer; width: 235px; height: 205px;" src="http://3.bp.blogspot.com/_btpyAerDQPU/SQxWI8BBrrI/AAAAAAAAAIA/ICVMQzyLI1w/s320/pezinho.jpg" alt="" id="BLOGGER_PHOTO_ID_5263676776038641330" border="0" /&gt;&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;/span&gt;&lt;ul style="font-family: trebuchet ms; font-weight: bold;"&gt;&lt;li&gt;   	&lt;meta equiv="CONTENT-TYPE" content="text/html; charset=utf-8"&gt;&lt;span style="font-size:100%;"&gt; 	 	 	    Em 1967, Guthrie desenvolveu o teste do pezinho.&lt;a onblur="try {parent.deselectBloggerImageGracefully();} catch(e) {}" href="http://3.bp.blogspot.com/_btpyAerDQPU/SQxZCzGRysI/AAAAAAAAAIY/fCY4yZNikds/s1600-h/gravida_300.jpg"&gt;&lt;img style="margin: 0px auto 10px; display: block; text-align: center; cursor: pointer; width: 201px; height: 226px;" src="http://3.bp.blogspot.com/_btpyAerDQPU/SQxZCzGRysI/AAAAAAAAAIY/fCY4yZNikds/s320/gravida_300.jpg" alt="" id="BLOGGER_PHOTO_ID_5263679969100417730" border="0" /&gt;&lt;/a&gt;&lt;/span&gt;&lt;title&gt;&lt;/title&gt;&lt;meta name="GENERATOR" content="OpenOffice.org 2.4  (Unix)"&gt;&lt;style type="text/css"&gt; 	&lt;!-- 		@page { margin: 2cm } 		P { margin-bottom: 0.21cm } 	--&gt; 	&lt;/style&gt;&lt;/li&gt;&lt;/ul&gt;&lt;ul style="text-align: justify; font-family: trebuchet ms; font-weight: bold;"&gt;&lt;li&gt;  &lt;p class="western" style="margin-bottom: 0cm;"&gt;&lt;span style="font-size:100%;"&gt;Foi reconhecida na década de 1970 que a PKU materna deve ser bastante estudada e discutida, pois se trata de uma questão séria e importante.&lt;/span&gt;&lt;/p&gt;&lt;/li&gt;&lt;/ul&gt;&lt;span style="font-weight: bold;font-size:100%;" &gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a style="font-family: trebuchet ms;" onblur="try {parent.deselectBloggerImageGracefully();} catch(e) {}" href="http://3.bp.blogspot.com/_btpyAerDQPU/SQxXIB5kg4I/AAAAAAAAAIQ/X7K0bVOobw8/s1600-h/cromossomos.gif"&gt;&lt;img style="margin: 0px auto 10px; display: block; text-align: center; cursor: pointer; width: 320px; height: 287px;" src="http://3.bp.blogspot.com/_btpyAerDQPU/SQxXIB5kg4I/AAAAAAAAAIQ/X7K0bVOobw8/s320/cromossomos.gif" alt="" id="BLOGGER_PHOTO_ID_5263677859949740930" border="0" /&gt;&lt;/a&gt;&lt;/span&gt;&lt;ul style="text-align: justify; font-family: trebuchet ms; font-weight: bold;"&gt;&lt;li&gt;&lt;p class="western" style="margin-bottom: 0cm;"&gt;&lt;span style="font-size:100%;"&gt;Na década de 1980, foi descoberto que o gene para a deficiência da enzima PAH está presente no cromossomo 12q22 a q24.1.&lt;/span&gt;&lt;/p&gt;&lt;/li&gt;&lt;/ul&gt;&lt;span style="font-weight: bold;font-size:100%;" &gt;&lt;br /&gt;&lt;br /&gt;&lt;/span&gt;&lt;span style="font-weight: bold; color: rgb(204, 51, 204); font-family: trebuchet ms;font-size:100%;" &gt;by: Amanda Biete&lt;/span&gt;&lt;span style="font-weight: bold;font-size:100%;" &gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;/span&gt;&lt;span style="font-weight: bold; color: rgb(102, 0, 204); font-family: trebuchet ms;font-size:100%;" &gt;Fonte:&lt;/span&gt;&lt;span style="font-weight: bold;font-size:100%;" &gt;&lt;span style="font-family: trebuchet ms;"&gt; &lt;/span&gt;&lt;a style="font-family: trebuchet ms;" onblur="try {parent.deselectBloggerImageGracefully();} catch(e) {}" href="http://2.bp.blogspot.com/_btpyAerDQPU/SQTSnpD5nrI/AAAAAAAAAFE/sGlDJZq_Guw/s1600-h/bebe+e+mae.png"&gt;L. kathleen Mahan e Sylvia Escott-Stump_ Krause Alimentos, Nutrição e Dietoterapia 11ª edição.&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;/span&gt;&lt;p class="western" style="margin-bottom: 0cm; font-family: trebuchet ms; font-weight: bold;"&gt;&lt;span style="font-size:100%;"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/p&gt;&lt;span style="font-weight: bold;font-size:100%;" &gt;&lt;br /&gt;&lt;/span&gt;&lt;br /&gt;&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/46256947993340856-901492595453662758?l=biobio-pku.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://biobio-pku.blogspot.com/feeds/901492595453662758/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=46256947993340856&amp;postID=901492595453662758' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/46256947993340856/posts/default/901492595453662758'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/46256947993340856/posts/default/901492595453662758'/><link rel='alternate' type='text/html' href='http://biobio-pku.blogspot.com/2008/11/contando-histria.html' title='Contando a História'/><author><name>Grupo de PKU</name><uri>http://www.blogger.com/profile/13253571819442069873</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><media:thumbnail xmlns:media='http://search.yahoo.com/mrss/' url='http://3.bp.blogspot.com/_btpyAerDQPU/SQxUSH2cGnI/AAAAAAAAAHw/eaCNBE5ae0w/s72-c/Folling+pku.jpg' height='72' width='72'/><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-46256947993340856.post-1873372563189827976</id><published>2008-10-27T13:34:00.000-07:00</published><updated>2008-11-08T04:08:56.802-08:00</updated><title type='text'>Fantástico sobre o Teste do Pezinho (Reportagem)</title><content type='html'>&lt;a onblur="try {parent.deselectBloggerImageGracefully();} catch(e) {}" href="http://3.bp.blogspot.com/_btpyAerDQPU/SQYo5kZwMnI/AAAAAAAAAGs/gz4yAf1YhCU/s1600-h/fantastico.jpg"&gt;&lt;img style="margin: 0px auto 10px; display: block; text-align: center; cursor: pointer; width: 320px; height: 267px;" src="http://3.bp.blogspot.com/_btpyAerDQPU/SQYo5kZwMnI/AAAAAAAAAGs/gz4yAf1YhCU/s320/fantastico.jpg" alt="" id="BLOGGER_PHOTO_ID_5261938184118350450" border="0" /&gt;&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;div style="text-align: justify;"&gt;&lt;span style="font-weight: bold; font-style: italic; color: rgb(102, 0, 204);"&gt;Para vocês entenderem melhor a trajetória do Test&lt;/span&gt;&lt;span style="font-weight: bold; font-style: italic; color: rgb(102, 0, 204);"&gt;e do Pezinho nós postamos uma reportagem do Fantástico do dia 26 de março de 2006 sobre o surgimento do teste do pezinho no Brasil e a importância para fenilcetonúricos. Contém vários depoimentos de pessoas com essa doença e pais destes dizendo sobre esse enorme passo: o Teste do Pezinho sendo direito de todos no Brasil!&lt;/span&gt;&lt;br /&gt;&lt;/div&gt;&lt;br /&gt;26.03.2006&lt;br /&gt;     &lt;b class="mat_tx"&gt;Diagnóstico precoce&lt;/b&gt;&lt;br /&gt; &lt;a onblur="try {parent.deselectBloggerImageGracefully();} catch(e) {}" href="http://3.bp.blogspot.com/_btpyAerDQPU/SQYoI41PmgI/AAAAAAAAAGc/Qz_zDuXsu5M/s1600-h/TESTEDOPEZINHO.jpg"&gt;&lt;img style="margin: 0px auto 10px; display: block; text-align: center; cursor: pointer; width: 215px; height: 176px;" src="http://3.bp.blogspot.com/_btpyAerDQPU/SQYoI41PmgI/AAAAAAAAAGc/Qz_zDuXsu5M/s400/TESTEDOPEZINHO.jpg" alt="" id="BLOGGER_PHOTO_ID_5261937347788773890" border="0" /&gt;&lt;/a&gt;&lt;p style="text-align: justify;"&gt;&lt;span style="font-weight: bold;font-size:180%;" &gt;&lt;span style="color: rgb(102, 0, 204);"&gt;"&lt;/span&gt;&lt;/span&gt;O Fantástico participou da luta para que todos tivessem o direito a esse exame tão simples, mas tão importante.&lt;/p&gt;&lt;div style="text-align: justify;"&gt; &lt;/div&gt;&lt;p style="text-align: justify;"&gt;“Eu me lembro da reportagem. Mais ou menos, porque já faz um tempinho”, conta o estudante Rodrigo Oliveira, de 27 anos.&lt;/p&gt;&lt;div style="text-align: justify;"&gt; &lt;/div&gt;&lt;p style="text-align: justify;"&gt;Em 1986, Rodrigo, com 7 anos, foi entrevistado pela repórter Helena de Grammont. Ele é portador de uma doença hereditária grave: a fenilcetonúria. &lt;/p&gt;&lt;div style="text-align: justify;"&gt; &lt;/div&gt;&lt;p style="text-align: justify;"&gt;“Além de estudar, gosto de ficar em volta da piscina”, disse o menino, na época.&lt;/p&gt;&lt;div style="text-align: justify;"&gt; &lt;/div&gt;&lt;p style="text-align: justify;"&gt;Rodrigo foi a primeira criança do Brasil a ser salva pelo teste do pezinho. Júlia não gostou nada da espetadinha no pé...Te&lt;/p&gt;&lt;div style="text-align: justify;"&gt; &lt;/div&gt;&lt;p style="text-align: justify;"&gt;“Quando ela crescer, ela vai agradecer, porque isso é muito importante”, garante o enfermeiro Marcus Augustus Logarzo.&lt;br /&gt;&lt;/p&gt;&lt;p style="text-align: justify;"&gt;(...)&lt;br /&gt;&lt;/p&gt;&lt;div style="text-align: justify;"&gt; &lt;/div&gt;&lt;p style="text-align: justify;"&gt;“Eu não ser porquê, não tenho essa informação”, declara a mãe de Júlia, Nicole de Almeida.&lt;br /&gt;&lt;br /&gt;O teste chegou ao Brasil há 30 anos e identifica se o bebê é portador de doenças hereditárias graves, entre elas, a fenilcetonúria. O organismo de quem possui a doença não consegue processar alimentos ricos em proteínas, como carnes, leite e feijão.&lt;br /&gt;&lt;/p&gt;&lt;p style="text-align: justify;"&gt;“Ela passa a não aprender, começa a apresentar convulsões. Isso já é detectado a partir dos seis meses de idade. Não há possibilidade de reversão”, esclarece o biólogo e coordenador do laboratório da APAE de São Paulo, José Eduardo Lauandos.&lt;/p&gt;&lt;div style="text-align: justify;"&gt; &lt;/div&gt;&lt;p style="text-align: justify;"&gt;Uma em cada 12 mil crianças nasce com fenilcetonúria. É uma doença incurável, que exige uma dieta rigorosa para a vida inteira. Carnes de todos os tipos são proibidas.&lt;/p&gt;&lt;div style="text-align: justify;"&gt; &lt;/div&gt;&lt;p style="text-align: justify;"&gt;“Eles podem comer arroz, frutas, verduras, mas de forma controlada”, declara a nutricionista Beatriz Frangipani.&lt;/p&gt;&lt;div style="text-align: justify;"&gt; &lt;/div&gt;&lt;p style="text-align: justify;"&gt;Só o diagnóstico precoce pode evitar as seqüelas. &lt;/p&gt;&lt;div style="text-align: justify;"&gt; &lt;/div&gt;&lt;p style="text-align: justify;"&gt;“A minha mãe descobriu que a doença quando eu tinha 1 ano e meio”, conta a auxiliar de cozinha Vivian Delfino.&lt;/p&gt;&lt;p style="text-align: justify;"&gt;(...)&lt;/p&gt;&lt;p style="text-align: justify;"&gt;Quem deu o alarme, na época, foi a enfermeira Tereza de Freitas, da Universidade Federal Fluminense. Ela publicou uma pesquisa que apontava que 62% dos médicos do Rio de Janeiro e 53,8% dos de São Paulo nunca tinham ouvido falar no teste do pezinho. Uma situação grave, que o Fantástico denunciou.&lt;/p&gt;&lt;div style="text-align: justify;"&gt;(...)&lt;br /&gt;&lt;br /&gt;&lt;/div&gt;&lt;p style="text-align: justify;"&gt;O Programa Nacional de Triagem Neonatal do Ministério da Saúde calcula que ainda hoje no Brasil um quarto dos recém-nascidos não faz o teste do pezinho. A pior situação é a do Piauí, onde mais da metade dos bebês – 53% - não são examinados.&lt;/p&gt;&lt;div style="text-align: justify;"&gt; &lt;/div&gt;&lt;p style="text-align: justify;"&gt;Em Cabeceiras do Piauí, a 93 quilômetros de Teresina, muitas mães não sabem o que é o exame.&lt;/p&gt;&lt;div style="text-align: justify;"&gt; &lt;/div&gt;&lt;p style="text-align: justify;"&gt;“Em uma questão de tempo eu espero que a gente vá ter, daqui a muito pouco tempo, 100% de cobertura que é o objetivo de todos nós”, avalia a presidente da Sociedade Brasileira de Triagem Neonatal, Tânia de Carvalho.&lt;/p&gt;&lt;div style="text-align: justify;"&gt; &lt;/div&gt;&lt;p style="text-align: justify;"&gt;O problema é que os bebês não podem esperar. A corrida contra o tempo foi o que salvou Rodrigo, há mais de 20 anos. Hoje, ele só precisa se preocupar com a dieta, para levar uma vida normal. &lt;/p&gt;&lt;div style="text-align: justify;"&gt; &lt;/div&gt;&lt;p style="text-align: justify;"&gt;“O maior beneficiado sou eu”, afirma.&lt;span style="font-weight: bold; color: rgb(102, 0, 204);font-size:180%;" &gt;"&lt;/span&gt;&lt;/p&gt;&lt;br /&gt;&lt;br /&gt;&lt;span style="color: rgb(51, 51, 255); font-weight: bold;"&gt;Para ver a reportagem na íntegra: &lt;a href="http://fantastico.globo.com/Jornalismo/Fantastico/0,,AA1165284-4005-0-0-26032006,00.html"&gt;http://fantastico.globo.com/Jornalismo/Fantastico/0,,AA1165284-4005-0-0-26032006,00.html&lt;/a&gt;&lt;/span&gt;&lt;br /&gt;&lt;br /&gt;&lt;span style="color: rgb(204, 51, 204); font-weight: bold;"&gt;by: Amanda Biete&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;/span&gt;&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/46256947993340856-1873372563189827976?l=biobio-pku.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://biobio-pku.blogspot.com/feeds/1873372563189827976/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=46256947993340856&amp;postID=1873372563189827976' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/46256947993340856/posts/default/1873372563189827976'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/46256947993340856/posts/default/1873372563189827976'/><link rel='alternate' type='text/html' href='http://biobio-pku.blogspot.com/2008/10/reportagens.html' title='Fantástico sobre o Teste do Pezinho (Reportagem)'/><author><name>Grupo de PKU</name><uri>http://www.blogger.com/profile/13253571819442069873</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><media:thumbnail xmlns:media='http://search.yahoo.com/mrss/' url='http://3.bp.blogspot.com/_btpyAerDQPU/SQYo5kZwMnI/AAAAAAAAAGs/gz4yAf1YhCU/s72-c/fantastico.jpg' height='72' width='72'/><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-46256947993340856.post-8972107292902974414</id><published>2008-10-26T13:24:00.001-07:00</published><updated>2008-11-10T08:51:35.748-08:00</updated><title type='text'>Fenilcetonúria materna</title><content type='html'>&lt;a onblur="try {parent.deselectBloggerImageGracefully();} catch(e) {}" href="http://4.bp.blogspot.com/_btpyAerDQPU/SQTSTcHQxlI/AAAAAAAAAE8/v7ye68Iwz10/s1600-h/mulher-gravida.jpg"&gt;&lt;img id="BLOGGER_PHOTO_ID_5261561496081581650" style="margin: 0px auto 10px; display: block; width: 240px; cursor: pointer; height: 320px; text-align: center;" alt="" src="http://4.bp.blogspot.com/_btpyAerDQPU/SQTSTcHQxlI/AAAAAAAAAE8/v7ye68Iwz10/s320/mulher-gravida.jpg" border="0" /&gt;&lt;/a&gt;&lt;span style="font-size:100%;"&gt;&lt;br /&gt;&lt;/span&gt;&lt;meta content="text/html; charset=utf-8" equiv="Content-Type"&gt;&lt;meta content="Word.Document" name="ProgId"&gt;&lt;meta content="Microsoft Word 9" name="Generator"&gt;&lt;meta content="Microsoft Word 9" name="Originator"&gt;&lt;link style="font-weight: bold; font-family: trebuchet ms;" href="file:///C:/DOCUME%7E1/Marina/CONFIG%7E1/Temp/msoclip1/01/clip_filelist.xml" rel="File-List"&gt;&lt;style&gt; &lt;!--  /* Style Definitions */ p.MsoNormal, li.MsoNormal, div.MsoNormal 	{mso-style-parent:""; 	margin:0cm; 	margin-bottom:.0001pt; 	mso-pagination:widow-orphan; 	font-size:12.0pt; 	font-family:"Times New Roman"; 	mso-fareast-font-family:"Times New Roman";} h1 	{mso-style-next:Normal; 	margin:0cm; 	margin-bottom:.0001pt; 	mso-pagination:widow-orphan; 	page-break-after:avoid; 	mso-outline-level:1; 	font-size:12.0pt; 	font-family:"Times New Roman"; 	mso-font-kerning:0pt;} @page Section1 	{size:612.0pt 792.0pt; 	margin:70.85pt 3.0cm 70.85pt 3.0cm; 	mso-header-margin:36.0pt; 	mso-footer-margin:36.0pt; 	mso-paper-source:0;} div.Section1 	{page:Section1;} --&gt; &lt;/style&gt;&lt;span style="font-size:100%;"&gt;&lt;br /&gt;&lt;/span&gt;&lt;p style="font-weight: bold; font-family: trebuchet ms;" class="MsoNormal"&gt; &lt;/p&gt;&lt;p class="MsoNormal" style="text-indent: 35.4pt; text-align: justify; font-weight: bold; font-family: trebuchet ms;"&gt;&lt;span style="font-size:100%;"&gt;Gestantes com hiperfenilalaninemia devem tomar um cuidado excessivo durante a gravidez, visto que há passagem de aminoácidos via placenta da mãe para o bebê, o que pode causar sérios danos à saúde da criança. Sendo assim, uma mulher grávida com elevado nível plasmático de fenilalanina está colocando em risco a saúde do feto, pois ele fica exposto ao dobro da quantidade de fenilalanina presente na corrente sangüínea materna, fazendo com que o bebê tenha defeitos cardíacos, crescimento retardado e retardo mental, em alguns casos pode até haver aborto espontâneo.&lt;/span&gt;&lt;/p&gt;&lt;p class="MsoNormal" style="text-indent: 35.4pt; text-align: justify; font-weight: bold; font-family: trebuchet ms;"&gt;&lt;span style="font-size:100%;"&gt;O cuidado nutricional na fenilcetonúria materna é muito importante, no entanto mesmo assim não há uma certeza absoluta de que o feto nascerá normal, visto que é bastante difícil monitorar minuciosamente a ingestão da fenilalanina, sendo complicado manter os níveis desse aminoácido adequados no sangue materno. De acordo com a Associação Européia de Fenilcetonúria (ESPKU) a concentração plasmática de fenilalanina materna deve estar entre 2&lt;sup&gt; &lt;/sup&gt;a 6mg/dl.&lt;/span&gt;&lt;/p&gt;&lt;p class="MsoNormal" style="text-indent: 35.4pt; text-align: justify; font-weight: bold; font-family: trebuchet ms;"&gt;&lt;span style="font-size:100%;"&gt;Mesmo assim faz-se necessário tomar os devidos cuidados para reduzir ao máximo possível as chances de o bebê apresentar tais defeitos. Por isso a gestante deve procurar acompanhamento profissional que possa orienta-la durante toda a gestação.&lt;/span&gt;&lt;/p&gt;&lt;p class="MsoNormal" style="text-indent: 35.4pt; text-align: justify;"&gt;&lt;br /&gt;&lt;/p&gt;&lt;p class="MsoNormal" style="text-indent: 35.4pt; text-align: justify; color: rgb(204, 51, 204); font-weight: bold; font-style: italic;"&gt;&lt;br /&gt;&lt;/p&gt;&lt;p class="MsoNormal" style="text-indent: 35.4pt; text-align: justify; color: rgb(204, 51, 204); font-weight: bold; font-style: italic;"&gt;By Camila Biete&lt;/p&gt;&lt;p class="MsoNormal" style="text-indent: 35.4pt;"&gt; &lt;/p&gt;&lt;span style="font-family:Times New Roman;"&gt;&lt;/span&gt;&lt;a onblur="try {parent.deselectBloggerImageGracefully();} catch(e) {}" href="http://2.bp.blogspot.com/_btpyAerDQPU/SQTSnpD5nrI/AAAAAAAAAFE/sGlDJZq_Guw/s1600-h/bebe+e+mae.png"&gt;&lt;img id="BLOGGER_PHOTO_ID_5261561843154525874" style="margin: 0px auto 10px; display: block; width: 258px; cursor: pointer; height: 320px; text-align: center;" alt="" src="http://2.bp.blogspot.com/_btpyAerDQPU/SQTSnpD5nrI/AAAAAAAAAFE/sGlDJZq_Guw/s320/bebe+e+mae.png" border="0" /&gt; &lt;meta content="text/html; charset=utf-8" equiv="Content-Type"&gt;&lt;meta content="Word.Document" name="ProgId"&gt;&lt;meta content="Microsoft Word 9" name="Generator"&gt;&lt;meta content="Microsoft Word 9" name="Originator"&gt;&lt;link style="color: rgb(255, 153, 255);" href="file:///C:/DOCUME%7E1/Marina/CONFIG%7E1/Temp/msoclip1/01/clip_filelist.xml" rel="File-List"&gt;&lt;style&gt; &lt;!--  /* Style Definitions */ p.MsoNormal, li.MsoNormal, div.MsoNormal 	{mso-style-parent:""; 	margin:0cm; 	margin-bottom:.0001pt; 	mso-pagination:widow-orphan; 	font-size:12.0pt; 	font-family:"Times New Roman"; 	mso-fareast-font-family:"Times New Roman";} h1 	{mso-style-next:Normal; 	margin:0cm; 	margin-bottom:.0001pt; 	mso-pagination:widow-orphan; 	page-break-after:avoid; 	mso-outline-level:1; 	font-size:12.0pt; 	font-family:"Times New Roman"; 	mso-font-kerning:0pt;} @page Section1 	{size:612.0pt 792.0pt; 	margin:70.85pt 3.0cm 70.85pt 3.0cm; 	mso-header-margin:35.4pt; 	mso-footer-margin:35.4pt; 	mso-paper-source:0;} div.Section1 	{page:Section1;} --&gt; &lt;/style&gt;&lt;br /&gt;&lt;p class="MsoNormal" style="color: rgb(204, 51, 204); text-indent: 35.4pt;"&gt;&lt;o:p&gt;&lt;/o:p&gt; &lt;/p&gt;&lt;p class="MsoNormal" style="color: rgb(204, 51, 204); text-indent: 35.4pt;"&gt;Bibliografia:&lt;/p&gt;&lt;p class="MsoNormal" style="color: rgb(204, 51, 204); text-indent: 35.4pt;"&gt;&lt;span style="font-size:0;"&gt;&lt;/span&gt;L. kathleen Mahan e Sylvia Escott-Stump_ Krause Alimentos, Nutrição e Dietoterapia&lt;span style="font-size:0;"&gt; &lt;/span&gt;11ª edição.&lt;/p&gt;&lt;p class="MsoNormal" style="color: rgb(204, 51, 204); text-indent: 35.4pt;"&gt;&lt;span style="font-size:0;"&gt;&lt;/span&gt;Nascer e Crescer revista do hospital de crianças Maria Pia&lt;span style="font-size:0;"&gt; &lt;/span&gt;ano 2004, vol XIII, n°2&lt;/p&gt;&lt;/a&gt;&lt;br /&gt;&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/46256947993340856-8972107292902974414?l=biobio-pku.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://biobio-pku.blogspot.com/feeds/8972107292902974414/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=46256947993340856&amp;postID=8972107292902974414' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/46256947993340856/posts/default/8972107292902974414'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/46256947993340856/posts/default/8972107292902974414'/><link rel='alternate' type='text/html' href='http://biobio-pku.blogspot.com/2008/10/fenilcetonria-materna.html' title='Fenilcetonúria materna'/><author><name>Grupo de PKU</name><uri>http://www.blogger.com/profile/13253571819442069873</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><media:thumbnail xmlns:media='http://search.yahoo.com/mrss/' url='http://4.bp.blogspot.com/_btpyAerDQPU/SQTSTcHQxlI/AAAAAAAAAE8/v7ye68Iwz10/s72-c/mulher-gravida.jpg' height='72' width='72'/><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-46256947993340856.post-5522980870400449441</id><published>2008-10-26T11:30:00.001-07:00</published><updated>2008-11-14T15:01:51.356-08:00</updated><title type='text'>Dietas para fenilcetonúricos</title><content type='html'>&lt;a onblur="try {parent.deselectBloggerImageGracefully();} catch(e) {}" href="http://2.bp.blogspot.com/_btpyAerDQPU/SR4DWJEJKuI/AAAAAAAAANw/6SjwaQmktdk/s1600-h/pku+imagem.jpg"&gt;&lt;img style="margin: 0px auto 10px; display: block; text-align: center; cursor: pointer; width: 400px; height: 400px;" src="http://2.bp.blogspot.com/_btpyAerDQPU/SR4DWJEJKuI/AAAAAAAAANw/6SjwaQmktdk/s400/pku+imagem.jpg" alt="" id="BLOGGER_PHOTO_ID_5268652292995361506" border="0" /&gt;&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;span style=";font-family:trebuchet ms;font-size:100%;"  &gt;&lt;br /&gt;&lt;/span&gt;&lt;div  style="text-align: justify; font-weight: bold;font-family:trebuchet ms;"&gt;&lt;span style="font-size:100%;"&gt;&lt;br /&gt;        A fenilcetonúria é tratada por meio de uma dieta restrita de fenilalanina, que é o aminoácido acumulado no organismo devido ao problema congênito, e suplementação de aminoácidos livres.&lt;br /&gt;&lt;br /&gt;       A ingestão desses suplementos que deveria ser feita lentamente para assemelharem-se mais as condições normais é difícil já que a mistura apresenta odor e paladar desagradáveis então é feita de uma só vez, porém acarreta prejuízo para absorção intestinal, pois as enzimas ficam saturadas.&lt;br /&gt;&lt;br /&gt;      A baixa ingestão de proteínas de alto valor biológico entre outros fatores diminuem a biodisponibilidade de alguns nutrientes como, por exemplo, o zinco que é indispensável ao funcionamento de mais de 70 enzimas e é influenciado pela dieta rica em fibras que aumenta a excreção fecal do zinco. Outro exemplo é a quantidade insuficiente de selênio (necessário para a síntese de glutationa peroxidase que atua na proteção contra os radicais livres) que está presente em carnes frutos do mar e outros alimentos que são restringidos aos fenilcetonúricos devido ao alto teor de fenilalanina.&lt;br /&gt;&lt;br /&gt;    Os pacientes estão mais propensos a desenvolver anemia megaloblástica conseqüência de uma dieta pobre em alimentos que contenham quantidade desejável de vitamina B12.&lt;br /&gt;As dificuldades da dietoterapia têm estimulado pesquisas que têm como objetivo o tratamento baseado na transferência de genes somáticos. Porém a dificuldade é obter um vetor que possa transferir o dna da proteína funcional da PAH para dentro dos hepatócitos ou células onde a enzima possa exercer sua função.&lt;br /&gt;&lt;br /&gt;   Enquanto as pesquisas ainda não podem trazer resultados e sabendo dos problemas quanto à suplementação da dieta, alguns países têm investido em pesquisa e tecnologia a fim de melhorar a aceitação do produto.&lt;br /&gt;&lt;/span&gt;   &lt;/div&gt;&lt;span style=";font-family:trebuchet ms;font-size:100%;"  &gt;&lt;br /&gt;&lt;a style="font-weight: bold;" href="http://www.scielosp.org/scielo.php?script=sci_arttext&amp;amp;pid=S0034-89102000000100016"&gt;http://www.scielosp.org/scielo.php?script=sci_arttext&amp;amp;pid=S0034-89102000000100016&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;span style="font-weight: bold; color: rgb(102, 0, 204); font-style: italic;"&gt;by: Jersica Oliveira&lt;/span&gt;&lt;/span&gt;&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/46256947993340856-5522980870400449441?l=biobio-pku.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://biobio-pku.blogspot.com/feeds/5522980870400449441/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=46256947993340856&amp;postID=5522980870400449441' title='1 Comentários'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/46256947993340856/posts/default/5522980870400449441'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/46256947993340856/posts/default/5522980870400449441'/><link rel='alternate' type='text/html' href='http://biobio-pku.blogspot.com/2008/10/fenilcetonria-tratada-por-meio-de-uma.html' title='Dietas para fenilcetonúricos'/><author><name>Grupo de PKU</name><uri>http://www.blogger.com/profile/13253571819442069873</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><media:thumbnail xmlns:media='http://search.yahoo.com/mrss/' url='http://2.bp.blogspot.com/_btpyAerDQPU/SR4DWJEJKuI/AAAAAAAAANw/6SjwaQmktdk/s72-c/pku+imagem.jpg' height='72' width='72'/><thr:total>1</thr:total></entry><entry><id>tag:blogger.com,1999:blog-46256947993340856.post-6787464637050383737</id><published>2008-10-26T10:41:00.001-07:00</published><updated>2008-11-08T04:06:42.417-08:00</updated><title type='text'>Sobre o Aspartame</title><content type='html'>&lt;a onblur="try {parent.deselectBloggerImageGracefully();} catch(e) {}" href="http://4.bp.blogspot.com/_btpyAerDQPU/SQS9nin_zvI/AAAAAAAAAE0/f4P3m1TB29U/s1600-h/aspartame.jpg"&gt;&lt;img id="BLOGGER_PHOTO_ID_5261538751682694898" style="margin: 0px auto 10px; display: block; width: 320px; cursor: pointer; height: 289px; text-align: center;" alt="" src="http://4.bp.blogspot.com/_btpyAerDQPU/SQS9nin_zvI/AAAAAAAAAE0/f4P3m1TB29U/s320/aspartame.jpg" border="0" /&gt;&lt;/a&gt;&lt;v:stroke&gt;&lt;v:f eqn="if lineDrawn pixelLineWidth 0"&gt;&lt;v:f eqn="sum @0 1 0"&gt;&lt;v:f eqn="sum 0 0 @1"&gt;&lt;v:f eqn="prod @2 1 2"&gt;&lt;v:f eqn="prod @3 21600 pixelWidth"&gt;&lt;v:f eqn="prod @3 21600 pixelHeight"&gt;&lt;v:f eqn="sum @0 0 1"&gt;&lt;v:f eqn="prod @6 1 2"&gt;&lt;v:f eqn="prod @7 21600 pixelWidth"&gt;&lt;v:f eqn="sum @8 21600 0"&gt;&lt;v:f eqn="prod @7 21600 pixelHeight"&gt;&lt;v:f eqn="sum @10 21600 0"&gt;&lt;v:path connecttype="rect" gradientshapeok="t" extrusionok="f"&gt;&lt;o:lock aspectratio="t" ext="edit"&gt;&lt;v:imagedata href="http://ricardo.pro.br/s/aspartame_clip_image002_0000.gif" src="file:///C:/DOCUME%7E1/Marina/CONFIG%7E1/Temp/msoclip1/01/clip_image001.gif"&gt; &lt;/v:imagedata&gt;&lt;/o:lock&gt;&lt;/v:path&gt;&lt;/v:f&gt;&lt;/v:f&gt;&lt;/v:f&gt;&lt;/v:f&gt;&lt;/v:f&gt;&lt;/v:f&gt;&lt;/v:f&gt;&lt;/v:f&gt;&lt;/v:f&gt;&lt;/v:f&gt;&lt;/v:f&gt;&lt;/v:f&gt;&lt;/v:stroke&gt;&lt;div style="text-align: justify;"&gt;&lt;v:stroke&gt;&lt;v:f eqn="if lineDrawn pixelLineWidth 0"&gt;&lt;v:f eqn="sum @0 1 0"&gt;&lt;v:f eqn="sum 0 0 @1"&gt;&lt;v:f eqn="prod @2 1 2"&gt;&lt;v:f eqn="prod @3 21600 pixelWidth"&gt;&lt;v:f eqn="prod @3 21600 pixelHeight"&gt;&lt;v:f eqn="sum @0 0 1"&gt;&lt;v:f eqn="prod @6 1 2"&gt;&lt;v:f eqn="prod @7 21600 pixelWidth"&gt;&lt;v:f eqn="sum @8 21600 0"&gt;&lt;v:f eqn="prod @7 21600 pixelHeight"&gt;&lt;v:f eqn="sum @10 21600 0"&gt;&lt;v:path connecttype="rect" gradientshapeok="t" extrusionok="f"&gt;&lt;o:lock aspectratio="t" ext="edit"&gt;&lt;v:imagedata href="http://ricardo.pro.br/s/aspartame_clip_image002_0000.gif" src="file:///C:/DOCUME%7E1/Marina/CONFIG%7E1/Temp/msoclip1/01/clip_image001.gif"&gt;&lt;p class="MsoBodyText" style="text-indent: 35.4pt;"&gt;&lt;span style="font-size:85%;"&gt;O aspartame é um composto artificial, descoberto em 1965, produzido pelos aminoácidos fenilalanina (50%) e ácido aspártico (40%), além de 10% de metanol (na forma de éster metílico). Este composto é um importante constituinte de adoçantes artificiais, sendo primeiramente utilizado apenas para diabéticos e mais tarde grande parte da população passou a consumi-lo, em razão de ele “substituir” o açúcar e poder ser um bom aliado na dietas de pessoas que querem perder peso. &lt;/span&gt;&lt;/p&gt;&lt;p class="MsoBodyText" style="text-indent: 35.4pt;"&gt;&lt;span style="font-size:85%;"&gt;Essa substância requer alguns cuidados, principalmente para pessoas portadores de fenilcetonúria (PKU). Produtos que contenham esse composto devem ser evitados pelos fenilcetonúricos, vistos que estes não metabolizam fenilalanina (presente na fórmula do aspartame). &lt;/span&gt;&lt;/p&gt;&lt;p class="MsoBodyText"  style="text-align: justify;font-family:georgia;"&gt;&lt;span style="font-size:85%;"&gt;A fenilalanina que circula no sangue materno pode atravessar tranqüilamente a barreira placentária e se acumular nos tecidos fetais. Níveis de 60 mmol/dl de fenilalanina no sangue de gestantes pode gerar deficiência nos neonatos, porém pesquisas feitas mostram que mesmo gestantes PKU-heterozigóticas ingerindo aspartame em altas doses (100 mg/kg), o máximo de fenilalanina que se pode chegar é 42mmol/dl. Por isso o consumo de aspartame é prejudicial em gestantes &lt;/span&gt;&lt;span style="font-size:85%;"&gt;PKU-homozigóticas. Assim, é recomendado a gestantes PKU-heterozigóticas e não portadoras evitar ou usar&lt;span style="font-size:85%;"&gt; &lt;/span&gt;pequenas doses de produtos com aspartame apenas por precaução.&lt;o:p&gt;&lt;/o:p&gt;&lt;/span&gt;&lt;/p&gt;&lt;p class="MsoBodyText" style="text-indent: 25.5pt; margin-right: 42.55pt;"&gt; &lt;/p&gt;&lt;p class="Assunto"  style="text-align: justify;font-family:georgia;"&gt;&lt;span style="font-size:85%;"&gt;&lt;b&gt;Produtos que contém aspartame&lt;o:p&gt;&lt;/o:p&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p class="Assunto"  style="text-align: justify;font-family:georgia;"&gt; &lt;/p&gt;&lt;p class="Assunto" face="georgia" style="text-align: justify;"&gt;&lt;span style="font-size:85%;"&gt;Existem aproximadamente 5000 produtos que contém este composto. Entre eles bebidas, iogurtes, gomas de mascar, gelatinas, adoçantes e outros.&lt;/span&gt;&lt;/p&gt;&lt;/v:imagedata&gt;&lt;/o:lock&gt;&lt;/v:path&gt;&lt;/v:f&gt;&lt;/v:f&gt;&lt;/v:f&gt;&lt;/v:f&gt;&lt;/v:f&gt;&lt;/v:f&gt;&lt;/v:f&gt;&lt;/v:f&gt;&lt;/v:f&gt;&lt;/v:f&gt;&lt;/v:f&gt;&lt;/v:f&gt;&lt;/v:stroke&gt;&lt;/div&gt;&lt;v:stroke&gt;&lt;v:f eqn="if lineDrawn pixelLineWidth 0"&gt;&lt;v:f eqn="sum @0 1 0"&gt;&lt;v:f eqn="sum 0 0 @1"&gt;&lt;v:f eqn="prod @2 1 2"&gt;&lt;v:f eqn="prod @3 21600 pixelWidth"&gt;&lt;v:f eqn="prod @3 21600 pixelHeight"&gt;&lt;v:f eqn="sum @0 0 1"&gt;&lt;v:f eqn="prod @6 1 2"&gt;&lt;v:f eqn="prod @7 21600 pixelWidth"&gt;&lt;v:f eqn="sum @8 21600 0"&gt;&lt;v:f eqn="prod @7 21600 pixelHeight"&gt;&lt;v:f eqn="sum @10 21600 0"&gt;&lt;v:path connecttype="rect" gradientshapeok="t" extrusionok="f"&gt;&lt;o:lock aspectratio="t" ext="edit"&gt;&lt;v:imagedata href="http://ricardo.pro.br/s/aspartame_clip_image002_0000.gif" src="file:///C:/DOCUME%7E1/Marina/CONFIG%7E1/Temp/msoclip1/01/clip_image001.gif"&gt;&lt;p class="ececstyle3"&gt; &lt;a onblur="try {parent.deselectBloggerImageGracefully();} catch(e) {}" href="http://1.bp.blogspot.com/_btpyAerDQPU/SQSsgqZwJkI/AAAAAAAAAEU/-2BWq3KrNdw/s1600-h/Zero+cal+liquido.jpeg"&gt;&lt;img id="BLOGGER_PHOTO_ID_5261519941813675586" style="margin: 0px auto 10px; display: block; width: 200px; cursor: pointer; height: 200px; text-align: center;" alt="" src="http://1.bp.blogspot.com/_btpyAerDQPU/SQSsgqZwJkI/AAAAAAAAAEU/-2BWq3KrNdw/s320/Zero+cal+liquido.jpeg" border="0" /&gt;&lt;/a&gt;&lt;/p&gt;&lt;p class="ececstyle3"&gt;&lt;em&gt;&lt;span style="color: rgb(102, 0, 204); font-weight: bold;font-family:trebuchet ms;font-size:180%;"  &gt;“&lt;/span&gt;Como calcular a quantidade de fenilalanina proveniente de um alimento adoçado com aspartame? &lt;/em&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;br /&gt;&lt;meta content="text/html; charset=utf-8" equiv="Content-Type"&gt;&lt;meta content="Word.Document" name="ProgId"&gt;&lt;meta content="Microsoft Word 9" name="Generator"&gt;&lt;meta content="Microsoft Word 9" name="Originator"&gt;&lt;link href="file:///C:/DOCUME%7E1/Marina/CONFIG%7E1/Temp/msoclip1/01/clip_filelist.xml" rel="File-List"&gt;&lt;link href="file:///C:/DOCUME%7E1/Marina/CONFIG%7E1/Temp/msoclip1/01/clip_editdata.mso" rel="Edit-Time-Data"&gt;&lt;style&gt; v\:* {behavior:url(#default#VML);} o\:* {behavior:url(#default#VML);} w\:* {behavior:url(#default#VML);} .shape {behavior:url(#default#VML);} &lt;/style&gt;&lt;br /&gt;&lt;style&gt; &lt;!--  /* Style Definitions */ p.MsoNormal, li.MsoNormal, div.MsoNormal 	{mso-style-parent:""; 	margin:0cm; 	margin-bottom:.0001pt; 	mso-pagination:widow-orphan; 	font-size:12.0pt; 	font-family:"Times New Roman"; 	mso-fareast-font-family:"Times New Roman";} h1 	{mso-style-next:Normal; 	margin:0cm; 	margin-bottom:.0001pt; 	mso-pagination:widow-orphan; 	page-break-after:avoid; 	mso-outline-level:1; 	font-size:12.0pt; 	font-family:"Times New Roman"; 	mso-font-kerning:0pt; 	font-weight:bold;} p.MsoBodyText, li.MsoBodyText, div.MsoBodyText 	{margin-top:0cm; 	margin-right:0cm; 	margin-bottom:6.0pt; 	margin-left:0cm; 	mso-pagination:widow-orphan; 	font-size:12.0pt; 	font-family:"Times New Roman"; 	mso-fareast-font-family:"Times New Roman";} p.MsoSalutation, li.MsoSalutation, div.MsoSalutation 	{mso-style-next:Normal; 	margin:0cm; 	margin-bottom:.0001pt; 	mso-pagination:widow-orphan; 	font-size:12.0pt; 	font-family:"Times New Roman"; 	mso-fareast-font-family:"Times New Roman";} a:link, span.MsoHyperlink 	{color:blue; 	text-decoration:underline; 	text-underline:single;} a:visited, span.MsoHyperlinkFollowed 	{color:purple; 	text-decoration:underline; 	text-underline:single;} p 	{margin-right:0cm; 	mso-margin-top-alt:auto; 	mso-margin-bottom-alt:auto; 	margin-left:0cm; 	mso-pagination:widow-orphan; 	font-size:12.0pt; 	font-family:"Times New Roman"; 	mso-fareast-font-family:"Times New Roman";} p.ececstyle3, li.ececstyle3, div.ececstyle3 	{mso-style-name:ec_ec_style3; 	margin-right:0cm; 	mso-margin-top-alt:auto; 	mso-margin-bottom-alt:auto; 	margin-left:0cm; 	mso-pagination:widow-orphan; 	font-size:12.0pt; 	font-family:"Times New Roman"; 	mso-fareast-font-family:"Times New Roman";} p.Assunto, li.Assunto, div.Assunto 	{mso-style-name:Assunto; 	margin:0cm; 	margin-bottom:.0001pt; 	mso-pagination:widow-orphan; 	font-size:12.0pt; 	font-family:"Times New Roman"; 	mso-fareast-font-family:"Times New Roman";} @page Section1 	{size:612.0pt 792.0pt; 	margin:70.85pt 3.0cm 70.85pt 3.0cm; 	mso-header-margin:36.0pt; 	mso-footer-margin:36.0pt; 	mso-paper-source:0;} div.Section1 	{page:Section1;}  /* List Definitions */ @list l0 	{mso-list-id:228155930; 	mso-list-type:hybrid; 	mso-list-template-ids:2144232594 -1561060070 -1142102020 711631878 365956668 -1842288772 948835636 -295664108 1453222926 -283105656;} @list l0:level1 	{mso-level-tab-stop:36.0pt; 	mso-level-number-position:left; 	text-indent:-18.0pt;} @list l1 	{mso-list-id:791752833; 	mso-list-type:hybrid; 	mso-list-template-ids:-514830976 -1408972588 667992038 1476191654 -904657668 2032014980 623138132 -792809824 -932962942 -2064464060;} @list l1:level1 	{mso-level-tab-stop:36.0pt; 	mso-level-number-position:left; 	text-indent:-18.0pt;} @list l2 	{mso-list-id:1012536468; 	mso-list-type:hybrid; 	mso-list-template-ids:1438809450 -1358643838 -1547817728 -1295112966 92144482 48511812 401502060 -293827348 -604333068 1941885278;} @list l2:level1 	{mso-level-tab-stop:36.0pt; 	mso-level-number-position:left; 	text-indent:-18.0pt;} @list l3 	{mso-list-id:1413429700; 	mso-list-type:hybrid; 	mso-list-template-ids:-1847835522 -523219442 -832136164 1487442330 1137472840 -1484607562 1560445120 -689506934 853078138 501409248;} @list l3:level1 	{mso-level-tab-stop:36.0pt; 	mso-level-number-position:left; 	text-indent:-18.0pt;} ol 	{margin-bottom:0cm;} ul 	{margin-bottom:0cm;} --&gt; &lt;/style&gt;&lt;v:stroke joinstyle="miter"&gt;&lt;v:f eqn="if lineDrawn pixelLineWidth 0"&gt;&lt;v:f eqn="sum @0 1 0"&gt;&lt;v:f eqn="sum 0 0 @1"&gt;&lt;v:f eqn="prod @2 1 2"&gt;&lt;v:f eqn="prod @3 21600 pixelWidth"&gt;&lt;v:f eqn="prod @3 21600 pixelHeight"&gt;&lt;v:f eqn="sum @0 0 1"&gt;&lt;v:f eqn="prod @6 1 2"&gt;&lt;v:f eqn="prod @7 21600 pixelWidth"&gt;&lt;v:f eqn="sum @8 21600 0"&gt;&lt;v:f eqn="prod @7 21600 pixelHeight"&gt;&lt;v:f eqn="sum @10 21600 0"&gt;&lt;v:path connecttype="rect" gradientshapeok="t" extrusionok="f"&gt;&lt;o:lock aspectratio="t" ext="edit"&gt;&lt;v:imagedata href="http://ricardo.pro.br/s/aspartame_clip_image002_0000.gif" src="file:///C:/DOCUME%7E1/Marina/CONFIG%7E1/Temp/msoclip1/01/clip_image001.gif"&gt;&lt;br /&gt;&lt;a onblur="try {parent.deselectBloggerImageGracefully();} catch(e) {}" href="http://4.bp.blogspot.com/_btpyAerDQPU/SQSsBcl4FxI/AAAAAAAAAEE/S0HdJEbrOY4/s1600-h/pepsi+twist+light.jpg"&gt;&lt;img id="BLOGGER_PHOTO_ID_5261519405530486546" style="margin: 0px auto 10px; display: block; width: 172px; cursor: pointer; height: 320px; text-align: center;" alt="" src="http://4.bp.blogspot.com/_btpyAerDQPU/SQSsBcl4FxI/AAAAAAAAAEE/S0HdJEbrOY4/s320/pepsi+twist+light.jpg" border="0" /&gt;&lt;/a&gt; &lt;meta content="text/html; charset=utf-8" equiv="Content-Type"&gt;&lt;meta content="Word.Document" name="ProgId"&gt;&lt;meta content="Microsoft Word 9" name="Generator"&gt;&lt;meta content="Microsoft Word 9" name="Originator"&gt;&lt;link href="file:///C:/DOCUME%7E1/Marina/CONFIG%7E1/Temp/msoclip1/01/clip_filelist.xml" rel="File-List"&gt;&lt;style&gt; &lt;!--  /* Style Definitions */ p.MsoNormal, li.MsoNormal, div.MsoNormal 	{mso-style-parent:""; 	margin:0cm; 	margin-bottom:.0001pt; 	mso-pagination:widow-orphan; 	font-size:12.0pt; 	font-family:"Times New Roman"; 	mso-fareast-font-family:"Times New Roman";} h1 	{mso-style-next:Normal; 	margin:0cm; 	margin-bottom:.0001pt; 	mso-pagination:widow-orphan; 	page-break-after:avoid; 	mso-outline-level:1; 	font-size:12.0pt; 	font-family:"Times New Roman"; 	mso-font-kerning:0pt; 	font-weight:bold;} p.MsoBodyText, li.MsoBodyText, div.MsoBodyText 	{margin-top:0cm; 	margin-right:0cm; 	margin-bottom:6.0pt; 	margin-left:0cm; 	mso-pagination:widow-orphan; 	font-size:12.0pt; 	font-family:"Times New Roman"; 	mso-fareast-font-family:"Times New Roman";} p.MsoSalutation, li.MsoSalutation, div.MsoSalutation 	{mso-style-next:Normal; 	margin:0cm; 	margin-bottom:.0001pt; 	mso-pagination:widow-orphan; 	font-size:12.0pt; 	font-family:"Times New Roman"; 	mso-fareast-font-family:"Times New Roman";} a:link, span.MsoHyperlink 	{color:blue; 	text-decoration:underline; 	text-underline:single;} a:visited, span.MsoHyperlinkFollowed 	{color:purple; 	text-decoration:underline; 	text-underline:single;} p 	{margin-right:0cm; 	mso-margin-top-alt:auto; 	mso-margin-bottom-alt:auto; 	margin-left:0cm; 	mso-pagination:widow-orphan; 	font-size:12.0pt; 	font-family:"Times New Roman"; 	mso-fareast-font-family:"Times New Roman";} p.ececstyle3, li.ececstyle3, div.ececstyle3 	{mso-style-name:ec_ec_style3; 	margin-right:0cm; 	mso-margin-top-alt:auto; 	mso-margin-bottom-alt:auto; 	margin-left:0cm; 	mso-pagination:widow-orphan; 	font-size:12.0pt; 	font-family:"Times New Roman"; 	mso-fareast-font-family:"Times New Roman";} p.Assunto, li.Assunto, div.Assunto 	{mso-style-name:Assunto; 	margin:0cm; 	margin-bottom:.0001pt; 	mso-pagination:widow-orphan; 	font-size:12.0pt; 	font-family:"Times New Roman"; 	mso-fareast-font-family:"Times New Roman";} @page Section1 	{size:612.0pt 792.0pt; 	margin:70.85pt 3.0cm 70.85pt 3.0cm; 	mso-header-margin:36.0pt; 	mso-footer-margin:36.0pt; 	mso-paper-source:0;} div.Section1 	{page:Section1;}  /* List Definitions */ @list l0 	{mso-list-id:228155930; 	mso-list-type:hybrid; 	mso-list-template-ids:2144232594 -1561060070 -1142102020 711631878 365956668 -1842288772 948835636 -295664108 1453222926 -283105656;} @list l0:level1 	{mso-level-tab-stop:36.0pt; 	mso-level-number-position:left; 	text-indent:-18.0pt;} @list l1 	{mso-list-id:791752833; 	mso-list-type:hybrid; 	mso-list-template-ids:-514830976 -1408972588 667992038 1476191654 -904657668 2032014980 623138132 -792809824 -932962942 -2064464060;} @list l1:level1 	{mso-level-tab-stop:36.0pt; 	mso-level-number-position:left; 	text-indent:-18.0pt;} @list l2 	{mso-list-id:1012536468; 	mso-list-type:hybrid; 	mso-list-template-ids:1438809450 -1358643838 -1547817728 -1295112966 92144482 48511812 401502060 -293827348 -604333068 1941885278;} @list l2:level1 	{mso-level-tab-stop:36.0pt; 	mso-level-number-position:left; 	text-indent:-18.0pt;} @list l3 	{mso-list-id:1413429700; 	mso-list-type:hybrid; 	mso-list-template-ids:-1847835522 -523219442 -832136164 1487442330 1137472840 -1484607562 1560445120 -689506934 853078138 501409248;} @list l3:level1 	{mso-level-tab-stop:36.0pt; 	mso-level-number-position:left; 	text-indent:-18.0pt;} ol 	{margin-bottom:0cm;} ul 	{margin-bottom:0cm;} --&gt; &lt;/style&gt;&lt;br /&gt;&lt;p&gt; &lt;/p&gt;&lt;ol type="1"&gt;&lt;li class="MsoNormal"&gt;&lt;strong&gt;&lt;span lang="EN-US"&gt;Refrigerante Pepsi Twist Light &lt;/span&gt;&lt;/strong&gt;&lt;span lang="EN-US"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/span&gt;&lt;/li&gt;&lt;/ol&gt;&lt;p&gt;&lt;span lang="EN-US"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/span&gt;&lt;/p&gt;&lt;p class="ececstyle3"&gt;No rótulo lemos: aspartame 35 mg/100 mL. &lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p class="ececstyle3"&gt;Considerando uma lata de 330 mL temos: &lt;/p&gt;&lt;p class="ececstyle3"&gt;Vale salientar que esta quantidade está bem abaixo da concentração permitida pela legislação brasileira &lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p class="MsoNormal"&gt;&lt;/p&gt;&lt;p class="MsoNormal"&gt;&lt;!--[if !supportEmptyParas]--&gt; &lt;!--[endif]--&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/p&gt;&lt;p class="ececstyle3"&gt;100 mL de refrigerante ----------------35 mg aspartame &lt;/p&gt;&lt;p class="ececstyle3"&gt;330 mL ---------------- x &lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p class="ececstyle3"&gt;x = 115,50 mg aspartame ----------- 100 % &lt;/p&gt;&lt;p class="ececstyle3"&gt;y ----------- 50 % &lt;strong&gt;Resposta: &lt;/strong&gt;Uma lata contém 57,60 mg. &lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;br /&gt;&lt;a onblur="try {parent.deselectBloggerImageGracefully();} catch(e) {}" href="http://4.bp.blogspot.com/_btpyAerDQPU/SQSr81CO0YI/AAAAAAAAAD8/_JMnT-lba6Q/s1600-h/molico.jpg"&gt;&lt;img id="BLOGGER_PHOTO_ID_5261519326192521602" style="margin: 0px auto 10px; display: block; width: 240px; cursor: pointer; height: 199px; text-align: center;" alt="" src="http://4.bp.blogspot.com/_btpyAerDQPU/SQSr81CO0YI/AAAAAAAAAD8/_JMnT-lba6Q/s320/molico.jpg" border="0" /&gt;&lt;/a&gt; &lt;meta content="text/html; charset=utf-8" equiv="Content-Type"&gt;&lt;meta content="Word.Document" name="ProgId"&gt;&lt;meta content="Microsoft Word 9" name="Generator"&gt;&lt;meta content="Microsoft Word 9" name="Originator"&gt;&lt;link href="file:///C:/DOCUME%7E1/Marina/CONFIG%7E1/Temp/msoclip1/01/clip_filelist.xml" rel="File-List"&gt;&lt;style&gt; &lt;!--  /* Style Definitions */ p.MsoNormal, li.MsoNormal, div.MsoNormal 	{mso-style-parent:""; 	margin:0cm; 	margin-bottom:.0001pt; 	mso-pagination:widow-orphan; 	font-size:12.0pt; 	font-family:"Times New Roman"; 	mso-fareast-font-family:"Times New Roman";} h1 	{mso-style-next:Normal; 	margin:0cm; 	margin-bottom:.0001pt; 	mso-pagination:widow-orphan; 	page-break-after:avoid; 	mso-outline-level:1; 	font-size:12.0pt; 	font-family:"Times New Roman"; 	mso-font-kerning:0pt; 	font-weight:bold;} p.MsoBodyText, li.MsoBodyText, div.MsoBodyText 	{margin-top:0cm; 	margin-right:0cm; 	margin-bottom:6.0pt; 	margin-left:0cm; 	mso-pagination:widow-orphan; 	font-size:12.0pt; 	font-family:"Times New Roman"; 	mso-fareast-font-family:"Times New Roman";} p.MsoSalutation, li.MsoSalutation, div.MsoSalutation 	{mso-style-next:Normal; 	margin:0cm; 	margin-bottom:.0001pt; 	mso-pagination:widow-orphan; 	font-size:12.0pt; 	font-family:"Times New Roman"; 	mso-fareast-font-family:"Times New Roman";} a:link, span.MsoHyperlink 	{color:blue; 	text-decoration:underline; 	text-underline:single;} a:visited, span.MsoHyperlinkFollowed 	{color:purple; 	text-decoration:underline; 	text-underline:single;} p 	{margin-right:0cm; 	mso-margin-top-alt:auto; 	mso-margin-bottom-alt:auto; 	margin-left:0cm; 	mso-pagination:widow-orphan; 	font-size:12.0pt; 	font-family:"Times New Roman"; 	mso-fareast-font-family:"Times New Roman";} p.ececstyle3, li.ececstyle3, div.ececstyle3 	{mso-style-name:ec_ec_style3; 	margin-right:0cm; 	mso-margin-top-alt:auto; 	mso-margin-bottom-alt:auto; 	margin-left:0cm; 	mso-pagination:widow-orphan; 	font-size:12.0pt; 	font-family:"Times New Roman"; 	mso-fareast-font-family:"Times New Roman";} p.Assunto, li.Assunto, div.Assunto 	{mso-style-name:Assunto; 	margin:0cm; 	margin-bottom:.0001pt; 	mso-pagination:widow-orphan; 	font-size:12.0pt; 	font-family:"Times New Roman"; 	mso-fareast-font-family:"Times New Roman";} @page Section1 	{size:612.0pt 792.0pt; 	margin:70.85pt 3.0cm 70.85pt 3.0cm; 	mso-header-margin:36.0pt; 	mso-footer-margin:36.0pt; 	mso-paper-source:0;} div.Section1 	{page:Section1;}  /* List Definitions */ @list l0 	{mso-list-id:228155930; 	mso-list-type:hybrid; 	mso-list-template-ids:2144232594 -1561060070 -1142102020 711631878 365956668 -1842288772 948835636 -295664108 1453222926 -283105656;} @list l0:level1 	{mso-level-tab-stop:36.0pt; 	mso-level-number-position:left; 	text-indent:-18.0pt;} @list l1 	{mso-list-id:791752833; 	mso-list-type:hybrid; 	mso-list-template-ids:-514830976 -1408972588 667992038 1476191654 -904657668 2032014980 623138132 -792809824 -932962942 -2064464060;} @list l1:level1 	{mso-level-tab-stop:36.0pt; 	mso-level-number-position:left; 	text-indent:-18.0pt;} @list l2 	{mso-list-id:1012536468; 	mso-list-type:hybrid; 	mso-list-template-ids:1438809450 -1358643838 -1547817728 -1295112966 92144482 48511812 401502060 -293827348 -604333068 1941885278;} @list l2:level1 	{mso-level-tab-stop:36.0pt; 	mso-level-number-position:left; 	text-indent:-18.0pt;} @list l3 	{mso-list-id:1413429700; 	mso-list-type:hybrid; 	mso-list-template-ids:-1847835522 -523219442 -832136164 1487442330 1137472840 -1484607562 1560445120 -689506934 853078138 501409248;} @list l3:level1 	{mso-level-tab-stop:36.0pt; 	mso-level-number-position:left; 	text-indent:-18.0pt;} ol 	{margin-bottom:0cm;} ul 	{margin-bottom:0cm;} --&gt; &lt;/style&gt;&lt;br /&gt;&lt;p&gt;&lt;o:p&gt;&lt;/o:p&gt; &lt;/p&gt;&lt;ol type="1"&gt;&lt;li class="MsoNormal"&gt;&lt;strong&gt;Iogurte Molico Beauty Nestlé 130 g (Laranja e Framboesa) &lt;/strong&gt;&lt;/li&gt;&lt;/ol&gt;&lt;p&gt;&lt;/p&gt;&lt;p class="ececstyle3"&gt;Nesse caso a quantidade presente no produto não é indicada no rótulo. Vamos considerar o que diz a legislação, esse alimento deve conter, no máximo, 0,075g de aspartame por 100 g de produto pronto para consumo. &lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p class="ececstyle3"&gt;&lt;span lang="EN-US"&gt;0,075 g -------100 g &lt;o:p&gt;&lt;/o:p&gt;&lt;/span&gt;&lt;/p&gt;&lt;p class="ececstyle3"&gt;&lt;span lang="EN-US"&gt;x ------- 130 g x = 0,0975 g &lt;o:p&gt;&lt;/o:p&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;span lang="EN-US"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/span&gt;&lt;/p&gt;&lt;p class="ececstyle3"&gt;&lt;span lang="ES-TRAD"&gt;0,0975 g ------ 100 % &lt;o:p&gt;&lt;/o:p&gt;&lt;/span&gt;&lt;/p&gt;&lt;p class="ececstyle3"&gt;&lt;span lang="ES-TRAD"&gt;y ------ 50 % y = 0,04875 g &lt;strong&gt;Resposta &lt;/strong&gt;= 48,75 mg de fenilalanina. &lt;o:p&gt;&lt;/o:p&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;span lang="ES-TRAD"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/span&gt;&lt;/p&gt;&lt;br /&gt;&lt;a onblur="try {parent.deselectBloggerImageGracefully();} catch(e) {}" href="http://2.bp.blogspot.com/_btpyAerDQPU/SQSr3tDVzOI/AAAAAAAAAD0/GnjB8cTr2ZA/s1600-h/royal+gelatina.jpg"&gt;&lt;img id="BLOGGER_PHOTO_ID_5261519238150343906" style="margin: 0px auto 10px; display: block; width: 200px; cursor: pointer; height: 200px; text-align: center;" alt="" src="http://2.bp.blogspot.com/_btpyAerDQPU/SQSr3tDVzOI/AAAAAAAAAD0/GnjB8cTr2ZA/s320/royal+gelatina.jpg" border="0" /&gt;&lt;/a&gt; &lt;meta content="text/html; charset=utf-8" equiv="Content-Type"&gt;&lt;meta content="Word.Document" name="ProgId"&gt;&lt;meta content="Microsoft Word 9" name="Generator"&gt;&lt;meta content="Microsoft Word 9" name="Originator"&gt;&lt;link href="file:///C:/DOCUME%7E1/Marina/CONFIG%7E1/Temp/msoclip1/01/clip_filelist.xml" rel="File-List"&gt;&lt;style&gt; &lt;!--  /* Style Definitions */ p.MsoNormal, li.MsoNormal, div.MsoNormal 	{mso-style-parent:""; 	margin:0cm; 	margin-bottom:.0001pt; 	mso-pagination:widow-orphan; 	font-size:12.0pt; 	font-family:"Times New Roman"; 	mso-fareast-font-family:"Times New Roman";} h1 	{mso-style-next:Normal; 	margin:0cm; 	margin-bottom:.0001pt; 	mso-pagination:widow-orphan; 	page-break-after:avoid; 	mso-outline-level:1; 	font-size:12.0pt; 	font-family:"Times New Roman"; 	mso-font-kerning:0pt; 	font-weight:bold;} p.MsoBodyText, li.MsoBodyText, div.MsoBodyText 	{margin-top:0cm; 	margin-right:0cm; 	margin-bottom:6.0pt; 	margin-left:0cm; 	mso-pagination:widow-orphan; 	font-size:12.0pt; 	font-family:"Times New Roman"; 	mso-fareast-font-family:"Times New Roman";} p.MsoSalutation, li.MsoSalutation, div.MsoSalutation 	{mso-style-next:Normal; 	margin:0cm; 	margin-bottom:.0001pt; 	mso-pagination:widow-orphan; 	font-size:12.0pt; 	font-family:"Times New Roman"; 	mso-fareast-font-family:"Times New Roman";} a:link, span.MsoHyperlink 	{color:blue; 	text-decoration:underline; 	text-underline:single;} a:visited, span.MsoHyperlinkFollowed 	{color:purple; 	text-decoration:underline; 	text-underline:single;} p 	{margin-right:0cm; 	mso-margin-top-alt:auto; 	mso-margin-bottom-alt:auto; 	margin-left:0cm; 	mso-pagination:widow-orphan; 	font-size:12.0pt; 	font-family:"Times New Roman"; 	mso-fareast-font-family:"Times New Roman";} p.ececstyle3, li.ececstyle3, div.ececstyle3 	{mso-style-name:ec_ec_style3; 	margin-right:0cm; 	mso-margin-top-alt:auto; 	mso-margin-bottom-alt:auto; 	margin-left:0cm; 	mso-pagination:widow-orphan; 	font-size:12.0pt; 	font-family:"Times New Roman"; 	mso-fareast-font-family:"Times New Roman";} p.Assunto, li.Assunto, div.Assunto 	{mso-style-name:Assunto; 	margin:0cm; 	margin-bottom:.0001pt; 	mso-pagination:widow-orphan; 	font-size:12.0pt; 	font-family:"Times New Roman"; 	mso-fareast-font-family:"Times New Roman";} @page Section1 	{size:612.0pt 792.0pt; 	margin:70.85pt 3.0cm 70.85pt 3.0cm; 	mso-header-margin:36.0pt; 	mso-footer-margin:36.0pt; 	mso-paper-source:0;} div.Section1 	{page:Section1;}  /* List Definitions */ @list l0 	{mso-list-id:228155930; 	mso-list-type:hybrid; 	mso-list-template-ids:2144232594 -1561060070 -1142102020 711631878 365956668 -1842288772 948835636 -295664108 1453222926 -283105656;} @list l0:level1 	{mso-level-tab-stop:36.0pt; 	mso-level-number-position:left; 	text-indent:-18.0pt;} @list l1 	{mso-list-id:791752833; 	mso-list-type:hybrid; 	mso-list-template-ids:-514830976 -1408972588 667992038 1476191654 -904657668 2032014980 623138132 -792809824 -932962942 -2064464060;} @list l1:level1 	{mso-level-tab-stop:36.0pt; 	mso-level-number-position:left; 	text-indent:-18.0pt;} @list l2 	{mso-list-id:1012536468; 	mso-list-type:hybrid; 	mso-list-template-ids:1438809450 -1358643838 -1547817728 -1295112966 92144482 48511812 401502060 -293827348 -604333068 1941885278;} @list l2:level1 	{mso-level-tab-stop:36.0pt; 	mso-level-number-position:left; 	text-indent:-18.0pt;} @list l3 	{mso-list-id:1413429700; 	mso-list-type:hybrid; 	mso-list-template-ids:-1847835522 -523219442 -832136164 1487442330 1137472840 -1484607562 1560445120 -689506934 853078138 501409248;} @list l3:level1 	{mso-level-tab-stop:36.0pt; 	mso-level-number-position:left; 	text-indent:-18.0pt;} ol 	{margin-bottom:0cm;} ul 	{margin-bottom:0cm;} --&gt; &lt;/style&gt;&lt;br /&gt;&lt;p&gt;&lt;span lang="ES-TRAD"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/span&gt; &lt;/p&gt;&lt;ol type="1"&gt;&lt;li class="MsoNormal"&gt;&lt;strong&gt;Royal gelatina diet 15 g (vários sabores) &lt;/strong&gt;&lt;/li&gt;&lt;/ol&gt;&lt;p&gt;&lt;/p&gt;&lt;p class="ececstyle3"&gt;Nesse caso a quantidade presente no produto não é indicada no rótulo. Vamos considerar o que diz a legislação, esse alimento deve conter, no máximo, 0,075g de aspartame por 100 g de produto pronto para consumo. &lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p class="ececstyle3"&gt;No preparo da gelatina são usados ± 500 mL de água. O produto preparado pesa aproximadamente 500 g. &lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p class="ececstyle3"&gt;&lt;span lang="EN-US"&gt;0,075 g -------100 g &lt;o:p&gt;&lt;/o:p&gt;&lt;/span&gt;&lt;/p&gt;&lt;p class="ececstyle3"&gt;&lt;span lang="EN-US"&gt;x ------- 500 g x = 0,375g &lt;o:p&gt;&lt;/o:p&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;span lang="EN-US"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/span&gt;&lt;/p&gt;&lt;p class="ececstyle3"&gt;&lt;span lang="ES-TRAD"&gt;0,375 g ------ 100 % &lt;o:p&gt;&lt;/o:p&gt;&lt;/span&gt;&lt;/p&gt;&lt;p class="ececstyle3"&gt;&lt;span lang="ES-TRAD"&gt;y ------ 50 % y = 0,1875g &lt;strong&gt;Resposta &lt;/strong&gt;= 187,5 mg de fenilalanina. &lt;o:p&gt;&lt;/o:p&gt;&lt;/span&gt;&lt;/p&gt;&lt;p class="ececstyle3"&gt;Esse é o valor total. Supondo que a gelatina seja dividida em 5 porções iguais o valor seria: 37,5 mg.&lt;span style="font-weight: bold; color: rgb(102, 0, 204);font-size:180%;" &gt;”&lt;/span&gt;&lt;/p&gt;&lt;p class="ececstyle3"&gt;&lt;span style="font-weight: bold; font-style: italic; color: rgb(204, 51, 204);"&gt;by: Amanda Biete&lt;/span&gt;&lt;br /&gt;&lt;/p&gt;&lt;p class="ececstyle3"&gt;&lt;o:p&gt;&lt;/o:p&gt; &lt;/p&gt;&lt;p class="ececstyle3" style="font-weight: bold; color: rgb(204, 51, 204);"&gt;&lt;strong&gt;Fonte: &lt;/strong&gt;&lt;a href="http://ricardo.pro.br/s/aspartame.htm" target="_blank"&gt;http://ricardo.pro.br/s/aspartame.htm&lt;/a&gt;&lt;/p&gt;&lt;p class="ececstyle3" style="color: rgb(153, 51, 153); font-weight: bold;"&gt;&lt;a href="http://www.scielo.br/scielo.php?pid=S0100-72032007000500008&amp;amp;script=sci_arttext&amp;amp;tlng=pt"&gt;&lt;strong&gt;http://www.scielo.br/scielo.php?pid=S0100-72032007000500008&amp;amp;script=sci_arttext&amp;amp;tlng=pt&lt;/strong&gt;&lt;/a&gt;&lt;/p&gt;&lt;p class="ececstyle3" style="color: rgb(153, 51, 153); font-weight: bold;"&gt;&lt;strong&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/strong&gt;&lt;a href="http://ricardo.pro.br/s/aspartame.htm" target="_blank"&gt;&lt;br /&gt;&lt;/a&gt;&lt;/p&gt;&lt;p class="ececstyle3"&gt;&lt;o:p&gt;&lt;/o:p&gt; &lt;/p&gt;&lt;p class="ececstyle3"&gt;&lt;strong&gt;Bibliografia&lt;/strong&gt;&lt;/p&gt;&lt;ol style="font-weight: bold; color: rgb(204, 51, 204);" type="1"&gt;&lt;li class="MsoNormal"&gt;&lt;span lang="EN-US"&gt;Christian Tschanz, Harriet H. Butchko, W. Wayne Stargel e Frank N. Kotsonis. The Clinical Evaluation of a Food aditive: Assessment of Aspartame. Ed. CRC Press, New York, (1996). &lt;o:p&gt;&lt;/o:p&gt;&lt;/span&gt;&lt;/li&gt;&lt;li class="MsoNormal"&gt;&lt;span lang="EN-US"&gt;Toledo, M. C. F., and Ioshi, S. H. Potencial intake of intensive sweeteners in Brazil. Food Addti. Contam. 12, 799-808. (1995). &lt;o:p&gt;&lt;/o:p&gt;&lt;/span&gt;&lt;/li&gt;&lt;li class="MsoNormal"&gt;&lt;span lang="EN-US"&gt;Butchko et al, Regulatory Toxicology and Pharmacology, 35, S1-S93, (2002). &lt;o:p&gt;&lt;/o:p&gt;&lt;/span&gt;&lt;/li&gt;&lt;li class="MsoNormal"&gt;&lt;span lang="EN-US"&gt;Sheryl A. Hutchinson, Greogory S. HO, and Chi-Tang Ho, Stability and degradation of the high-intensity sweeteners: aspartame, alitmame and sucralose. Food. Rev. Int. 15(2), 249-261 (1999). &lt;o:p&gt;&lt;/o:p&gt;&lt;/span&gt;&lt;/li&gt;&lt;li class="MsoNormal"&gt;Seizi Oga, Fundamentos de toxicologia, Ed. Ateneu, 1996. &lt;/li&gt;&lt;li class="MsoNormal"&gt;Anvisa: Decreto nº 2.314, de 4 de setembro de 1997 &lt;/li&gt;&lt;li class="MsoNormal"&gt;Anvisa: Resolução - RDC nº 1, de 2 de janeiro de 2001 &lt;/li&gt;&lt;li class="MsoNormal"&gt;Anvisa: Resolução - RDC nº 2, de 2 de janeiro de 2001 &lt;/li&gt;&lt;li class="MsoNormal"&gt;Anvisa: Resolução - RDC nº 3, de 2 de janeiro de 2001 &lt;/li&gt;&lt;/ol&gt;&lt;p class="ececstyle3" style="font-weight: bold; color: rgb(204, 51, 204);"&gt;&lt;o:p&gt;&lt;/o:p&gt; &lt;/p&gt;&lt;p class="MsoNormal" style="font-weight: bold; color: rgb(204, 51, 204);"&gt;&lt;strong&gt;&lt;/strong&gt;&lt;/p&gt;&lt;p class="ececstyle3" style="font-weight: bold; color: rgb(204, 51, 204);"&gt;&lt;strong&gt;&lt;/strong&gt;&lt;/p&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;/v:imagedata&gt;&lt;/o:lock&gt;&lt;/v:path&gt;&lt;/v:f&gt;&lt;/v:f&gt;&lt;/v:f&gt;&lt;/v:f&gt;&lt;/v:f&gt;&lt;/v:f&gt;&lt;/v:f&gt;&lt;/v:f&gt;&lt;/v:f&gt;&lt;/v:f&gt;&lt;/v:f&gt;&lt;/v:f&gt;&lt;/v:stroke&gt;&lt;/v:imagedata&gt;&lt;/o:lock&gt;&lt;/v:path&gt;&lt;/v:f&gt;&lt;/v:f&gt;&lt;/v:f&gt;&lt;/v:f&gt;&lt;/v:f&gt;&lt;/v:f&gt;&lt;/v:f&gt;&lt;/v:f&gt;&lt;/v:f&gt;&lt;/v:f&gt;&lt;/v:f&gt;&lt;/v:f&gt;&lt;/v:stroke&gt;&lt;v:stroke&gt;&lt;v:f eqn="if lineDrawn pixelLineWidth 0"&gt;&lt;v:f eqn="sum @0 1 0"&gt;&lt;v:f eqn="sum 0 0 @1"&gt;&lt;v:f eqn="prod @2 1 2"&gt;&lt;v:f eqn="prod @3 21600 pixelWidth"&gt;&lt;v:f eqn="prod @3 21600 pixelHeight"&gt;&lt;v:f eqn="sum @0 0 1"&gt;&lt;v:f eqn="prod @6 1 2"&gt;&lt;v:f eqn="prod @7 21600 pixelWidth"&gt;&lt;v:f eqn="sum @8 21600 0"&gt;&lt;v:f eqn="prod @7 21600 pixelHeight"&gt;&lt;v:f eqn="sum @10 21600 0"&gt;&lt;v:path connecttype="rect" gradientshapeok="t" extrusionok="f"&gt;&lt;o:lock aspectratio="t" ext="edit"&gt;&lt;v:imagedata href="http://ricardo.pro.br/s/aspartame_clip_image002_0000.gif" src="file:///C:/DOCUME%7E1/Marina/CONFIG%7E1/Temp/msoclip1/01/clip_image001.gif"&gt;&lt;v:stroke joinstyle="miter"&gt;&lt;v:f eqn="if lineDrawn pixelLineWidth 0"&gt;&lt;v:f eqn="sum @0 1 0"&gt;&lt;v:f eqn="sum 0 0 @1"&gt;&lt;v:f eqn="prod @2 1 2"&gt;&lt;v:f eqn="prod @3 21600 pixelWidth"&gt;&lt;v:f eqn="prod @3 21600 pixelHeight"&gt;&lt;v:f eqn="sum @0 0 1"&gt;&lt;v:f eqn="prod @6 1 2"&gt;&lt;v:f eqn="prod @7 21600 pixelWidth"&gt;&lt;v:f eqn="sum @8 21600 0"&gt;&lt;v:f eqn="prod @7 21600 pixelHeight"&gt;&lt;v:f eqn="sum @10 21600 0"&gt;&lt;v:path connecttype="rect" gradientshapeok="t" extrusionok="f"&gt;&lt;o:lock aspectratio="t" ext="edit"&gt;&lt;v:imagedata href="http://ricardo.pro.br/s/aspartame_clip_image002_0000.gif" src="file:///C:/DOCUME%7E1/Marina/CONFIG%7E1/Temp/msoclip1/01/clip_image001.gif"&gt;&lt;/v:imagedata&gt;&lt;/o:lock&gt;&lt;/v:path&gt;&lt;/v:f&gt;&lt;/v:f&gt;&lt;/v:f&gt;&lt;/v:f&gt;&lt;/v:f&gt;&lt;/v:f&gt;&lt;/v:f&gt;&lt;/v:f&gt;&lt;/v:f&gt;&lt;/v:f&gt;&lt;/v:f&gt;&lt;/v:f&gt;&lt;/v:stroke&gt;&lt;/v:imagedata&gt;&lt;/o:lock&gt;&lt;/v:path&gt;&lt;/v:f&gt;&lt;/v:f&gt;&lt;/v:f&gt;&lt;/v:f&gt;&lt;/v:f&gt;&lt;/v:f&gt;&lt;/v:f&gt;&lt;/v:f&gt;&lt;/v:f&gt;&lt;/v:f&gt;&lt;/v:f&gt;&lt;/v:f&gt;&lt;/v:stroke&gt;&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/46256947993340856-6787464637050383737?l=biobio-pku.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://biobio-pku.blogspot.com/feeds/6787464637050383737/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=46256947993340856&amp;postID=6787464637050383737' title='4 Comentários'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/46256947993340856/posts/default/6787464637050383737'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/46256947993340856/posts/default/6787464637050383737'/><link rel='alternate' type='text/html' href='http://biobio-pku.blogspot.com/2008/10/sobre-o-aspartame.html' title='Sobre o Aspartame'/><author><name>Grupo de PKU</name><uri>http://www.blogger.com/profile/13253571819442069873</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><media:thumbnail xmlns:media='http://search.yahoo.com/mrss/' url='http://4.bp.blogspot.com/_btpyAerDQPU/SQS9nin_zvI/AAAAAAAAAE0/f4P3m1TB29U/s72-c/aspartame.jpg' height='72' width='72'/><thr:total>4</thr:total></entry><entry><id>tag:blogger.com,1999:blog-46256947993340856.post-1396479803204250115</id><published>2008-10-26T10:27:00.000-07:00</published><updated>2008-11-10T08:49:47.714-08:00</updated><title type='text'>Teste do Pezinho</title><content type='html'>&lt;a onblur="try {parent.deselectBloggerImageGracefully();} catch(e) {}" href="http://1.bp.blogspot.com/_btpyAerDQPU/SQSqEK_WlFI/AAAAAAAAADk/DtVBVKWkZ-I/s1600-h/Pezinho.jpg"&gt;&lt;img style="margin: 0px auto 10px; display: block; text-align: center; cursor: pointer; width: 156px; height: 240px;" src="http://1.bp.blogspot.com/_btpyAerDQPU/SQSqEK_WlFI/AAAAAAAAADk/DtVBVKWkZ-I/s320/Pezinho.jpg" alt="" id="BLOGGER_PHOTO_ID_5261517253321856082" border="0" /&gt;&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;ul&gt;&lt;li&gt; &lt;span style="font-weight: bold;font-size:100%;" &gt;&lt;span style="font-family:trebuchet ms;"&gt;O que é?&lt;/span&gt;&lt;/span&gt;&lt;/li&gt;&lt;/ul&gt;&lt;span style="font-weight: bold;font-size:100%;" &gt;&lt;br /&gt;&lt;/span&gt;&lt;div  style="text-align: justify; font-weight: bold;font-family:trebuchet ms;"&gt;&lt;span style="font-size:100%;"&gt;A triagem neonatal, conhecida popularmente como teste do pezinho, é um exame laboratorial bastante importante, pois é a partir dele que se detecta doenças metabólicas e genéticas, portanto podem ser tratadas precocemente. Detecta mais de 45 doenças diferentes. Um exemplo é a fenilcetonúria (PKU), uma doença metabólica genética causada pela deficiência da enzima fenilalanina-hidroxilase que converte fenilalanina em tirosina.&lt;br /&gt;&lt;/span&gt;&lt;/div&gt;&lt;span style="font-weight: bold;font-size:100%;" &gt;&lt;br /&gt;&lt;/span&gt;&lt;ul  style="font-weight: bold;font-family:trebuchet ms;"&gt;&lt;li&gt;&lt;span style="font-size:100%;"&gt;Quando deve ser feito?&lt;/span&gt;&lt;/li&gt;&lt;/ul&gt;&lt;span style="font-weight: bold;font-size:100%;" &gt;&lt;br /&gt;&lt;/span&gt;&lt;div  style="text-align: justify; font-weight: bold;font-family:trebuchet ms;"&gt;&lt;span style="font-size:100%;"&gt;É essencial que o exame seja feito na primeira semana de vida do bebê, a amostra de sangue deve ser coletada a partir do 3º dia de vida.&lt;br /&gt;&lt;/span&gt;&lt;/div&gt;&lt;span style="font-weight: bold;font-size:100%;" &gt;&lt;br /&gt;&lt;a style="font-family: trebuchet ms;" onblur="try {parent.deselectBloggerImageGracefully();} catch(e) {}" href="http://3.bp.blogspot.com/_btpyAerDQPU/SQSrJVrLz6I/AAAAAAAAADs/EZJP3AZ34ho/s1600-h/img_teste_do_pezinho.jpg"&gt;&lt;img style="margin: 0px auto 10px; display: block; text-align: center; cursor: pointer; width: 233px; height: 171px;" src="http://3.bp.blogspot.com/_btpyAerDQPU/SQSrJVrLz6I/AAAAAAAAADs/EZJP3AZ34ho/s320/img_teste_do_pezinho.jpg" alt="" id="BLOGGER_PHOTO_ID_5261518441601028002" border="0" /&gt;&lt;/a&gt;&lt;/span&gt;&lt;ul  style="font-weight: bold;font-family:trebuchet ms;"&gt;&lt;li&gt;&lt;span style="font-size:100%;"&gt;Como é feito?&lt;br /&gt;&lt;/span&gt;&lt;/li&gt;&lt;/ul&gt;&lt;div  style="text-align: justify; font-weight: bold;font-family:trebuchet ms;"&gt;&lt;span style="font-size:100%;"&gt;O teste consiste em coletar gotinhas de sangue do calcanhar do bebê. Não traz riscos à criança.&lt;br /&gt;&lt;br /&gt;&lt;/span&gt;&lt;/div&gt;&lt;span style="font-weight: bold;font-size:100%;" &gt;&lt;br /&gt;&lt;br /&gt;&lt;a style="font-family: trebuchet ms;" onblur="try {parent.deselectBloggerImageGracefully();} catch(e) {}" href="http://1.bp.blogspot.com/_btpyAerDQPU/SQSpEltMTOI/AAAAAAAAADU/t_gecQnwPvY/s1600-h/triagem_neonatal.jpg"&gt;&lt;img style="margin: 0px auto 10px; display: block; text-align: center; cursor: pointer; width: 250px; height: 150px;" src="http://1.bp.blogspot.com/_btpyAerDQPU/SQSpEltMTOI/AAAAAAAAADU/t_gecQnwPvY/s320/triagem_neonatal.jpg" alt="" id="BLOGGER_PHOTO_ID_5261516160981814498" border="0" /&gt;&lt;/a&gt;&lt;/span&gt;&lt;ul  style="font-weight: bold;font-family:trebuchet ms;"&gt;&lt;li&gt;&lt;span style="font-size:100%;"&gt;Teste do Pezinho e PKU&lt;/span&gt;&lt;/li&gt;&lt;/ul&gt;&lt;span style="font-weight: bold;font-size:100%;" &gt;&lt;br /&gt;&lt;/span&gt;&lt;div  style="text-align: justify; font-weight: bold;font-family:trebuchet ms;"&gt;&lt;span style="font-size:100%;"&gt;Após o teste, caso o bebê apresente nível  de fenilalanina acima de 20 mg/dl de sangue e nível normal ou reduzido de tirosina é bastante provável que o diagnóstico para esse bebê seja o de fenilcetonúria.&lt;br /&gt;&lt;/span&gt;&lt;/div&gt;&lt;span style="font-weight: bold;font-size:100%;" &gt;&lt;br /&gt;&lt;/span&gt;&lt;ul  style="font-weight: bold;font-family:trebuchet ms;"&gt;&lt;li&gt;&lt;span style="font-size:100%;"&gt; Aos pais&lt;/span&gt;&lt;/li&gt;&lt;/ul&gt;&lt;div  style="text-align: justify; font-weight: bold;font-family:trebuchet ms;"&gt;&lt;span style="font-size:100%;"&gt;O teste do pezinho é um direito de todos os brasileirose assegurado por lei. É dever dos pais exigirem do hospital ou maternidade que façam o teste. É gratuito e muito importante para a vida de seus filhos! "Quem ama cuida!"&lt;br /&gt;&lt;/span&gt;&lt;/div&gt;&lt;span style="font-weight: bold;font-size:100%;" &gt;&lt;a style="font-family: trebuchet ms;" onblur="try {parent.deselectBloggerImageGracefully();} catch(e) {}" href="http://3.bp.blogspot.com/_btpyAerDQPU/SQSo3lvuoOI/AAAAAAAAADE/qDrdxJDNLhc/s1600-h/70_Teste+do+pezinho+-+photo.jpg"&gt;&lt;img style="margin: 0px auto 10px; display: block; text-align: center; cursor: pointer; width: 200px; height: 190px;" src="http://3.bp.blogspot.com/_btpyAerDQPU/SQSo3lvuoOI/AAAAAAAAADE/qDrdxJDNLhc/s320/70_Teste+do+pezinho+-+photo.jpg" alt="" id="BLOGGER_PHOTO_ID_5261515937654153442" border="0" /&gt;&lt;/a&gt;&lt;br /&gt;&lt;span style="font-family:trebuchet ms;"&gt;Fonte: &lt;/span&gt;&lt;a style="font-family: trebuchet ms;" href="http://www.apaesp.org.br/testedopezinhohome.aspx"&gt;http://www.apaesp.org.br/testedopezinhohome.aspx&lt;/a&gt;&lt;br /&gt;&lt;a style="font-family: trebuchet ms;" href="http://www.unimedsorocaba.com.br/mater/teste_pezinho.php"&gt;http://www.unimedsorocaba.com.br/mater/teste_pezinho.php&lt;/a&gt;&lt;br /&gt;&lt;a style="font-family: trebuchet ms;" href="http://guiadobebe.uol.com.br/recemnasc/teste_do_pezinho1.htm"&gt;http://guiadobebe.uol.com.br/recemnasc/teste_do_pezinho1.htm&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;span style="font-style: italic; color: rgb(102, 51, 255);font-family:trebuchet ms;" &gt;by: Amanda Biete&lt;/span&gt;&lt;/span&gt;&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/46256947993340856-1396479803204250115?l=biobio-pku.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://biobio-pku.blogspot.com/feeds/1396479803204250115/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=46256947993340856&amp;postID=1396479803204250115' title='2 Comentários'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/46256947993340856/posts/default/1396479803204250115'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/46256947993340856/posts/default/1396479803204250115'/><link rel='alternate' type='text/html' href='http://biobio-pku.blogspot.com/2008/10/o-que-triagem-neonatal-conhecida.html' title='Teste do Pezinho'/><author><name>Grupo de PKU</name><uri>http://www.blogger.com/profile/13253571819442069873</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><media:thumbnail xmlns:media='http://search.yahoo.com/mrss/' url='http://1.bp.blogspot.com/_btpyAerDQPU/SQSqEK_WlFI/AAAAAAAAADk/DtVBVKWkZ-I/s72-c/Pezinho.jpg' height='72' width='72'/><thr:total>2</thr:total></entry><entry><id>tag:blogger.com,1999:blog-46256947993340856.post-4271085961785598284</id><published>2008-10-26T09:49:00.001-07:00</published><updated>2008-11-08T04:11:58.634-08:00</updated><title type='text'>O que é Fenilcetonúria?</title><content type='html'>&lt;p class="MsoNormal" style="text-indent: 35.4pt; text-align: justify;"&gt;A fenilcetonúria é uma doença hereditária determinada por um alelo recessivo e ocorre no cromossomo par 12 que codifica a enzima fenilalanina hidroxilase (enzima hepática). As pessoas afetadas com essa doença não conseguem fazer a conversão do aminoácido fenilalanina em tirosina (importante para a formação dos neurotransmissores dopamina e noradrenalina e precursora da melanina), pois não possuem ou está defeituosa a enzima fenilalanina hidroxilase (PAH). Sendo assim, a fenilalanina fica acumulando no sangue e nos tecidos e há uma diminuição dos níveis de tirosina disponível, causando sérias lesões no organismo.&lt;/p&gt;&lt;p class="MsoNormal" style="text-indent: 35.4pt; text-align: justify;"&gt;&lt;br /&gt;&lt;/p&gt;&lt;p class="MsoNormal" style="text-indent: 35.4pt; text-align: justify;"&gt;&lt;br /&gt;&lt;/p&gt;&lt;p class="MsoNormal" style="text-indent: 35.4pt; text-align: justify;"&gt;&lt;a onblur="try {parent.deselectBloggerImageGracefully();} catch(e) {}" href="http://1.bp.blogspot.com/_btpyAerDQPU/SQTqYw7b8fI/AAAAAAAAAF0/JwyYZPjMf24/s1600-h/picture.2.1.gif"&gt;&lt;img id="BLOGGER_PHOTO_ID_5261587975847539186" style="margin: 0px auto 10px; display: block; width: 400px; cursor: pointer; height: 194px; text-align: center;" alt="" src="http://1.bp.blogspot.com/_btpyAerDQPU/SQTqYw7b8fI/AAAAAAAAAF0/JwyYZPjMf24/s400/picture.2.1.gif" border="0" /&gt;&lt;/a&gt;&lt;/p&gt;&lt;p class="MsoNormal" style="text-indent: 35.4pt; text-align: justify;"&gt;&lt;br /&gt;&lt;/p&gt;&lt;p class="MsoNormal" style="text-indent: 35.4pt; text-align: justify;"&gt;&lt;a onblur="try {parent.deselectBloggerImageGracefully();} catch(e) {}" href="http://3.bp.blogspot.com/_btpyAerDQPU/SQTqr-s1t7I/AAAAAAAAAF8/trpVq80OXfw/s1600-h/picture.2.2.gif"&gt;&lt;img id="BLOGGER_PHOTO_ID_5261588305961924530" style="margin: 0px auto 10px; display: block; width: 295px; cursor: pointer; height: 400px; text-align: center;" alt="" src="http://3.bp.blogspot.com/_btpyAerDQPU/SQTqr-s1t7I/AAAAAAAAAF8/trpVq80OXfw/s400/picture.2.2.gif" border="0" /&gt;&lt;/a&gt;&lt;a onblur="try {parent.deselectBloggerImageGracefully();} catch(e) {}" href="http://2.bp.blogspot.com/_btpyAerDQPU/SQTrVqyJH1I/AAAAAAAAAGM/16edhOCzti0/s1600-h/picture_2_4.png"&gt;&lt;img id="BLOGGER_PHOTO_ID_5261589022169964370" style="margin: 0px auto 10px; display: block; width: 316px; cursor: pointer; height: 400px; text-align: center;" alt="" src="http://2.bp.blogspot.com/_btpyAerDQPU/SQTrVqyJH1I/AAAAAAAAAGM/16edhOCzti0/s400/picture_2_4.png" border="0" /&gt;&lt;/a&gt;&lt;a onblur="try {parent.deselectBloggerImageGracefully();} catch(e) {}" href="http://2.bp.blogspot.com/_btpyAerDQPU/SQTq7kslXpI/AAAAAAAAAGE/wEHukQ-pVAY/s1600-h/picture_2_3.png"&gt;&lt;img id="BLOGGER_PHOTO_ID_5261588573859438226" style="margin: 0px auto 10px; display: block; width: 303px; cursor: pointer; height: 400px; text-align: center;" alt="" src="http://2.bp.blogspot.com/_btpyAerDQPU/SQTq7kslXpI/AAAAAAAAAGE/wEHukQ-pVAY/s400/picture_2_3.png" border="0" /&gt;&lt;/a&gt;&lt;/p&gt;&lt;p class="MsoNormal" style="text-indent: 35.4pt; text-align: justify;"&gt;&lt;br /&gt;&lt;/p&gt;&lt;p class="MsoNormal" style="text-indent: 35.4pt; text-align: justify;"&gt;&lt;br /&gt;&lt;/p&gt;&lt;br /&gt;&lt;meta content="text/html; charset=utf-8" equiv="Content-Type"&gt;&lt;meta content="Word.Document" name="ProgId"&gt;&lt;meta content="Microsoft Word 9" name="Generator"&gt;&lt;meta content="Microsoft Word 9" name="Originator"&gt;&lt;link href="file:///C:/DOCUME%7E1/Marina/CONFIG%7E1/Temp/msoclip1/01/clip_filelist.xml" rel="File-List"&gt;&lt;style&gt; &lt;!--  /* Font Definitions */ @font-face 	{font-family:Wingdings; 	panose-1:5 0 0 0 0 0 0 0 0 0; 	mso-font-charset:2; 	mso-generic-font-family:auto; 	mso-font-pitch:variable; 	mso-font-signature:0 268435456 0 0 -2147483648 0;}  /* Style Definitions */ p.MsoNormal, li.MsoNormal, div.MsoNormal 	{mso-style-parent:""; 	margin:0cm; 	margin-bottom:.0001pt; 	mso-pagination:widow-orphan; 	font-size:12.0pt; 	font-family:"Times New Roman"; 	mso-fareast-font-family:"Times New Roman";} h1 	{mso-style-next:Normal; 	margin:0cm; 	margin-bottom:.0001pt; 	text-align:justify; 	mso-pagination:widow-orphan; 	page-break-after:avoid; 	mso-outline-level:1; 	font-size:12.0pt; 	font-family:"Times New Roman"; 	mso-font-kerning:0pt;} p.MsoBodyText, li.MsoBodyText, div.MsoBodyText 	{margin:0cm; 	margin-bottom:.0001pt; 	text-align:justify; 	mso-pagination:widow-orphan; 	font-size:12.0pt; 	font-family:"Times New Roman"; 	mso-fareast-font-family:"Times New Roman";} @page Section1 	{size:612.0pt 792.0pt; 	margin:70.85pt 3.0cm 70.85pt 3.0cm; 	mso-header-margin:36.0pt; 	mso-footer-margin:36.0pt; 	mso-paper-source:0;} div.Section1 	{page:Section1;}  /* List Definitions */ @list l0 	{mso-list-id:554243189; 	mso-list-type:hybrid; 	mso-list-template-ids:-485165552 68550669 68550659 68550661 68550657 68550659 68550661 68550657 68550659 68550661;} @list l0:level1 	{mso-level-number-format:bullet; 	mso-level-text:; 	mso-level-tab-stop:36.0pt; 	mso-level-number-position:left; 	text-indent:-18.0pt; 	font-family:Wingdings;} @list l1 	{mso-list-id:953512152; 	mso-list-type:hybrid; 	mso-list-template-ids:-677325720 68550669 68550659 68550661 68550657 68550659 68550661 68550657 68550659 68550661;} @list l1:level1 	{mso-level-number-format:bullet; 	mso-level-text:; 	mso-level-tab-stop:36.0pt; 	mso-level-number-position:left; 	text-indent:-18.0pt; 	font-family:Wingdings;} ol 	{margin-bottom:0cm;} ul 	{margin-bottom:0cm;} --&gt; &lt;/style&gt;&lt;br /&gt;&lt;p class="MsoNormal" style="text-indent: 35.4pt; text-align: justify;"&gt;Quando a doença não é diagnosticada precocemente através da triagem neonatal a criança desenvolve uma série de problemas como:&lt;/p&gt;&lt;p class="MsoNormal" style="text-indent: 35.4pt; text-align: justify;"&gt;&lt;br /&gt;&lt;/p&gt;&lt;p class="MsoNormal" style="text-indent: 35.4pt; text-align: justify;"&gt;&lt;meta content="text/html; charset=utf-8" equiv="Content-Type"&gt;&lt;meta content="Word.Document" name="ProgId"&gt;&lt;meta content="Microsoft Word 9" name="Generator"&gt;&lt;meta content="Microsoft Word 9" name="Originator"&gt;&lt;link href="file:///C:/DOCUME%7E1/Marina/CONFIG%7E1/Temp/msoclip1/01/clip_filelist.xml" rel="File-List"&gt;&lt;style&gt; &lt;!--  /* Font Definitions */ @font-face 	{font-family:Wingdings; 	panose-1:5 0 0 0 0 0 0 0 0 0; 	mso-font-charset:2; 	mso-generic-font-family:auto; 	mso-font-pitch:variable; 	mso-font-signature:0 268435456 0 0 -2147483648 0;}  /* Style Definitions */ p.MsoNormal, li.MsoNormal, div.MsoNormal 	{mso-style-parent:""; 	margin:0cm; 	margin-bottom:.0001pt; 	mso-pagination:widow-orphan; 	font-size:12.0pt; 	font-family:"Times New Roman"; 	mso-fareast-font-family:"Times New Roman";} h1 	{mso-style-next:Normal; 	margin:0cm; 	margin-bottom:.0001pt; 	mso-pagination:widow-orphan; 	page-break-after:avoid; 	mso-outline-level:1; 	font-size:12.0pt; 	font-family:"Times New Roman"; 	mso-font-kerning:0pt; 	font-weight:bold;} p 	{margin-right:0cm; 	mso-margin-top-alt:auto; 	mso-margin-bottom-alt:auto; 	margin-left:0cm; 	mso-pagination:widow-orphan; 	font-size:12.0pt; 	font-family:"Times New Roman"; 	mso-fareast-font-family:"Times New Roman";} @page Section1 	{size:612.0pt 792.0pt; 	margin:70.85pt 3.0cm 70.85pt 3.0cm; 	mso-header-margin:36.0pt; 	mso-footer-margin:36.0pt; 	mso-paper-source:0;} div.Section1 	{page:Section1;}  /* List Definitions */ @list l0 	{mso-list-id:793060596; 	mso-list-type:hybrid; 	mso-list-template-ids:-1007804954 1789397992 552892572 1807373758 -958397620 -896496230 -670251442 1460538792 664202192 145793194;} @list l0:level1 	{mso-level-number-format:bullet; 	mso-level-text:; 	mso-level-tab-stop:36.0pt; 	mso-level-number-position:left; 	text-indent:-18.0pt; 	mso-ansi-font-size:10.0pt; 	font-family:Symbol;} ol 	{margin-bottom:0cm;} ul 	{margin-bottom:0cm;} --&gt; &lt;/style&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;ul&gt;&lt;li&gt;&lt;span style="color: rgb(102, 0, 204);"&gt;&lt;span style="color: rgb(102, 0, 204); font-weight: bold;font-size:180%;" &gt;"&lt;/span&gt;Retardo Mental&lt;/span&gt;&lt;/li&gt;&lt;li style="color: rgb(102, 0, 204);"&gt;&lt;span style="font-family:Symbol;"&gt;&lt;span style="font-style: normal; font-variant: normal; font-weight: normal; line-height: normal; font-size-adjust: none; font-stretch: normal;font-family:'Times New Roman';font-size:7;"  &gt;&lt;/span&gt;&lt;/span&gt;Distúrbios neurológicos com anormalidades eletroencefalográficas&lt;span style="font-family:Symbol;"&gt;&lt;span style="font-style: normal; font-variant: normal; font-weight: normal; line-height: normal; font-size-adjust: none; font-stretch: normal;font-family:'Times New Roman';font-size:7;"  &gt;&lt;/span&gt;&lt;/span&gt;&lt;/li&gt;&lt;li style="color: rgb(102, 0, 204);"&gt;&lt;span style="font-family:Symbol;"&gt;&lt;span style="font-style: normal; font-variant: normal; font-weight: normal; line-height: normal; font-size-adjust: none; font-stretch: normal;font-family:'Times New Roman';font-size:7;"  &gt;&lt;/span&gt;&lt;/span&gt;Incapacidade motora&lt;span style="font-family:Symbol;"&gt;&lt;span style="font-style: normal; font-variant: normal; font-weight: normal; line-height: normal; font-size-adjust: none; font-stretch: normal;font-family:'Times New Roman';font-size:7;"  &gt;&lt;/span&gt;&lt;/span&gt;&lt;/li&gt;&lt;li style="color: rgb(102, 0, 204);"&gt;&lt;span style="font-family:Symbol;"&gt;&lt;span style="font-style: normal; font-variant: normal; font-weight: normal; line-height: normal; font-size-adjust: none; font-stretch: normal;font-family:'Times New Roman';font-size:7;"  &gt;&lt;/span&gt;&lt;/span&gt;Incontinência esfincteriana&lt;/li&gt;&lt;li style="color: rgb(102, 0, 204);"&gt;&lt;span style="font-family:Symbol;"&gt;&lt;span style="font-style: normal; font-variant: normal; font-weight: normal; line-height: normal; font-size-adjust: none; font-stretch: normal;font-family:'Times New Roman';font-size:7;"  &gt;&lt;/span&gt;&lt;/span&gt;Tremores&lt;/li&gt;&lt;li style="color: rgb(102, 0, 204);"&gt;&lt;span style="font-family:Symbol;"&gt;&lt;span style="font-style: normal; font-variant: normal; font-weight: normal; line-height: normal; font-size-adjust: none; font-stretch: normal;font-family:'Times New Roman';font-size:7;"  &gt;&lt;/span&gt;&lt;/span&gt;Hipertensão muscular&lt;/li&gt;&lt;li style="color: rgb(102, 0, 204);"&gt;Ausência de mielinização&lt;span style="color: rgb(102, 0, 204); font-weight: bold;font-size:180%;" &gt;"&lt;/span&gt;&lt;/li&gt;&lt;/ul&gt;&lt;p class="MsoNormal" style="text-indent: 35.4pt; text-align: justify;"&gt;&lt;/p&gt;&lt;p&gt;&lt;span style="color: rgb(102, 51, 255);font-family:Times New Roman;" &gt;&lt;/span&gt; &lt;/p&gt;&lt;p style="text-align: justify;"&gt;Porém, quando detectada precocemente as pessoas que possuem essa doença podem levar uma vida normal se seguirem alguns cuidados veementemente importantes, como seguir uma dieta rígida com alimentos que não possuam o aminoácido fenilalanina. &lt;/p&gt;&lt;p style="text-align: justify;"&gt;&lt;/p&gt;&lt;p style="text-align: justify;" class="MsoNormal"&gt;&lt;/p&gt;&lt;div style="text-align: justify;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;span style="font-weight: bold; color: rgb(255, 153, 255);"&gt;by: Camila Biete&lt;/span&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;span style="color: rgb(204, 51, 204); font-style: italic; font-weight: bold;"&gt;Fonte:&lt;/span&gt;&lt;span style="font-weight: bold; color: rgb(102, 0, 204);"&gt; &lt;a href="http://www.assis.unesp.br/egalhard/errmetab.htm"&gt;&lt;span style="color: rgb(51, 0, 153);"&gt;http://www.assis.unesp.br/egalhard/errmetab.htm&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;br /&gt;&lt;a href="http://rarasdoencas.blogspot.com/2008/02/fenilcetonria-ou-pku-abreviatura-de.html"&gt;&lt;span style="color: rgb(51, 0, 153); font-weight: bold;"&gt;http://rarasdoencas.blogspot.com/2008/02/fenilcetonria-ou-pku-abreviatura-de.html&lt;/span&gt;&lt;/a&gt;&lt;br /&gt;&lt;a href="http://www.scielosp.org/scielo.php?script=sci_arttext&amp;amp;pid=S0034-89102000000100016"&gt;&lt;span style="color: rgb(51, 0, 153); font-weight: bold;"&gt;http://www.scielosp.org/scielo.php?script=sci_arttext&amp;amp;pid=S0034-89102000000100016&lt;/span&gt;&lt;/a&gt;&lt;br /&gt;&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/46256947993340856-4271085961785598284?l=biobio-pku.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://biobio-pku.blogspot.com/feeds/4271085961785598284/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=46256947993340856&amp;postID=4271085961785598284' title='1 Comentários'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/46256947993340856/posts/default/4271085961785598284'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/46256947993340856/posts/default/4271085961785598284'/><link rel='alternate' type='text/html' href='http://biobio-pku.blogspot.com/2008/10/o-que-fenilcetonria.html' title='O que é Fenilcetonúria?'/><author><name>Grupo de PKU</name><uri>http://www.blogger.com/profile/13253571819442069873</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><media:thumbnail xmlns:media='http://search.yahoo.com/mrss/' url='http://1.bp.blogspot.com/_btpyAerDQPU/SQTqYw7b8fI/AAAAAAAAAF0/JwyYZPjMf24/s72-c/picture.2.1.gif' height='72' width='72'/><thr:total>1</thr:total></entry></feed>
